table content 2 shareholder 54 outlook 100 consolidated financial statement 6 summary fiscal year 54 general midterm 101 consolidated statement income 8 fresenius share outlook 101 consolidated statement 12 business segment future market 55 comprehensive income 2016 12 fresenius medical care 56 health care sector 102 consolidated statement 14 fresenius kabi market financial position 16 fresenius helios 58 group sale earnings 103 consolidated statement cash flow 18 fresenius vamed 58 sale earnings 104 consolidated statement business segment change equity 59 financing 106 consolidated segment reporting 20 management report 59 investment 108 note see detailed register page 20 59 procurement see detailed register page 108 21 fundamental information 59 research development 109 general note group 60 planned change 124 note consolidated annual report 21 group business model human resource statement income 25 goal strategy social area 128 note consolidated corporate performance 26 60 dividend statement financial position criterion 61 opportunity risk report 156 note 27 fresenius cease voluntary 61 opportunity management 182 note accordance u gaap reporting 61 risk management german commercial code 27 research development 62 risk area hgb 29 employee 70 assessment overall risk 30 change supervisory board management board 185 auditor report 31 procurement 71 corporate governance declaration 31 quality management report responsibility environmental 33 186 report supervisory board management sustainability 36 economic report 194 board 36 health care industry 194 supervisory board 40 overall business development fresenius se co kgaa 42 result operation financial 196 management board position asset liability fresenius management se 54 overall assessment 197 supervisory board business situation fresenius management se 198 glossary table content 2 shareholder 54 outlook 100 consolidated financial statement 6 summary fiscal year 54 general midterm 101 consolidated statement income 8 fresenius share outlook 101 consolidated statement 12 business segment future market 55 comprehensive income 12 fresenius medical care 56 health care sector 102 consolidated statement 14 fresenius kabi market financial position 16 fresenius helios 58 group sale earnings 103 consolidated statement cash flow 18 fresenius vamed 58 sale earnings 104 consolidated statement business segment change equity 59 financing 106 consolidated segment reporting 20 management report 59 investment 108 note see detailed register page 20 59 procurement see detailed register page 108 21 fundamental information 59 research development 109 general note group 60 planned change 124 note consolidated 21 group business model human resource statement income 25 goal strategy social area 128 note consolidated corporate performance 26 60 dividend statement financial position criterion 61 opportunity risk report 156 note 27 fresenius cease voluntary 61 opportunity management 182 note accordance u gaap reporting 61 risk management german commercial code 27 research development 62 risk area hgb 29 employee 70 assessment overall risk 30 change supervisory board management board 185 auditor report 31 procurement 72 corporate governance declaration 31 quality management report responsibility environmental 33 186 report supervisory board management sustainability 36 economic report 194 board 36 health care industry 194 supervisory board 40 overall business development fresenius se co kgaa 42 result operation financial 196 management board position asset liability fresenius management se 54 overall assessment 197 supervisory board business situation fresenius management se 198 glossary financial calendar report 1st quarter 2017 conference call live webcast may 3 2017 annual general meeting frankfurt main germany may 12 2017 fresenius medical care fresenius kabi payment dividend 1 may 17 2017 report 2nd quarter 2017 conference call live webcast august 1 2017 dialysis product iv drug clinical nutrition report 3rd quarter 2017 health care service infusion therapy medical device conference call live webcast november 2 2017 dialysis service transfusion technology 1 subject prior approval annual general meeting care coordination schedule update information live webcasts event wwwfreseniuscomeventsandpresentations fresenius group figure u gaap 2016 2015 2016 2015 million 2016 2015 2014 2013 2012 u million u million change million million change sale earnings sale 17911 16738 7 6007 5950 1 sale 29083 27626 23231 20331 19290 ebit 2638 2327 13 1224 1189 2 3 fresenius share adr ebitda 1 5500 5073 4095 3888 3851 net income 1 1243 1029 21 716 669 2 7 ebit 1 4327 3958 3158 3045 3075 operating cash flow 2140 1960 9 991 913 9 net income 2 1593 1423 1086 1051 938 capital expenditure depreciation amortization 1173 1115 937 843 776 acquisition 1887 1380 37 436 389 12 ordinary share adr earnings per share 2 292 261 201 196 181 r expense 162 140 16 353 336 2 5 security identification 578 560 cusip 35804m105 cash flow balance sheet employee december 31 116120 110242 5 34917 33195 5 ticker symbol fre ticker symbol fsnuy operating cash flow 3574 3327 2585 2320 2438 isin de0005785604 isin us35804m1053 operating cash flow sale 123 120 111 114 126 bloomberg symbol fre gr structure sponsored level 1 adr total asset 46447 42959 39788 32663 30558 reuters symbol fregde ratio 4 adr 1 share noncurrent asset 34648 32480 29776 24703 22456 fresenius helios fresenius vamed main trading location frankfurt xetra trading platform otcqx equity 3 20420 18003 15483 13260 12758 equity ratio 3 44 42 39 41 42 net debt 13201 13725 14170 11845 10037 hospital operation project service net debt ebitda 4 5 234 268 324 254 257 hospital investment 6 2547 2029 3795 3827 4179 health care facility key figure business segment profitability ebit margin 1 149 143 136 150 159 2016 2015 2016 2015 contact return equity tax roe 2 127 130 116 128 123 million million change million million change return operating asset rooa 4 101 101 91 106 110 sale 5843 5578 5 1160 1118 4 return invested capital roic 4 85 83 75 88 90 ebit 682 640 2 7 69 64 8 dividend per share 062 7 055 044 042 037 net income 1 543 483 2 12 45 44 2 employee december 31 232873 222305 216275 178337 169324 corporate headquarters postal address contact shareholder contact journalist operating cash flow 622 618 1 27 53 49 elsekrönerstraße 1 fresenius se co kgaa investor relation corporate communication 1 012 2015 special item 2 capital expenditure 2 net income attributable shareholder fresenius se co kgaa 2012 2015 special item acquisition 390 376 4 11 15 27 bad homburg v h 61346 bad homburg v h telephone 49 61 72 6 0824 87 telephone 49 61 72 6 0823 02 3 including noncontrolling interest germany germany telefax 49 61 72 6 0824 88 telefax 49 61 72 6 0822 94 4 2016 pro forma acquisition 2012 2015 special item 2014 pro forma acquisition order intake na na 1017 904 13 email irfrefreseniuscom email prfrefreseniuscom 2013 pro forma excluding advance made amount 218 billion fiduciary employee december 31 72687 69728 4 8198 8262 1 agreement acquisition hospital rhönklinikum ag 2012 pro forma acquisition 5 ltm average exchange rate net debt ebitda 6 investment property plant equipment intangible asset acquisition 7 proposal 1 net income attributable parent company respective business segment 2 special item interactive tool 10year overview additional key figure available wwwfreseniuscominteractivetool detailed overview special item please see reconciliation table page 44 financial calendar report 1st quarter 2017 conference call live webcast may 3 2017 annual general meeting frankfurt main germany may 12 2017 fresenius medical care fresenius kabi payment dividend 1 may 17 2017 report 2nd quarter 2017 conference call live webcast august 1 2017 dialysis product iv drug clinical nutrition report 3rd quarter 2017 health care service infusion therapy medical device conference call live webcast november 2 2017 dialysis service transfusion technology 1 subject prior approval annual general meeting care coordination schedule update information live webcasts event wwwfreseniuscomeventsandpresentations 2016 2015 2016 2015 u million u million change million million change sale 17911 16738 7 6007 5950 1 ebit 2638 2327 13 1224 1189 2 3 fresenius share adr net income 1 1243 1029 21 716 669 2 7 operating cash flow 2140 1960 9 991 913 9 capital expenditure acquisition 1887 1380 37 436 389 12 ordinary share adr r expense 162 140 16 353 336 2 5 security identification 578 560 cusip 35804m105 employee december 31 116120 110242 5 34917 33195 5 ticker symbol fre ticker symbol fsnuy isin de0005785604 isin us35804m1053 bloomberg symbol fre gr structure sponsored level 1 adr reuters symbol fregde ratio 4 adr 1 share fresenius helios fresenius vamed main trading location frankfurt xetra trading platform otcqx hospital operation project service hospital health care facility key figure business segment 2016 2015 2016 2015 sale million 5843 million 5578 change 5 million 1160 million 1118 change 4 contact ebit 682 640 2 7 69 64 8 net income 1 543 483 2 12 45 44 2 corporate headquarters postal address contact shareholder contact journalist operating cash flow 622 618 1 27 53 49 elsekrönerstraße 1 fresenius se co kgaa investor relation corporate communication capital expenditure acquisition 390 376 4 11 15 27 bad homburg v h 61346 bad homburg v h telephone 49 61 72 6 0824 87 telephone 49 61 72 6 0823 02 germany germany telefax 49 61 72 6 0824 88 telefax 49 61 72 6 0822 94 order intake na na 1017 904 13 email irfrefreseniuscom email prfrefreseniuscom employee december 31 72687 69728 4 8198 8262 1 1 net income attributable parent company respective business segment 2 special item detailed overview special item please see reconciliation table page 44 fresenius global health care group providing product service dialysis hospital outpatient medical care addition fresenius focus hospital operation also manage project provide service hospital health care facility 230000 employee dedicated service health 100 country worldwide 2 shareholder shareholder stephan sturm chairman management board great pleasure write today first quirónsalud spain leading private hospital operator time position fresenius chief executive officer network comprises 43 hospital 39 outpatient center excited honored leading great unique 300 occupational risk prevention center located company know new fresenius chief every metropolitan region spain quirónsalud financial officer since 2005 worked closely germanybased fresenius helios combine two leader predecessor ceo ulf mark schneider helped term quality size acquisition offering advance company always put patient first whose growth synergy potential opportunity product service stand quality reliability com exchange knowledge experience lead improved pany whose employee never get complacent medical care patient country already achieved instead work hard find even better solution path continue pursue acquisition quirónsalud turn fresenius helios inter consistency commitment national fresenius medical care fresenius kabi fresenius vamed decade creates addi 2016 eventful year fresenius four tional opportunity cooperation among four business business segment continued make progress milestone segment initially spain prospectively coun acquisition spanish hospital operator quirón try well salud fresenius helios based purchase price largest acquisition fresenius history shareholder 3 shareholder fresenius helios also remains highly successful home market last summer acquired niederberg hospital north rhinewestphalia company 112th hospital across germany increased number patient treated invested almost 350 million upgrading modernizing facility something continue wiesbaden example spend well 200 million completely new hospital building 900 bed 22 operating room large invest ment completed 2020 highly modern facility functional design concept minimizes dis tances patient staff one improve medical quality provide fresenius medical care introduced completely new generation hemodialysis machine 6008 caresystem successfully developed among many step improve dialysis therapy activity fresenius medical care last year introduced completely four business segment new generation hemodialysis machine 6008 care system simplifies workflow clinical staff reduces waste make overall treatment even safer effi cient increased number dialysis clinic reached another milestone last autumn fresenius part acquiring india secondlargest dialysis chain sandor medical care celebrated 20th anniversary fresenius nephro service expanded care coordina active renal replacement therapy since back tion initiative service dialysisrelated area late 1960s fresenius medical care founding acquiring xenios ag germany extended range 1996 evolve pure product supplier verti service area cardiac lung therapy cally integrated dialysis company offering dialysis treatment well dialysis product next 20 year fresenius fresenius kabi also continued grow region medical care increased number patient fivefold dia product area particular highlight resumption lyzer production 10fold sale 12fold expanding strong growth china latin america broadened position world leading dialysis company product offering worldwide intravenous generic alone launched 80 new product united state acquired production facility prefilled syrinx continued invest high quality efficiency 4 shareholder shareholder manufacturing process plant melrose park near chicago significantly expanded modernized around u 250 million addition started expansion medical disposable plant mihla eastern germany order intake surpassing 1 billion mark first time sale growth project service business fresenius vamed also developed well last year europe remains fresenius vameds important region term sale continuously expanding activity africa asia latin america middle east fresenius vamed thereby important pioneering milestone acquisition spanish hospital operator work make highquality medical care accessible steadily quirónsalud fresenius helios increasing number patient around world way opening healthcare market future every reason believe continue success combined make 2016 fresenius 13th successful development year expect increase consecutive record year sale net income rose sale 15 17 percent net income even strongly subject shareholder approval annual 17 20 percent also see outstanding medium long general meeting increase dividend 24th term growth potential fresenius accordingly consecutive time shown even set ambitious new target 2020 business year time political economic uncertainty company aiming sale 43 47 billion net post stable growth said share price income 24 27 billion mean goal fresenius share gained 13 percent 2016 germany increase sale net income 50 percent dax index rose 7 percent since last year three next four year leading rating agency award fresenius investment grade corporate credit rating additional proof financial mar growth size end however kets trust company stability efficiency potential greatest value serving important goal patient health wellbeing successful business develop new therapy invest better yet affordable medicine similarly size important factor consider fresenius helios draw comparative data 100 hospital germany qual ity management system established based data industryleading term structure trans parency addition doctor nurse specialist shareholder 5 shareholder area exchange information colleague thanks international production network encompass fresenius helios hospital knowledge transfer ing 70 facility every continent react quickly taken even higher level following acquisition increase demand ensure patient supplied quirónsalud reliably often lifesaving drug fresenius medical care patient benefit fresenius vamed meanwhile implemented almost 800 experience gained 3500 dialysis clinic health care project 80 country company almost 50 country use knowledge refine clearly market leader field size give u procedure clinic improve treatment continu access uniquely wide range experience help u ally develop dialysis product least reason turn design customized solution health care facili fresenius medical care long market tech tie around world industrialized country nology leader every intention keep way developing nation effort better coordinate many medical service related dialysis call care coordination fresenius reason want continue growing medical care size economic strength enormous expe growth enable u offer even better product rience huge advantage decisive factor enabling treatment contribute provision highquality u provide even better comprehensive care yet affordable health care bringing continuous improve patient ments care ever people remain challenge well future happy proud ceo opportunity bringing continuous lead company pursue goal valued improvement care ever shareholder also proud commitment dedication fresenius investment people remain trust helping u continue growing want challenge well thank sincerely future size also help u fresenius kabi strengthen capa bility assure steady supply urgently needed highest quality drug patient large economically success ful company afford huge investment production stephan sturm process making melrose park chairman management board take production technology develop inside company introduce plant worldwide 6 summary summary fiscal year sale group sale increased 5 earnings group ebit 1 increased 29083 million 2015 27626 million 4327 million ebit margin organic sale growth 6 acquisi 149 group net income 1 2 increased summary tions contributed 1 divestiture reduced 12 1593 million growth con sale growth 1 currency translation stant currency 13 negative effect 1 sale region earnings development 4327 3958 1 3075 1 3158 1 3045 1 latin america region 5 asiapacific 10 159 150 143 north america 47 149 1593 2 136 1423 1 2 1051 1 2 1086 1 2 europe 38 938 1 2 2016 291 billion million 2012 2013 2014 2015 2016 ebit net income ebit margin 1 b efore special item 2 net income attributable shareholder fresenius se co kgaa detailed overview special item please see reconciliation table page 44 summary 7 cash flow operating cash flow balance sheet total asset increased creased 7 3574 million 8 46447 million mainly due cash flow margin increased 123 business expansion total shareholder summary cash flow acquisition equity including nonc ontrolling interest dividend increased 6 1971 increased 13 20420 million million december 31 2016 net debt ebitda ratio 234 3 5 december 31 2015 268 3 4 operating cash flow asset equity liability 3574 3327 75 75 42 44 2585 2438 2320 34 32 126 120 123 114 111 11 11 24 24 14 14 million 2012 2013 2014 2015 2016 million 42959 46447 42959 46447 dec 31 2015 dec 31 2016 dec 31 2015 dec 31 2016 operating cash flow operating cash flow margin noncurrent asset equity noncontrolling interest trade account receivable debt current asset liability 3 ltm average exchange rate net debt ebitda 4 special item 5 pro forma acquisition 8 fresenius share fresenius share fresenius share continued excellent performance 2016 reaching record high 7426 december increase 13 fresenius significantly performed dax fresenius share stock market development dax rose 95 period fresenius fresenius share share gained 212 following year volatile start surprising result market capitalization fresenius 406 billion brexit referendum financial market recovered december 31 2016 increase 13 compared course year slight recovery global economy previous year average daily trading volume xetra calming effect market decreased 15 1176579 fresenius share compared dax increased 7 euro stoxx 50 gained previous year 2015 1390878 dax trading volume 1 year stoxx europe 600 index ended remained nearly unchanged comparison time year 1 index subsector health care period decreased 10 leading u index performed united state fresenius sponsored level follows p 500 increased 10 dow jones american depositary receipt adr program program industrial average increased 13 four fresenius adr correspond one fresenius share closing price fresenius share december 31 adrs traded otcqx international premier mar 2016 7426 represents gain 13 ket segment closing price 2015 comparison five year fresenius share capital structure performed benchmark dax 117 percentage point total number issued share end 2016 547208371 december 31 2015 545727950 share increase due exercise option stock fresenius share 9 relative share price performance 2011 2016 absolute share price performance 2016 fresenius share v dax fresenius share 350 84 8000 300 72 7500 250 60 7000 200 48 6500 150 36 6000 100 24 5500 fresenius share 50 12 5000 30122011 30122012 30122013 30122014 30122015 30122016 dec 15 feb 16 apr 16 jun 16 aug 16 oct 16 dec 16 fresenius share dax fresenius high low fresenius share monthly price range option plan information stock option plan found 3431 million equivalent 22 group net income page 173 180 note annual report based proposed dividend closing price end 2016 dividend yield 08 dividend fresenius share attractive investment anyone 2016 fresenius delivered excellent financial result invested 1000 five year ago reinvested dividend 24th consecutive year proposing share would increased capital 3179 decem holder increase dividend 13 per share 062 ber 31 2016 average annual return 27 2015 055 total proposed dividend distribution expense tax key data fresenius share 2016 2015 2014 2013 2012 number share 547208371 545727950 541532600 539084487 534564780 stock exchange quotation 1 high 7426 6975 4412 3731 3212 low 5305 4241 3500 2730 2402 yearend quotation 7426 6597 4316 3720 2903 market capitalization 2 million 40636 36002 23373 20054 15520 total dividend distribution million 3431 3 3002 2383 2246 1960 dividend per share 062 3 055 044 042 037 earnings per share 292 4 261 4 201 4 196 4 181 4 1 x etra closing price frankfurt stock exchange 2 total number ordinary share multiplied respective xetra yearend quotation frankfurt stock exchange 3 proposal 4 net income attributable shareholder fresenius se co kgaa 2012 2015 special item 10 fresenius share september 2016 award best european divi development dividend dend share hosted society dividendenadel fresenius 062 se co kgaa received special dividendenadel award 055 award jury honored annual dividend increase fresenius share seen two decade 044 042 shareholder structure 037 chart show shareholder structure end 2016 else krönerfresenius foundation largest 032 029 shareholder fresenius se co kgaa 2644 025 share according notification pursuant german 022 023 security trading act wphg allianz global investor gmbh held 511 share blackrock inc held 498 information notification please fresenius share visit wwwfreseniuscomshareholderstructure december 31 2016 shareholder survey identified ownership 92 subscribed capital 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 1 shareholder base fresenius solid total 580 1 proposal institutional investor held 3301 million share 60 subscribed capital 278 million share identi fied retail holding topten investor held 20 analyst recommendation share capital share mostly held investor recommendation published financial analyst germany united state great britain important guide institutional private investor making investment decision according survey february 21 2017 rated 17 buy 6 hold sell recommendation shareholder structure region shareholder structure investor 1 region 4 retail holding 5 identified 8 identified 8 great britain 13 germany 43 else krönerfresenius institutional foundation 26 investor 60 rest europe 16 usa 16 1 due rounding difference figure add 100 fresenius share 11 list bank provide regular analyst coverage analyst recommendation fresenius latest recommendation found wwwfreseniuscomanalystsandconsensus equalweight hold investor relation neutral 26 investor relation activity accordance accumulate add buy transparency rule german corporate governance code outperform overweight 74 communicate comprehensively promptly openly private institutional investor well financial ana lysts equal treatment market actor impor tant u intensified dialog capital market 2016 addition quarterly conference call web particularly well time investor relation team cast fresenius gave presentation major european named best medtech sector europe fresenius share u financial market expanded contact also continued dialog private investor institutional investor analyst 31 international inves especially via internet wwwfreseniuscomeventsand tor conference 10 roadshows numerous oneonone presentation private shareholder follow live web meeting also organized field trip bank giving cast conference call use continuously investor analyst opportunity discus matter increased information offer website management board would like contact u find 2017 fresenius investor relation team manage financial calendar please take look last page ment team recognized result extel survey report visit u wwwfreseniuscominvestors broad survey conducted company thomson reuters annually survey 15000 investor analyst various aspect good investor relation fresenius 12 business segment fresenius medical care 2016 fresenius medical care achieved strong sale earnings growth strengthened leading position global dialysis market especially service area fresenius medical care world leading provider business development dialysis product service individual chronic kid fresenius medical care increased sale 7 u 17911 business segment ney failure kidney function patient million 2016 2015 u 16738 million organic sale disease fails dialysis take vital task cleansing growth 7 acquisition divestiture increased sale blood toxin surplus water vertically integrated 1 currency effect negatively affected sale 1 company fresenius medical care offer service dialysis health care service sale dialysis service care product along entire dialysis value chain 120 coordination increased 8 9 constant currency country fresenius medical care worldwide network u 14519 million 2015 u 13392 million dialysis 37 production site expanded leading product sale increased 1 4 constant currency market position 2016 treated 308471 patient 3624 u 3392 million 2015 u 3346 million dialysis clinic worldwide number treatment ebit increased 13 u 2638 million 2015 increased 4 465 million us2327 million ebit margin 147 2015 139 onetime item 1 ebit increased 10 net income 2 increased 21 u 1243 million 2015 u 1029 million onetime item 3 net income increased 16 sale region total currency fresenius translation medical care u million 2016 2015 change effect sale north america 12886 11813 9 0 72 europe middle east africa 2667 2629 1 3 15 asiapacific 1632 1502 9 1 9 latin america 712 766 7 20 4 corporate 14 28 48 0 0 total 17911 16738 7 1 100 1 2016 acquisition u 39 million tax 2015 settlement cost agreement principle granuflo naturalyte case u 60 million tax acquisition us16 million tax 2 net income attributable shareholder fresenius medical care ag co kgaa 3 2016 acquisition u 15 million tax 2015 settlement cost agreement principle granuflo naturalyte case u 37 million tax acquisition u 9 mil lion tax business segment fresenius medical care 13 regional development sale segment north america remained fresenius medical care largest u million 2016 2015 change business region 2016 sale grew 9 u 12886 north america million compared u 11813 million 2015 health care service 1 11982 10932 10 ebit increased 18 u 2119 million 2015 dialysis product 904 881 3 u 1798 million ebit margin 164 2015 total 12886 11813 9 international 2 152 health care service 1 2537 2460 3 average revenue per treatment united state dialysis product 2474 2437 2 u 351 2016 compared u 346 2015 aver total 5011 4897 2 age cost per treatment united state decreased worldwide u 279 2015 u 278 2016 health care service 1 14519 13392 8 2016 business development outside north amer dialysis product 3 3392 3346 1 total 17911 16738 7 ica business segment emea europe middle east 1 sale dialysis service care coordination africa asiapacific latin america impacted 2 nternational represents business segment emea europe middle east africa asiapacific latin america currency translation effect sale increased 2 7 3 including sale generated corporate function u 14 million 2016 constant currency u 5011 million 2015 u 4897 u 28 million 2015 million ebit decreased 2 u 909 million 2015 u 923 million ebit margin 181 2015 188 treatment quality 2016 physician clinical staff dialysis acquisition divestiture clinic offered patient highestquality treatment illus business segment 2016 fresenius medical care expanded clinical trated clinical quality parameter shown table network please see page 31 management report last year acquired 85 stake indian dialysis detail treatment quality group sandor nephro service group investor secondlargest provider dialysis treatment please refer page 58 f management report india operates 50 dialysis center 2017 financial outlook fresenius medical care sparsh nephrocare brand acquisition strengthens information please see fresenius medical care annual report fresenius medical care core business one world 2016 visit website wwwfreseniusmedicalcarecom fastestgrowing economy fresenius medical care region europe middle east total change north america africa latin america asiapacific 2016 2016 2015 dialysis clinic december 31 2306 711 233 374 3624 6 dialysis patient december 31 188987 59767 30389 29328 308471 5 treatment 28882107 8872231 4770859 4003957 46529154 4 quality parameter fresenius medical care patient 1 usa emea latin america asiapacific 2016 2015 2016 2015 2016 2015 2016 2015 kt v 12 98 98 96 96 91 92 97 97 hemoglobin 10 12 g dl 73 72 78 77 52 52 60 60 hemoglobin 10 13 g dl 79 78 77 77 68 69 68 68 albumin 35 g dl 2 78 81 91 92 91 90 89 89 phosphate 55 mg dl 2 64 64 77 79 77 75 72 72 hospitalization day 100 100 94 95 38 35 44 42 1 data refer last quarter 2 international standard bcr crm470 14 business segment fresenius kabi business grew organi c ally region product segment emerging market china latin america showed particularly strong growth organic sale growth 5 ebit growth 5 1 exceeded original expectation fresenius kabi specializes therapy care chronic business development ally critically ill people portfolio includes iv drug sale increased 1 6007 million 2016 organic business segment ie intravenously administered generic anesthetic anal sale growth 5 divestment australian gesics antiinfectives drug treatment onco german oncology compounding business 2015 reduced logical critical disease another product segment sale 1 negative currency translation effect 3 clinical nutrition segment one mainly related devaluation argentine peso company worldwide offer parenteral enteral chinese yuan euro nutrition product infusion therapy portfolio includes europe achieved organic sale growth 3 infusion solution blood volume substitute north america organic sale growth 3 mainly driven medical device transfusion technology segment new product launch fresenius kabi showed strong offer infusion nutrition pump well consum overall growth emerging market achieved organic ables administration pharmaceutical clinical sale growth 17 latin america asiapacific organic nutrition product moreover portfolio includes prod sale growth 7 719 million china worth special ucts used collection processing blood compo mention nents well transfusion medicine sale region currency total translation fresenius kabi million 2016 2015 change effect sale europe 2135 2123 1 1 36 north america 2170 2093 4 0 36 asiapacific 1108 1141 3 4 18 latin america africa 594 593 0 14 10 total 6007 5950 1 3 100 1 2015 special item constant currency business segment fresenius kabi 15 sale product segment follows product segment generic iv drug segment expanded product organic million 2016 2015 sale growth portfolio additional regional market worldwide intro iv drug 2531 2429 5 duced approximately 80 iv drug united state clinical nutrition 1576 1560 7 introduced nine iv drug year review two infusion therapy 861 914 6 medical device prefilled syringe product continuously transfusion technology 1039 1047 1 working offering product packaging dosage total 6007 5950 5 form like prefilled syrinx especially userfriendly safe ebit rose 3 1224 million currency translation 1 clinical nutrition expanded global market negative effect 2 presence threechamber bag parenteral nutrition distribute product smoflipid 65 coun million 2016 2015 change try last year received regulatory approval sell europe 343 352 3 product united state enteral nutrition intro north america 837 798 5 duced highprotein tubefeed product early enteral nutri asiapacific latin america africa 348 314 11 tion intensive care patient european country administrative fresubin intensive developed patient increased corporate r expense 304 275 11 protein requirement low moderate energy require ebit 1 1224 1189 3 ments ebit margin 1 204 200 infusion therapy product segment able business segment net income 2 716 669 7 1 efore special item b help alleviate shortage supply standard infusion net income attributable shareholder fresenius kabi ag special item product basis temporary prolonged import permit 2 granted u food drug administration fda medical device transfusion technology segment acquisition investment received ce approval new amicore apheresis 2016 fresenius kabi acquired production facility device introduced product malaysia thailand portfolio seven iv drug prefilled syrinx vietnam apheresis certain blood component obtained u medical technology company becton dickinson blood donor addition successfully company prefilled syrinx gaining importance due introduced cat mart device country high demand placed application safety hospital united state catsmart device automated auto efficiency transfusion process make possible quickly provide invested manufacturing facility launched patient erythrocyte operation certain investment program year example event heavy blood loss reduces need melrose park near chicago invest total around transfusion donor blood u 250 million 2026 order increase modernize production capacity drug another example please refer page 58 f management report germany began expansion location 2017 financial outlook fresenius kabi mihla thuringia amount invested 12 million information please see fresenius kabis website mihla plant produce component medical disposable wwwfreseniuskabicom 1 2015 special item detailed overview special item please see reconciliation table page 44 special item reported group corporate segment 16 business segment fresenius helios acquisition quirónsalud important strategic step significantly expands position largest p rivate hospital operator europe f urther improved business germany reached sale earnings target fresenius helios leading hospital operator germany million 2016 2015 change end 2016 helios group operated 112 hospi sale 5843 5578 5 business segment thereof acute care 5332 5080 5 tals 88 acute care hospital including 7 maximum care ho thereof postacute pitals berlinbuch duisburg erfurt krefeld schwerin care 370 348 6 wiesbaden wuppertal well 24 postacute care clin ebit 1 682 640 7 ic addition also operated 78 outpatient clinic 4 ebit margin 1 117 115 net income 2 543 483 12 patient postacute care center 18 prevention center 2015 special item 13 nursing home group approximately 35000 1 2 net income attributable helios kliniken gmbh bed treat 52 million patient including 2015 special item approximately 13 million inpatient year established sixyear development plan acute business development care postacute care clinic acquired germany 2016 fresenius helios increased sale 5 5843 development plan provides ebit margin improve million 2015 5578 million organic sale growth 4 two percentage point year target margin acquisition contributed 1 12 15 achieved acute care hospital accounted 91 sale 2015 91 postacute care clinic accounted acquisition 6 2015 6 3 attributable revenue september 2016 fresenius helios announced acquisi 2015 3 tion idc salud holding slu quirónsalud spain largest fresenius helios increased ebit 1 7 682 million private hospital operator quirónsaluds network comprises 43 2015 640 million ebit margin 117 2015 1 hospital 39 outpatient center around 300 occupational 115 increase attributable broadbased posi risk prevention orp center located economically tive performance across hospital network important area spain company offer full spectrum net income increased 12 543 million 2015 2 inpatient outpatient care quirónsalud treat approxi 483 million mately 320000 inpatient approximately 94 million patient per year operates total approximately 6600 bed 1 2015 special item 2 net income attributable helios kliniken gmbh 2015 special item business segment fresenius helios 17 2016 quirónsalud sale 2540 million ebitda 1 investment 461 million 2016 fresenius helios invested total 500 million purchase price 576 billion cash debt 2015 480 million amount 38 million accounted free basis relevant spanish antitrust authority approved acquisition 470 million primarily new building transaction december 22 2016 without imposing con modernization hospital schleswig duisburg ditions acquisition closed january 31 2017 pforzheim wiesbaden investment 352 mil quirónsalud consolidated february 1 2017 lion 6 sale may 2016 fresenius helios closed acquisition municipal hospital velbert german state million 2016 2015 change north rhinewestphalia hospital 519 bed sale investment 500 480 6 investment 69 million 2015 property plant addition helios expanded outpatient clinic network equipment 352 277 27 72 78 2016 subsidy 1 property plant equipment 110 104 13 hospital admission treatment acquisition 38 99 62 due broad range service high treatment quality 1 total purposerelated public investment subsidy according section 9 hospital funding act khg helios number inpatient outpatient treated increased 2016 strategic initiative helios hospital partner wir für gesundheit business segment 2016 2015 change inpatient semi network comprising 130 hospital across germany inpatient admission 1287808 1251982 3 subject strict measurable quality criterion acute care hospital 1229125 1193423 3 postacute care pluscard wir für gesundheit includes supplemental clinic 58683 58559 0 occupational health insurance provides special service outpatient admission 3985746 3488045 14 high level comfort partner hospital infor mation hospital network pluscard avail key structural data performance indicator developed able wwwwirfuergesundheitde german follows helios also fostering digitalization health care company new helioshub platform first kind 2016 2015 change germany support entrepreneur startup devel acute care hospital 88 87 1 oping innovation directly benefit patient well bed 29618 28914 2 family member physician network 112 length stay day 64 64 0 postacute care clinic 24 24 0 helios hospital across germany offer excellent opportuni bed 5088 5162 1 tie implement pilot project assess improve length stay day 261 264 1 working closely doctor patient please visit occupancy 82 82 wwwhelioshubcom information please refer page 58 f management report 2017 financial outlook fresenius helios information please see fresenius helios website wwwheliosklinikende german 1 special item primarily relating transaction 18 business segment fresenius vamed service project business developed well sale earn ings target achieved order intake exceeded 1 billion mark first time form excellent basis future growth fresenius vamed manages project provides service table show sale development activity hospital health care facility worldwide business segment total portfolio range along entire value chain project fresenius million 2016 2015 change vamed sale development planning turnkey construction via mainte project business 594 575 3 51 nance technical management total operational man service business 566 543 4 49 agement illustrated diagram page 19 offer ings target different area health care prevention acute care postacute care outpatient care range ebit grew 8 69 million 2015 64 million competency enables u support complex health care ebit margin increased 59 2015 57 project facility efficiently successfully stage life business ebit grew 27 million 2015 25 million cycle specialist provider deliver full spec service business 42 million 2015 39 million net trum service worldwide vamed unique position income 1 improved 45 million 2015 44 million thus far successfully completed 800 business low capital intensity reflected project 79 country share property plant equipment bal ance sheet 16 pretax return equity 196 business development 2015 194 2016 fresenius vamed increased sale 4 1160 million 2015 1118 million organic growth 5 project business divestiture reduced sale 1 currency translation project business comprises consulting project devel effect major impact sale opment planning turnkey construction financing man agement project vamed responds flexibly local sale region need client providing customtailored solution total one source also carry project cooperation fresenius million 2016 2015 change vamed sale partner vamed pioneer publicprivate partnership europe 828 833 1 71 ppp model end 2016 24 model africa 98 96 2 8 implemented asiapacific 193 156 24 17 latin america 41 33 24 4 total 1160 1118 4 100 1 net income attributable vamed ag business segment fresenius vamed 19 vamed value chain project business service business project development planning project management service operational management construction technical technical management commercial total operational infrastructural management europe remains vameds strongest sale market ger equipment maintenance medical technology manage many completed construction surgery area ment technical management operational intensive care station main emergency ward well management integrated portfolio service aimed redesigned highrise inpatient building berlin optimal operation health care facility charité hospital first milestone reached largest responsible total operational manage ppp project german health care sector construc ment 52 health care facility 4 continent approxi tion modernization universitätsklinikum schleswig mately 7000 bed 2016 addition part techni holstein uksh austria vamed received additional cal operation service vamed provides service globally order including ppp order general planning con approximately 600 hospital approximately 143000 bed struction financing well technical operation austria continued partnership main radiooncology facility two location vienna decem tained since 1986 vienna general hospital akh one business segment ber 2016 expansion neurological rehabilitation europe largest hospital germany began providing facility completed vienna vamed also manages technical service uksh mid2015 vamed also led project ia poland switzerland consortium responsible technical infrastructural also expanded operation africa including service berlin charité hospital since 2006 addition ghana government commissioned vamed pro vamed signed additional service contract major european vide turnkey construction five regional hospital market germany austria switzerland italy polyclinic tunisia building oncology center 12 facility make u largest private rehabilitation asiapacific region vamed successfully worked provider austria also operate wellknown rehabil realization lifecycle project abu dhabi itation facility switzerland czech republic contract china lao vamed commissioned turnkey construction hospital vamed vitality world latin america vamed managing medical service portfolio vamed vitality world bridge equipment project nicaragua bolivia build gap preventive medicine health care tourism regional hospital market leader austria eight thermal spa wellness resort vamed also operates aqua world buda order intake order backlog project pest hungary largest thermal spa country facility recognized austria internationally million 2016 2015 change innovative service high quality order intake 1017 904 13 order backlog december 31 1961 1650 19 please refer page 58 f management report 2017 financial outlook information please see fresenius vameds website wwwvamedcom service business vamed offer full range facility management service health care facility modular design service offering encompasses every aspect technical commercial infra structural facility management range building 20 management report table content management report 21 fundamental information group 54 overall assessment business situation 21 group business model 22 important market competitive position 22 legal economic factor 54 outlook 22 management control 54 general midterm outlook 23 capital shareholder article association 55 future market 25 goal strategy 56 health care sector market 26 corporate performance criterion 58 group sale earnings 27 fresenius cease voluntary u gaap reporting 58 sale earnings business segment 27 research development 59 financing 29 employee 59 investment 30 change supervisory board management board 59 procurement 31 procurement 59 research development 31 quality management 60 planned change human resource social area 33 responsibility environmental management sustainability 60 dividend 36 economic report 61 opportunity risk report 36 health care industry 61 opportunity management 36 dialysis market 61 risk management 38 market generic iv drug clinical nutrition 62 risk area management report infusion therapy medical device 70 assessment overall risk transfusion technology 39 hospital market 40 market project service hospital health care facility 40 overall business development 40 management board assessment effect general economic development health care sector fresenius 40 management board assessment business result significant factor affecting operating performance 41 comparison actual business result forecast 42 result operation financial position asset liability 42 result operation financial position 45 51 asset liability 53 corporate rating management report fundamental information group 21 management report 2016 successful year fresenius met guidance achieved 291 billion sale 16 billion net income operating cash flow margin 123 fundamental information renal pharmaceutical among important group product line addition fresenius medical care offer dialysisrelated service among others field care group business model coordination fresenius global health care group legal form fresenius kabi specializes intravenously adminis se co kgaa partnership limited share offer tered generic drug iv drug clinical nutrition infu product service dialysis hospital outpatient sion therapy company also supplier medi medical care addition fresenius focus hospital oper cal device product transfusion technology management report ations also manage project provide service company sell product mainly hospital hospital health care facility worldwide fresenius helios largest hospital operator ger operating business comprises four business segment many end 2016 fresenius helios operated legally independent entity managed total 112 hospital around 35000 bed germany operating parent company fresenius se co kgaa busi addition 88 acute care hospital including 7 maxi ness segment regional decentralized structure mum care hospital berlinbuch duisburg erfurt krefeld schwerin wiesbaden wuppertal helios fresenius medical care offer service product group 24 postacute care clinic following patient chronic kidney failure december 31 closing acquisition quirónsalud january 2017 2016 fresenius medical care treated 308471 patient fresenius helios also largest private hospital ope 3624 dialysis clinic dialyzer dialysis machine rator spain end 2016 quirónsalud operated 43 hospital 39 outpatient center around 300 occupa tional risk prevention center group structure fresenius vamed manages project provides service hospital health care facility worldwide fresenius se co kgaa portfolio range along entire value chain project development planning turnkey construction 31 100 100 77 via maintenance technical management total fresenius fresenius fresenius fresenius operational management medical care kabi helios vamed 22 management report fresenius international sale network maintains fiscal year however slightly negative currency translation approximately 90 production site large production site effect income statement resulted particular located united state china japan germany depreciation latin american currency chinese sweden production plant also located euro yuan euro 2016 fiscal year result pean country latin america asiapacific south exchange rate change 109 u dollar decem africa ber 31 2015 105 u dollar december 31 2016 balance sheet total increased 2 due currency trans important market competitive lation effect position legal aspect significantly affected busi fresenius operates 80 country subsid ness performance 2016 iaries main market north america europe 47 38 sale respectively management control fresenius medical care hold leading position world legal form kgaa company corporate body wide dialysis care serf 10 dialysis general meeting supervisory board patient well dialysis product market share general partner fresenius management se fresenius man 34 fresenius kabi hold leading market position agement se wholly owned else krönerfresenius europe significant market share growth stiftung kgaa twotier management system market asiapacific latin america united state management control strictly separated fresenius kabi one leading supplier generic general partner represented management iv drug fresenius helios largest hospital operator board conduct business represents company germany following closing acquisition dealing third party management board generally quirónsalud january 2017 also largest private seven member according management board hospital operator spain fresenius vamed one rule procedure member accountable world leading company field area responsibility however member joint responsibility management group addi legal economic factor tion supervisory board fresenius se co kgaa management report overall legal economic factor fresenius group fresenius management se supervisory board largely unchanged lifesaving lifesustaining management board required report supervisory product therapy group offer intrinsic board fresenius management se regularly particular importance people worldwide therefore market corporate policy strategy business profitability fundamentally stable relatively independent economic current operation matter could cycle detailed information market please see significance company profitability liquidity page 36 ff supervisory board fresenius management se also advises furthermore diversification across four business supervises management board management segment global reach provide additional stability company prohibited managing company group directly however management board rule procedure fluctuating exchange rate particularly require obtain approval supervisory board u dollar euro effect income fresenius management se specific activity statement balance sheet euro exchange rate member management board appointed unchanged yearonyear 111 u dollar dismissed supervisory board fresenius manage material effect income statement 2016 ment se appointment dismissal accordance article 39 se regulation article association fresenius management se also provide deputy member management board may appointed management report fundamental information group 23 supervisory board fresenius se co kgaa advises increase subscribed capital fresenius se co supervises management company business kgaa total amount 12096 million general partner review annual financial statement may 15 2019 single multiple issuance consolidated financial statement performs new bearer ordinary share cash contribution function assigned law company arti contribution kind authorized capital cles association involved corporate planning shareholder preemptive right subscription strategy matter fundamental importance excluded company supervisory board fresenius se co kgaa six shareholder representative six employee represen report general partner pursuant section 203 2 tatives nomination committee supervisory board sentence 2 german stock corporation act aktg fresenius se co kgaa instituted election pro conjunction section 186 4 sentence 2 aktg con posals shareholder representative activity junction section 278 3 aktg partial utiliza aligned provision law corporate gover tion authorized capital resolved annual share nance code shareholder representative elected holder meeting 16 may 2014 general meeting fresenius se co kgaa euro 2 september 2016 management board general pean work council elect employee representative partner consent supervisory board com supervisory board fresenius se co kgaa pany resolved substantiated another reso supervisory board must meet least twice per calen lution 12 january 2017 partially utilize autho dar halfyear supervisory board fresenius se co rization granted pursuant article 4 4 article kgaa two permanent committee audit committee association increase company share capital consisting five member nomination committee 6108176 issuing 6108176 new nonpar value ordinary consisting three member member committee bearer share way capital increase contribu listed page 195 annual report company tions kind excluding shareholder subscription right annual corporate governance declaration describes proce implementation capital increase 545727950 dures supervisory board committee declara 551836126 registered commercial register tion found page 72 86 annual report 31 january 2017 volume capital increase management report website wwwfreseniuscomcorporategovernance equivalent 112 share capital time description compensation system utilization individual amount paid management board super new nonpar value share carry dividend entitle visory board fresenius management se super ments 1 january 2016 issued hc investment visory board fresenius se co kgaa included bv contribution kind share idc salud slu compensation report page 87 99 annual report quirónsalud capital increase made compensation report part group manage context acquisition share quirónsalud ment report aggregate amount 576 billion cash debtfree basis implemented part 4548101 capital shareholder article 32518921 quirónsalud share issuance new association share apart cash purchase price subscribed capital fresenius se co kgaa amounted contributed 4548101 share represent 14 547208371 ordinary share december 31 2016 value quirónsalud december 31 2015 545727950 exclusion subscription right based share fresenius se co kgaa nonparvalue authorization pursuant article 4 4 subsection 2 bearer share share represents 100 capital article association increase share capital stock shareholder right regulated german stock contribution kind acquisition company corporation act aktg aktiengesetz opportunity act quickly flexibly used best fresenius management se general partner authorized subject consent supervisory board fresenius se co kgaa 24 management report interest company thereby requirement debt share capital conditionally increased financing purchase price could reduced value 2520000000 issuance new ordinary bearer contribution kind adequate relation value share conditional capital iv conditional capital new share due limited volume capital increase implemented extent increase shareholder wish maintain sharehold subscription right issued accor ing quota could acquire additional share via dance stock option program 2013 stock exchange thus interest shareholder term holder subscription right exercise right financial interest voting right appropri company grant share satisfy ately protected subscription right addition following conditional capital company authorized may 15 2019 purchase conditional capital ii adjusted stock use share maximum amount 10 option exercised meantime subscribed capital addition purchasing share company authorized use equity derivative subscribed capital conditionally increased possible exclusion tender right company 501758500 issuance new bearer ordi utilized authorization december 31 2016 nary share conditional capital conditional capi largest shareholder else krönerfreseniusstiftung tal increase executed extent con bad homburg germany informed company decem vertible bond ordinary share issued ber 16 2016 held 144695094 ordinary share 2003 stock option plan holder con fresenius se co kgaa corresponds equity interest vertible bond exercise conversion right 2644 december 31 2016 subscribed capital conditionally increased amendment article association made 598088800 issuance new bearer accordance section 278 3 section 179 2 ordinary share conditional capital ii conditional german stock corporation act aktg conjunction capital increase executed extent article 17 3 article association fresenius se subscription right issued 2008 stock co kgaa unless mandatory legal provision require management report option plan holder subscription right exer wise amendment article association require sim cise right company use ple majority subscribed capital represented share service subscription right exer resolution voting result tie motion deemed cise right make payment cash rejected furthermore accordance section 285 2 general partner authorized approval sentence 1 german stock corporation act aktg supervisory board may 15 2019 issue option amendment article association require consent bearer bond convertible bearer bond general partner fresenius management se several time total nominal amount 25 bil supervisory board entitled make amendment lion fulfill granted subscription right sub article association concern wording scribed capital fresenius se co kgaa increased without resolution general meeting conditionally 4897120200 issuance certain circumstance change control new bearer ordinary share conditional capital iii result takeover bid could impact longterm conditional capital increase shall implemented financing agreement contain customary change con extent holder convertible bond issued trol provision grant creditor right terminate cash warrant option bond issued agreement early request early repayment outstand cash exercise conversion option right long ing amount case change control termina form settlement used tion right partly become effective change control followed decline company rating respective financing instrument management report fundamental information group 25 goal strategy ing product united state market share goal strengthen position fresenius lead expanded launch new product ing global provider product therapy critically field iv drug infusion therapy clinical nutrition chronically ill people four business segment well medical device transfusion technology concentrating limited number health care 112 hospital fresenius helios operating area thanks clear focus developed unique nearly whole germany building fresenius competency following longterm strategy helios position develop new patient care consistently seizing opportunity model take advantage growth opportuni tie arising privatization consolidation pro key element fresenius group strategy goal cess german hospital market january 2017 fresenius helios closed acquisition quirónsalud spain largest operator private hospital open expand market position worldwide presence opportunity exploiting synergy expansion fresenius seek ensure expand longterm posi construction hospital potential tion leading international provider product consolidation highly fragmented private hospital service health care industry end geo market spain graphically expand business plan grow organi fresenius vamed expand position cally well selective small mediumsized global specialist project service hospital acquisition complementing existing portfolio health care facility focus market strong growth rate strengthen innovation fresenius strategy continue fresenius medical care worldwide leader building strength technology competence dialysis strong market position united state quality patient care ability manufacture future opportunity dialysis arise costeffectively want develop product system international expansion dialysis care product provide high level safety userfriendliness well expansion field care coordination enable tailoring individual patient need intend area fresenius medical care offer additional ser continue meet requirement bestinclass management report vice dialysis patient include eg vascular medical standard developing offering effec care service laboratory service well hospital tive product treatment method critically ist intensivist service expanding business chronically ill company address growing need integrated enhance profitability last least goal patient care improve group profitability contain cost con fresenius kabi market leader infusion therapy centrating particularly making production plant clinical nutrition europe key market efficient exploiting economy scale leveraging asiapacific latin america united state existing marketing distribution infrastructure fresenius kabi one leading player market intensively practicing strict cost control generic iv drug addition fresenius kabi one focusing operating cash flow employing effi important provider transfusion technol cient working capital management increase ogy fresenius kabi plan roll product investment flexibility improve balance sheet ratio existing portfolio growth market launch exist another goal optimize weighted average cost capital wacc deliberately employing balanced mix equity debt funding present capital market 26 management report financial performance indicator growth profitability liquidity capital efficiency capital management sale growth operating income ebit operating cash flow ebit net debt constant currency financial result sale income tax ebitda income tax sale growth minority interest cash flow margin nopat leverage ratio organic invested capital net income roic ebit growth constant currency ebit operating asset net income growth rooa constant currency condition optimize cost capital hold liquidity net debt ebitda ratio within range 25 30 please corporate level cash flow margin used main see following section corporate performance criterion liquidity indicator order analyze optimize page 42 53 detail contribution business segment operating cash flow also use additional performance indicator dso 1 report goal detail outlook section day sale outstanding soi 1 scope inventory page 54 60 show amount receivables inventory relation sale cost service rendered past corporate performance criterion reporting period management board make operational strategic management decision based groupwide performance capital efficiency indicator growth profitability liquidity capital efficiency work profitably efficiently possible capital management important financial per capital provided u shareholder lender order management report formance indicator u explained defini manage primarily calculate return invested tion provided glossary financial term page capital roic return operating asset rooa 2 200 202 capital management growth sale use ratio net debt ebitda key parameter line growth strategy sale growth constant managing capital structure measure indicates currency group business segment organic degree company able meet payment sale growth particular central importance obligation business segment usually hold leading position growing mostly noncyclical market since profitability majority customer high credit quality use earnings interest tax ebit ebit generate mainly stable predictable cash flow group growth constant currency measure profitability therefore able use debt finance growth greater segment group level primarily use net income extent company industry net income growth constant currency order able better compare operating performance several period result also adjusted special item 1 reflect core performance indicator 2 detailed calculation roic rooa please see page 200 202 management report fundamental information group 27 investment process r expense segment investment carried using detailed coordination evaluation process first step management board set group investment target budget based fresenius medical care 29 investment proposal next step respective busi fresenius kabi 71 ness segment internal acquisition investment council aic determine proposed project measure taking account overall strategy total investment budget required potential return investment 2016 500 million evaluate investment project based commonly used method internal rate return irr net present value npv based investment volume project sub research development mitted approval executive committee respective product process development improvement management business segment management therapy core growth strategy fresenius board fresenius management se supervisory board focus r effort core competency following area fresenius cease voluntary u gaap reporting dialysis fresenius se co kgaa publicly traded company based generic iv drug european union member country required prepare infusion nutrition therapy publish consolidated financial statement accordance medical device international financial reporting standard ifrs pursu ant section 315a german commercial code hgb apart new product concentrating develop addition compulsory ifrs accounting fresenius ing optimized completely new therapy treatment meth also publishes consolidated u gaap financial statement od service provided comparability group largest sub research development expense 500 million management report sidiary fresenius medical care required report 2015 464 million approximately 56 product accordance u gaap socalled pooling sale 2015 52 fresenius medical care increased r agreement however fresenius medical care 2016 annual spending 17 fresenius kabi increased r spend general meeting lifted obligation ing 5 detailed figure included segment report interest harmonizing management ing page 106 f accounting fresenius group business seg december 31 2016 2770 employee ments fresenius group business segment research development 2015 2247 number report solely accordance ifrs starting 816 employed fresenius medical care 2015 671 2017 fiscal year 1954 fresenius kabi 2015 1576 key figure research development 2016 2015 2014 2013 2012 r expense million 500 464 369 348 305 product sale 56 52 48 46 44 r employee 2770 2247 2107 1969 1903 28 management report main research site europe united state especially emerging market work india productrelated development activity also carried conducted development center china china r project mainly conducted location house external research commissioned limited scale fresenius kabi fresenius kabis research development activity concen fresenius medical care trate product therapy care critically complex interaction side effect lead kidney chronically ill patient product help support medical failure better explored today ever techno advancement acute postacute care improve logical advance develop parallel improve possibili patient quality life tie treating patient r activity fresenius development expertise includes related com medical care aim translate new insight novel devel ponents drug raw material pharmaceutical opments bring market quickly possible formulation primary packaging medical device thus make important contribution towards rendering needed application drug infusion produc treatment patient increasingly comfortable safe tion technology individualized area iv drug continuously working global r portfolio management seek extension drug portfolio aim launch new standardize basic function single component generic drug formulation directly patent therapy system internationally standardize process branded product expire also develop new formulation control structure allows u address local require nonpatented iv drug 2016 107 active pro ments reduce development time bundle jects area generic focus among item resource benefit vertical integration complex formulation active ingredient liposo development new technology application mal1 solution develop readytouse product give u access experience patient specialized especially convenient safe including example medical personnel readytouse solution freeflex infusion bag pre 2016 fresenius medical care continued filled syrinx drug prefilled syrinx simpler management report develop product introduce innovation including new safer use traditional application help therapy system 6008 care system optimizes dialysis improve patient care treatment minimizes operating step required clinical nutrition provides care patient cannot procedure consists new allinone cartridge system nourish normally sufficiently includes completely preconnected bloodline treatment example patient intensive care serious modality since also reduces amount waste dialysis chronic illness malnourishment early correct treatment 6008 care system simultaneously cost intervention help patient avoid malnutrition con efficient environmentally friendly sequence addition 2016 collected first clinical data parenteral nutrition devote effort product new dialyzer modified inner wall hollow make significant contribution improving clinical fiber produce hemocompatible fiber surface treatment nutritional condition patient inno enabled u reduce heparin requirement standard dialy vative container multichamber bag si treatment safe convenient everyday use 2016 contin working partner develop portfolio ued development parenteral formulation focus stateoftheart technology automated peritoneal dial formulation designed meet need individual ysis apd patient group addition researching new parenteral also developing portfolio product meet strictest requirement term quality efficiency 1 liposome tiny capsule used vehicle active pharmaceutical ingredient allow targeted transportation ingredient location needed within organism management report fundamental information group 29 nutrition product enable optimized absorption employee region nutrient research development work also includes development marketspecific parenteral formulation latin america region 8 2016 worked product united state asiapacific 10 china among market development enteral nutrition concen europe 51 trate new product packaging order take account thereof germany 36 north america 31 specific requirement local market would like break addition working development formulation facilitate daily intake 2016 232873 enteral nutrition product patient work medical device transfusion technology included expansion product range application personnel expense fresenius group 11671 technology agilia brand make possible u offer million 2016 2015 10862 million equivalent 401 broad portfolio safe efficient application technology sale 2015 393 increase 7 mainly attri inpatient outpatient last year developed butable increase headcount salary increase infusion pump allows patient administer painkiller acquisition personnel expense per employee 510 analgesic intravenously form pain thousand 2015 493 thousand 512 thousand therapy usually used surgery new pump agilia constant currency germany fresenius company connect pca software link help simplify dayto signed tariff agreement ig bce marburger bund day operation patient safety medical care plan verdi labor union service significant introduce new pump 2017 structural change compensation employment agree ments 2016 employee knowledge experience commitment employ human resource management ee critical success reason fresenius constantly adapting human resource tool meet management report value culture diversity interplay wide range new requirement arising demographic transfor view opinion cultural background experience val mation service economy skill shortage compati ues help u achieve full potential contributes bility job family life example offer flexible success working hour longterm account longterm pro number employee increased 232873 employee fessional planning employee voluntarily contribute vacation end 2016 5 last year day make contribution salary long term account use training nursing care early retirement number employee dec 31 2016 dec 31 2015 change total fresenius medical care 116120 110242 5 50 fresenius kabi 34917 33195 5 15 fresenius helios 72687 69728 4 31 fresenius vamed 8198 8262 1 4 corporate 951 878 8 0 total 232873 222305 5 100 30 management report part identity health care company includes creating fresenius group devotes lot attention vocational right condition foster health employee training trained 3700 young people 30 2016 fresenius se co kgaa named healthy com different occupation german location 2016 pany gesundes unternehmen initiative award also put 100 university student 15 degree focus attention throughout germany company set program cooperation dual institution higher especially high standard promotion health learning order meet challenge digitization workplace work process fresenius increased number training study place offer related profes employee recruitment personnel sion offer new dual course study example development area digital medium alongside traditional channel order ensure longterm need highly quali direct job entry fresenius offer trainee program uni fied employee met recruit new employee versity graduate make use online personnel marketing regularly participate fresenius involved two initiative vocational recruiting event career fair organize integration young refugee bad homburg frankfurt recruiting event addition encourage longterm reten main aim initiative integrate refugee tion attractive development program vocational training voca approach measure employee recruitment tional orientation phase successfully completed personnel development business segment initial qualification based market requirement segment visit awardwinning career portal coordinated developed realized independently wwwcareerfreseniuscom business segment support development employee profes profitsharing scheme sional personal skill across group personal stock option plan career talk well comprehensive range many year paid stockbased profitsharing training session seminar continue expand bonus distributed fresenius group ebit hierarchy level earnings target defined program management report fresenius promotes longterm sustainable advance achieved table show development ment woman fresenius qualification profitsharing bonus last several year thing matter selection personnel consequently long term incentive program 2013 global com fresenius woman men comparable qualification pensation instrument linking management entrepreneurial continue career opportunity responsibility future opportunity risk comprises december 31 2016 proportion female employee stock option plan 2013 well phantom stock within fresenius group 68 woman also held 30 plan 2013 combine granting stock option senior management position based number granting phantom stock award informa worldwide participant stock option plan detailed infor tion stock option please see page 173 ff annual mation statutory target participation woman report men management position available within corporate governance declaration pursuant section 289 change supervisory board german commercial code hgb website see management board wwwfreseniuscomcorporategovernance well page general meeting may 13 2016 prof dr med iris 84 annual report löwfriedrich m hauke star elected profitsharing bonus 2015 2014 2013 2012 2011 profitsharing bonus 1 2200 2335 2134 2164 2036 eligible employee 2 2385 2310 2155 2313 2220 1 profitsharing bonus paid retroactively respective fiscal year form part compensation german group company 2 without eligible employee fresenius medical care ag co kgaa management report fundamental information group 31 cost material business segment 1 quality management quality product service therapy fresenius vamed 9 basis optimal medical care process subject highest quality safety standard benefit fresenius helios 15 patient protect employee quality man fresenius medical care 52 agement following three main objective fresenius kabi 24 identify valueenhancing process oriented toward efficiency need customer monitor manage process basis 2016 7599 million performance indicator 1 consolidation improve procedure supervisory board shareholder representative m stefanie fresenius medical care lang m frauke lehmann mr oscar romero de paco lifesaving treatment highest demand placed elected european work council employee dialysis term safety quality applies representative board supervisory board production dialysis product administra fresenius se co kgaa law requires quota least tion dialysis treatment hospital rea 30 woman 30 men mandatory quota son fresenius medical care established quality manage met supervisory board election 2016 ment system production site dialysis clinic june 26 2016 fresenius se co kgaa announced commission regular external audit use supervisory board fresenius management se europe german technical certification organiza unanimously appointed stephan sturm 52 chief executive tion tüv audit clinical organization annually verify officer fresenius july 1 2016 stephan sturm suc compliance iso 9001 quality management ceeds dr ulf mark schneider 50 decided leave iso 14001 environmental management united state company effective june 30 2016 pursue another oppor clinic monitored center medicare management report tunity medicaid service cm public health care authority also regularly review quality management system procurement internal audit 2016 cost raw material supply pur measure compare quality performance chased component service 7599 million dialysis clinic using generally recognized quality standard 2015 7493 million increased 1 due business addition industryspecific clinical benchmark expansion include quality target set fresenius medical care linked service advice provide exam million 2016 2015 ple fresenius medical care us quality parameter cost raw material supply 6572 6466 generally recognized dialysis industry eg hemo cost purchased component service 1027 1027 globin value total 7599 7493 fresenius kabi efficient value chain important profitability global quality management system fresenius kabi environment characterized ongoing costcontainment pres based internationally recognized iso 9001 standard sure health insurer well price pressure security includes example good clinical practice gcp quality supply play crucial role within business good manufacturing practice gmp good distribution practice segment fresenius group procurement process gdp code federal regulation cfr u food coordinated centrally enabling u bundle similar require ments negotiate global framework agreement constantly monitor market price trend ensure safety quality material 32 management report drug administration fda iso 13485 quality helios quality performance indicator extract management standard medical device global quality indication standardized mortality ratio management system certified audited tüv süd smr 1 2016 smr 2015 smr 2 quality management comprises chronic obstructive pulmonary disease copd 071 077 acute myocardial infarction ami 070 074 global process standard specialist team develop heart failure 058 065 enterprisewide standard guideline ischemic stroke 082 086 implemented subsidiary country pneumonia 062 069 early warning system established reporting hip fracture 080 082 process standard procedure unforeseen event 1 mr 1 corresponds german average smr 1 mean mortality german average evaluated key performance indicator 2 adjusted helios hospital niederberg acquired 2016 german federal statistical office 2014 reference value converted giqi 50 new reference value 2017 eg complaint rate information found wwwheliosklinikendemedizinqualitaetsmanagement global product risk management safety officer respond immediately informed problem quality patient safety manage product recall expanded helios quality management system centrally conversion giqi indicator version 50 improved key figure updated reference rate used 2017 fresenius kabi inspection regulatory authority statistical abnormality arise helios examines audit independent organization customer per peer review process using patient data issue formed along entire value chain hygiene remains focus 2016 first time inter however quality management system professional team assembled address selected issue extend internal process also cover application area intensive care medicine example spe product service customer order able cially trained employee nursing occupation supported receive information issue timely manner medical team 11 19 peer review process deal appropriately fresenius kabi set addition make intensive use pool quality global monitoring reporting system vigilance sys indicator eg obstetrics created part statutory quality management report tem responsible regulatory authority monitor sys assurance result peer review procedure instruction tem keep increasingly close eye interest training program initiated make childbirth even patient safety safer 2016 made progress transferring goal helios establish interdisciplinary quality management process electronic quality system group treatment patient malignant tumor global system support harmonization medical advisory board 10 experienced helios chief process availability data risk prevention physician various discipline produce quarterly quality analysis monitor implementation helios wide fresenius helios decision helios us procedure combine internal measure addition helios involved initiative quality quality management use quality indicator medicine iqm exchange idea knowledge use key figure administrative data measure quality hospital operator iqm member committed observing medical outcome treatment quality medical three basic principle quality measurement adminis outcome resulting different treatment measured trative data publication result peer review process using key indicator compiled administrative data made transparent basis giqi quality indicator german inpatient quality indicator 2016 management report fundamental information group 33 iqm member provide acute care approximately 63 four different category vamed company respon million patient 400 hospital germany sible technical operation akh vienna including switzerland germany share acute care 30 excellence award prize winner exemplary european defined specific target 46 1 giqi quality company employee success 2010 2013 innovation indicator target set level national 2012 customer benefit 2015 average germany 2016 achieved target 43 addition fresenius vamed company certified quality indicator success rate 93 2015 91 accordance numerous relevant technical standard convinced transparency creates best three facility managed vamed austria incentive improvement helios provides full transparency obtained certification jci joint commission inter quality data acute care hospital result national hospital certified highest medical treatment quality result patient survey level quality firstly regarding patient care secondly regar key indicator field hygiene published ding hygiene safety thirdly regarding patient website wwwheliosklinikende helios exceeds mandatory employee satisfaction status regularly confirmed legal requirement recertification process provided jci national quality institute iqtig commis sioned federal joint committee recommend quality responsibility environmental indicator form suitable basis qualityoriented management sustainability decision hospital planning initial indicator orient activity within fresenius group long area gynecological surgery obstetrics breast surgery term goal thus ensure work aligned collected external inpatient quality assu need patient employee well shareholder rance established tested 2017 business partner sustainable manner responsibil onwards quality management system helios ity health care group go beyond business opera prepared new procedure tions committed protecting nature basis life using resource responsibly mission fresenius vamed constantly improve performance area environ planning construction hospital fresenius vamed mental protection occupational health technical safety management report set high quality standard particular aimed product responsibility logistics comply optimizing process care level ensuring maximum legal requirement flexibility use building ward international iso standard 14001 environmental internally fresenius vamed design process effi management implemented various production plant ciency sustainability using interdisciplinary quality dialysis clinic among thing key standard based iso 9001 quality management environmental performance indicator instance system iso 13485 quality management system medical energy water consumption also volume device iso 17020 inspection medical device product waste recycling rate location iso 17025 competence testing calibration laborato europe production site subject eu reg ries iso 14001 environmental management iso 19600 com ulation reach registration evaluation authorization pliance management system iso 50001 systematic energy ch emicals aim reach protect human health management iso 27001 information security management environment hazard risk chemical system efqm standard european foundation substance quality management efqm already granted award 1 decision specialist gynecology march 2016 indicator nonabdominal hysterectomy upgraded observed value target value 2016 total 46 goal attainable 34 management report 2016 fresenius established groupwide project expand fresenius kabi sustainability reporting part expansion integral component quality management fresenius carried extensive materiality analysis fourth quar kabi environmental management system complies ter involved relevant internal external international standard iso 14001 fresenius kabi ag stakeholder continue project 2017 plan several site certified standard also report extensively 2017 annual report implemented occupational health safety assessment system ohsas 18001 several site set guideline fresenius medical care site worldwide 2016 site fresenius kabi environmental management operation deutschland gmbh certified iso 50001 inter work comply environmental regulation make national standard energy management system internati product process resourceefficient also sup onally production unit wuxi china la châtre port business segment creating added value france also iso 50001certified continued implement client ecofriendly product service environmental measure production site worldwide europe middle east africa emea tüvcerti specific focus outside europe fied environmental management part integrated site graz austria able keep energy management system end 2016 eight 2015 eight consumption previous year level despite higher pro european production site medical device develop duction volume expanded production area three heat ment department certified according iso 14001 exchanger installed recover heat flash steam use energy management system per iso 50001 boiler blowdown warmingup city water german production site st wendel schweinfurt fed steam boiler measure possible also implemented certified environmental manage reduce gas consumption steam boiler addi ment system 14 2015 14 european country tion gas burner renewed reduce gas con one central concern reduce sumption emission specifically nox recycling pack environmental effect dialysis treatment central aging material nearly 2200 ton co2 saved element managing resource efficiency dialysis recycling rate 80 could maintained 2016 center emea latin america software econ5 uppsala site sweden energy consumption per management report use 526 2015 518 european 213 2015 liter solution produced unchanged 28 kwh l 209 latin american dialysis center 2016 approximately 42 energy needed swedish environmental data management system allows site uppsala brunna provided renewable source u capture compare data resource efficiency take 2015 40 maintained recycling rate 995 prompt advantage opportunity improvement production site pune india reduced 2009 2016 reduced average water con briquette consumption 8 compared previ sumption per dialysis treatment 7 electricity con ous year period able reduce water sumption 15 dialysis center additionally consumption 5 haina site dominican able reduce amount contaminated blood waste republic reduced plastic waste 30 last year significantly last year goal keep reduced electricity consumption 8 using figure already low level comply existing new lighting airconditioning technology legal framework future moreover environmental program established 2013 aim reduce average water consumption per dialysis treatment 11 electricity consumption 7 2018 management report fundamental information group 35 fresenius helios fresenius vamed hospital require great deal energy water order project business already integrate national environ create awareness among employee economical mental standard regulation planning con use resource intensified environmental struction hospital health care facility vameds campaign within helios extensive expertise environmental management structural condition hospital building impor important success factor especially growth market africa tant influence energy consumption new construction asia sewage treatment disposal medical project modernization conform latest standard technology waste meet highest possible standard efficient heat insulation accordance current energy also achieved success service business saving regulation improvement based area environmental protection vamed instance comprehensive controlling system real estate manage responsible technical management akh ment enables u compare target actual value hospital vienna 30 year period regularly promptly compared previous year adjusted energy water consumption significantly reduced energy consumption reduced 3 represents energy consumption decreased 14 demand long co2 reduction around 1571 mg save approximately distance heat 23 drinking water consumption 14 million usefully invested medicine 45 volume waste classified hazardous medical system also formed basis certification waste akh fell 90 helios hospital accordance requirement since 2015 energy management fresenius new energy service act energiedienstleistungsgesetz vamed austria certified compliant iso edlg continually review measure reduce 500012011 resource required implement measure promptly possible addition continue shift heating renewable energy instance wood pellet form heating co2neutral therefore ecofriendly gas oil heating helios still us electricity heat fossil fuel natural gas built combined heat power management report plant nine site thanks step taken saved approximately 4680 mg co2 2016 2015 29747 mg co2 water consumption helios hospital 4760500 m3 2015 4434810 m3 majority water consumed sterilization process process cooling water recycling plant reduce consumption ho pitals using well water instance cooling tow er airconditioning system proper waste disposal great importance hospital helios view waste disposal management process start avoiding future waste end consis tent recycling environmentally friendly disposal requirement pertaining environmental protection occupational health safety infection protection hospital hygiene taken account relates particu larly major waste group clinical waste ie diagnosis treatment human disease 2016 total amount clinical waste generated helios ho pitals 21560 2015 20775 36 management report economic report previous year united state highest per caput spending u 9451 germany ranked sixth among health care industry oecd country per caput spending u 5267 health care sector one world largest industry germany 85 health spending funded pub relatively insensitive economic fluctuation compared lic source 2015 average 73 oecd sector posted aboveaverage growth country past several year oecd country enjoyed large gain life expectancy past decade thanks improved main growth factor living standard public health intervention progress medical care 2014 average life expectancy oecd rising medical need deriving aging population country 806 year growing number chronically ill multimorbid health care structure reviewed costcutting patient potential identified order contain steadily rising stronger demand innovative product therapy health care expenditure however measure cannot advance medical technology compensate cost pressure marketbased element growing health consciousness increase increasingly introduced health care system demand health care service facility create incentive cost qualityconscious behavior overall treatment cost reduced improved emerging country additional driver quality standard addition evergreater importance placed disease prevention innovative reimbursement expanding availability correspondingly greater model linked treatment quality standard demand basic health care important market developed follows increasing national income hence higher spending health care dialysis market 2016 global dialysis market product service time cost health care rising claim worth approximately u 76 billion constant currency management report ing everincreasing share national income health care global dialysis market grew 4 spending averaged 90 gdp oecd country worldwide approximately 37 million patient chronic 2015 average u 3814 spent per caput renal failure treated 2016 patient around 30 million received dialysis treatment 726000 living transplanted kidney 88 treated hemodialysis 12 peritoneal dialysis health care spending gdp 2015 2000 1990 1980 1970 usa 169 125 113 82 62 france 110 95 80 67 52 germany 111 98 80 81 57 switzerland 115 93 74 66 49 source oecd health data 2016 source oecd health data 2016 management report economic report 37 major growth driver growing number patient dialysis patient region suffering diabetes high blood pressure two dis eas often precede onset chronic kidney failure latin america 10 number dialysis patient worldwide increased 6 2016 u japan western central europe patient growth slower economically north america 21 asiapacific 45 weaker region growth mostly 6 prevalence rate number people terminal kidney failure treated per million population differs europe middle east africa 24 widely region region developing country 2016 2980000 patient well 100 average 1100 country european union prevalence high country japan united state well 2000 dialysis reimbursement system differ country coun significant divergence prevalence rate due try often vary even within individual country public one hand difference age demographic incidence health care program center medicare medicaid renal risk factor genetic predisposition cultural habit service cm cover medical service majority nutrition hand access dialysis treat dialysis patient united state ment still limited many country great many individ uals terminal kidney failure receive treatment dialysis product therefore included prevalence statistic 2016 global dialysis product market worth approximately u 14 billion dialysis care fresenius medical care leading provider dialysis 2016 global dialysis care market including renal product world market share 34 pharmaceutical worth approximately u 62 billion followed largest competitor baxter 28 10 worldwide dialysis patient treated competitor held singledigit percentage market fresenius medical care 3624 dialysis clinic 308471 share management report dialysis patient 45 country fresenius medical care fresenius medical care leading supplier worldwide operates far largest international network hemodialysis product market share 38 clinic united state fresenius medical care treated market share approximately 21 fresenius medical care approximately 38 185000 dialysis patient 2016 secondlargest provider worldwide product peri market dialysis care united state already toneal dialysis baxter highly consolidated taken together fresenius medical care davita another provider dialysis care treat 75 care coordination u dialysis patient field care coordination currently includes service outside united state market dialysis care relating vascular cardiovascular endovascular surgery much fragmented fresenius medical care com nondialysis laboratory testing physician practice service petes mainly clinic chain independent clinic well coordinating hospitalist intensivist service clinic affiliated hospital specialist physician health plan service coordinated delivery pharmacy service care service example 38 management report united state fresenius medical care provides care stay less nursing care estimate 3 regarding euro coordination among others within network pean union situation indicate many 20 million indi 2200 provider working across entire acute episode viduals risk malnutrition market clinical care emergency medicine hospitalists intensivists nutrition fresenius kabi one leading company transitional care provider around 350 hospital worldwide parenteral nutrition company lead postacute facility company cared 15 mil ing supplier worldwide market enteral nutrition lion patient 2016 fresenius kabi one leading supplier europe parenteral nutrition competitor include baxter b braun market generic iv drug clinical kelun pharmaceutical market enteral nutrition nutrition infusion therapy medical fresenius kabi competes among others danone device transfusion technology 1 nestlé abbott global market generic iv drug clinical nutrition fresenius kabi considers global market infusion infusion therapy medical device transfusion technology therapy worth 5 billion 2016 worth 48 billion 2016 growth european market due restriction thereof global market generic iv drug worth imposed use blood volume substitute region 29 billion 2 fresenius kabi able enter addi asiapacific latin america africa market infu tional market segment global addressable market due sion therapy grew 8 selected market infusion thera targeted investment expansion product pie electrolyte standard medical product portfolio among others area complex formulation hospital worldwide market growth mainly driven increas liposomal solution prefilled syrinx ing product demand emerging market fresenius kabi europe united state market iv drug market leader infusion therapy europe competitor grew 12 growth mainly achieved product include baxter b braun brought market original drug go global market medical device transfusion patent well original offpatent product technology worth 6 billion 2016 including offered steady price due unique selling proposition approximately 4 billion medical device additionally market growth based sharp price increa 2 billion transfusion technology market grew management report s single molecule individual competitor approximately 3 2016 medical device market united state important generic iv drug market main growth driver itbased solution focus fresenius kabi company one leading supplier application safety therapy efficiency transfusion competitor include pfizer sandoz teva pharmaceutical technology market growth driven generally increased industry demand blood bag emerging market new therapy global market clinical nutrition worth treatment reduced demand blood bag europe 8 billion 2016 europe market grew 2 united state related overcapacities involve price emerging market asiapacific latin america reduction africa clinical nutrition market saw growth 10 medical device segment fresenius kabi rank individual country growth potential offered among leading supplier worldwide international com often insufficient administration nutrition therapy within petitors include baxter b braun becton ickinson patient care although study demonstrated medi company well icu medical transfusion technol cal economical benefit case health ageinduced ogy fresenius kabi one world leading compa nutritional deficiency example administration ny competitor include haemonetics macopharma clinical nutrition reduce hospital cost shorter terumo 1 arket data based company research refers fresenius kabis addressable market subject annual volatility due currency fluctuation patent expiry original drug iv drug market among thing 2 market definition adjusted compared prior year among others sale volume nonpatented branded drug included 3 german society nutritional medicine dgem 2009 ljungqvist clinical nutrition 2010 29 149 150 management report economic report 39 hospital market 1 hospital bed operator 2015 market acute care hospital germany 94 billion 2 personnel cost accounted 62 private hospital 18 hospital cost material cost 38 personnel material cost rose approximately 4 increase admission organic growth public hospital 48 acute care hospital market around 1 addition independent nonprofit potential growth private hospital operator arises hospital 34 hospital acquisition privatization although economic situation improved com 2015 499351 pared previous year third 33 german hospital source german federal statistical office 2016 recorded loss 2015 10 broke even 57 able generate profit year difficult economic financial situation often accompanied fresenius helios leading hospital operator germany significant investment need due large part share 6 acute care market ho investment backlog accumulated pitals fresenius helios compete mainly individual past federal state failed meet statutory obligation hospital local regional hospital association among finance necessary investment major maintenance private hospital chain main competitor asklepios measure sufficiently due budget constraint rhönklinikum sana kliniken time investment need driven technological advance socalled change value figure relevant higher quality requirement necessary modernization increase reimbursement hospital treatment rheinischwestfälisches institut für wirtschaftsforschung used compensate rising cost hospital market rwi estimate annual investment requirement particularly regard personnel material cost german hospital including university hospital least change value figure redetermined year fol 55 billion twice funding investment cur lowing year year 2016 295 2015 253 rently provided federal state postacute care market germany comprised 1152 management report number hospital 2015 1956 clinic total 165013 bed twothirds number bed 499351 figure ger 66 private preventive postacute care clinic man hospital market please see table 16 independent nonprofit clinic 18 public clinic number treated patient nationwide remained nearly unchanged 197 million average length stay 253 day 2014 253 day key figure inpatient care germany change 2015 2014 2013 2012 2011 2015 2014 hospital 1956 1980 1996 2017 2045 12 bed 499351 500680 500671 501475 502029 03 bed per 1000 population 611 618 621 624 626 11 length stay day 73 74 75 76 77 14 number admission million 1924 1915 1879 1862 1834 05 average cost per admission 1 5060 4893 4792 4663 4547 34 1 total cost gross source german federal statistical office 2016 1 recent data available german hospital market 2 total cost gross german hospital less academic research teaching source german federal statistical office 2016 german hospital institute dki krankenhaus barometer 2016 oecd health data 2016 rheinischwestfälisches institut für wirtschaftsforschung rwi krankenhaus rating report 2016 40 management report closing acquisition spain largest private process outsourcing medicaltechnical support hospital group quirónsalud january 2017 private service external specialist enables hospital con spanish hospital market become relevant market centrate core competency treating patient 13 billion 2015 particular increasing 1 emerging market focus building developing number privately insured patient opening growth infrastructure improving level health care opportunity private operator spain private health fresenius vamed one world leading company insurance required order make use service market company competitor cover private hospital among factor comparatively short comprehensive portfolio service across entire life waiting time scheduled treatment make private ho cycle worldwide competitor offer part fresenius pitals attractive private supplemental insurance spain vameds service portfolio depending service com relatively inexpensive pany competes international company consortium opportunity private hospital operator expand well smaller local provider network building additional new hospital open potential since market highly fragmented overall business development also considerable consolidation potential quirónsalud clear market leader market management board assessment share 10 private hospital market term effect general economic development sale quirónsalud competes large number stand health care sector alone private hospital well smaller regional hospi fresenius tal chain asisa hm hospitales hospiten ribera overall development world economy salud sanitas vithas negligible impact industry 2016 whole health care sector mature growth market market project service developed positively continued increasing demand hospital health care facility health service positive effect business market project service hospital development health care facility fragmented therefore management report market size cannot determined market country management board assessment specific depends large extent factor b usiness result significant factor public health care policy government regulation level affecting operating performance privatization well demographic economic management board opinion fresenius political condition market established health care group performance 2016 excellent sale system mounting cost pressure challenge ho earnings growth across business segment pitals health care facility increase effi fresenius medical care sale increased 7 ciency demand especially high sustainable plan u 17911 million increase mainly due good ning energyefficient construction optimized hospital development health care service net income attributable shareholder fresenius medical care excluding onetime item increased 16 2 fresenius kabi achieved organic 1 market data based company research related addressable market quirónsalud market definition neither include public private partnership ppp occupational risk prevention center orp market definition may differ definition context eg regulatory definition 2 2016 acquisition u 15 million tax 2015 settlement cost agreement principle granuflo naturalyte case u 37 million tax acquisition u 9 million tax management report economic report 41 sale growth 5 increased ebit 1 3 5 con expectation especially fresenius kabi united stant currency 1224 million new product launch state improved group earnings guidance twice united state led better expected development year region organic sale growth fresenius helios forecast currencyadjusted sale growth 4 increase admission price increase hospi achieved fresenius group 6 well line tal service contributed organic growth company targeted range net income 2 increased 13 increased ebit 7 682 million fresenius vamed 1 constant currency well line targeted achieved organic sale growth 5 ebit grew 8 range 12 14 69 million fresenius invested 1621 million property plant equipment 2015 1512 million line comparison actual business result budgeted level 6 percentage sale forecast operating cash flow 3574 million 2015 3327 2016 assumed strong demand prod million cash flow margin 123 2015 120 ucts service would continue proved case therefore expectation expected table show guidance development 2016 achieve cash flow margin 9 11 group well business segment based strong business development exceeding original achieved group target 2016 target 2016 guidance guidance announced announced announced achieved february 2016 august 2016 october 2016 2016 group sale growth constant currency 6 8 6 net income 1 growth constant currency 8 12 11 14 12 14 13 fresenius medical care 2 management report sale growth constant currency 7 10 7 net income growth 3 4 15 20 16 fresenius kabi 5 sale growth organic low singledigit 3 5 4 6 5 ebit growth constant currency roughly flat 3 5 4 6 5 fresenius helios sale growth organic 3 5 4 ebit 670 700 682 fresenius vamed sale growth organic 5 10 5 ebit growth 5 10 8 1 n et income attributable shareholder fresenius se co kgaa 2015 integration cost 12 million tax hospital acquired rhönklinikum ag cost efficiency program fresenius kabi 105 million tax disposal gain divestment two helios hospital 34 million tax 2 saving global efficiency program included acquisition 2015 2016 3 net income attributable shareholder fresenius medical care ag co kgaa 4 2016 acquisition u 15 million tax 2015 settlement cost agreement principle granuflo naturalyte case u 37 million tax acquisition u 9 million tax hence basis net income outlook 2016 u 1057 million 5 2015 cost efficiency program fresenius kabi 105 million tax 1 2 015 special item 2 net income attributable shareholder fresenius se co kgaa 2015 special item detailed overview special item please see reconciliation table page 44 special item reported group corporate segment 42 management report group net debt ebitda 234 1 thus level sale growth analysis approximately 25 level originally expected 1 1 group roic increased 850 2 2015 826 3 6 1 group rooa 1013 2 2015 1011 3 hence 5 expected level 2015 result operation financial position asset liability result operation organic sale acquisition divestiture currency total sale sale growth growth 2016 increased group sale 6 constant cur rency 5 actual rate 29083 million 2015 27626 million chart right show various million dialysis product sale increased 2 influence fresenius group sale 3065 million due improved sale dialyzer 2016 major effect due change product acute care treatment dialysis machine product mix expected organic sale growth 7 acquisition net con price effect occurred fresenius medical care medi tributed 1 care reimbursement rate remained virtually unchanged fresenius kabi increased sale 1 6007 million 2016 personnel cost increased 2015 5950 million sale growth mainly driven sale growth region shown table new product launch united state company achieved organic sale growth 5 divestiture reduced sale growth business segment follows sale 1 negative currency translation effect 3 mainly related euro appreciation fresenius medical care increased sale 7 8 latin american currency chinese yuan constant currency 16181 million 2015 15086 fresenius helios increased sale 5 5843 million management report million mainly due good development 2015 5578 million increase admission health care service sale increased 9 price increase hospital service contributed organic 13116 million care coordination north america sale growth 4 acquisition contributed 1 sale increased 23 23 constant currency 2084 growth sale region currency organic translation acquisition total million 2016 2015 change sale growth effect divestiture sale north america 13735 12621 9 7 0 2 47 europe 10839 10557 3 3 0 0 38 asiapacific 2928 2779 5 8 2 1 10 latin america 1223 1297 6 12 16 2 4 africa 358 372 4 2 6 0 1 total 29083 27626 5 6 1 0 100 1 average exchange rate last 12 month net debt ebitda pro forma acquisition 2 pro forma acquisition 3 special item management report economic report 43 fresenius vamed increased sale 4 1160 million group ebitda 2 increased 8 5500 million 2015 2015 1118 million divestiture reduced sale 1 5073 million corresponds increase 9 sale project business increased 3 594 mil constant currency group ebit 2 increased 9 lion 2015 575 million sale service business 4327 million 2015 3958 million corresponds grew 4 566 million 2015 543 million increase 10 constant currency increase sale due new existing business order intake project business developed well ebit development business segment follows increased level 1 billion first time 2015 904 million fresenius vamed increased fresenius medical care ebit increased 14 con order backlog 19 1961 million december 31 stant currency 14 2383 million 2015 2097 2015 1650 million fresenius vamed busi million unchanged medicare reimbursement rate ness segment within fresenius group whose business north america offset cost saving procure significantly determined order intake order ment side pharmaceutical product cost saving backlog global efficiency program ebit margin fresenius medical care group increased 147 2015 earnings structure 139 adjusted onetime item 3 ebit increased group net income 1 2 rose 12 1593 million 2015 10 u 2599 million 1423 million growth constant currency 13 fresenius kabis ebit 2 increased 3 5 constant earnings per share 1 2 rose 292 2015 261 rep currency 1224 million 2015 1189 million resents increase 12 actual rate 13 increase mainly driven new product launch constant currency weighted average number share solid sale earnings growth united state 5464 million ebit 2 margin increased 204 2015 200 inflation significant effect result operation fresenius helios increased ebit 2 7 682 million 2016 2015 640 million ebit 2 margin increased 117 2015 115 increase attributable increased admission continuous cost efficiency management report improvement hospital clinic sale business segment organic currency sale translation acquisition total million 2016 2015 change growth effect divestiture sale fresenius medical care 16181 15086 7 7 1 1 56 fresenius kabi 6007 5950 1 5 3 1 20 fresenius helios 5843 5578 5 4 0 1 20 fresenius vamed 1160 1118 4 5 0 1 4 order intake order backlog fresenius vamed million 2016 2015 2014 2013 2012 order intake 1017 904 840 744 657 order backlog december 31 1961 1650 1398 1139 987 1 net income attributable shareholder fresenius se co kgaa 2 2015 special item 3 2016 acquisition u 39 million tax 2015 settlement cost agreement principle granuflo naturalyte case u 60 million tax acquisition u 16 million tax detailed overview special item please see reconciliation table page 44 special item reported group corporate segment 44 management report fresenius vamed increased ebit 8 69 million earnings structure special item 2015 64 million ebit margin increased 59 2015 57 100 686 reconciliation group net income group u gaap financial result december 31 2016 comprise special item whereas financial result december 31 2015 comprise special item order show operating performance group reporting period relevant position profit 165 314 group gross loss statement adjusted special item profit margin table show special item reconciliation 149 ebit margin net income special item earnings according u gaap sale cost operating sale expense development major item statement income group gross profit rose 9128 million exceeding group sale decreased 686 2016 compared previous year gross profit 8534 million 7 8 691 2015 constant currency gross margin increased 314 selling general administrative expense consisted 2015 309 cost sale rose 5 19955 primarily personnel cost marketing distribution million 2015 19092 million cost sale percentage cost depreciation amortization expense rose 3 4301 million 2015 4195 million increase primarily due business expansion ratio management report reconciliation q1 4 q1 4 2016 2015 q1 4 integration disposal according q1 4 integration disposal according 2016 cost gain 2015 cost gain kabi acquired two u gaap kabi acquired two u gaap special efficiency rhön helios incl spe special efficiency rhön helios incl spe million item program hospital hospital cial item item program hospital hospital cial item sale 29083 29083 27626 27626 ebit 4327 0 0 0 4327 3958 105 12 34 3875 interest result 582 582 613 613 net income tax 3745 0 0 0 3745 3345 105 12 34 3262 income tax 1051 0 0 0 1051 983 16 2 0 965 net income 2694 0 0 0 2694 2362 89 10 34 2297 less noncontrolling interest 1101 1101 939 939 net income 1 1593 0 0 0 1593 1423 89 10 34 1358 1 net income attributable shareholder fresenius se co kgaa cost reported group corporate segment management report economic report 45 percentage group sale therefore decreased 148 financial position 2015 152 r expense 500 million 2015 464 million 6 targeted range financial management policy goal approximately 4 5 product sale depreciation financing strategy fresenius group follow amortization 1173 million 2015 1115 million ing main objective ratio percentage sale 40 2015 40 group personnel cost increased 11671 million 2015 ensure financial flexibility 10862 million personnel cost ratio 401 2015 optimize weightedaverage cost capital 393 chart left show earnings structure 2016 ensuring financial flexibility key financing strategy group net interest decreased 582 million 2015 fresenius group achieved broad 613 million mainly due favorable financing term spectrum financing instrument taking market capacity interest rate saving lower net debt investor diversification flexibility credit covenant group tax rate special item 281 current maturity profile consideration group hence prioryear level 2015 294 maturity profile characterized broad spread maturi noncontrolling interest increased 1101 million tie large proportion mid longterm financing 2015 939 million 96 attributable also take account currency earnings noncontrolling interest fresenius medical care cash flow generated selecting financing table page 46 show profit margin development instrument match appropriate debt struc 2016 tures respective currency statement income summary change million 2016 2015 change constant currency sale 29083 27626 5 6 cost good sold 19955 19092 5 6 management report gross profit 9128 8534 7 8 selling general administrative expense 4301 4195 3 4 research development expense 500 464 8 8 ebit 4327 3875 12 12 net interest 582 613 5 5 income tax 1051 965 9 10 noncontrolling interest profit 1101 939 17 17 net income special item 1 1593 1423 12 13 net income 1 1593 1358 17 18 earnings per ordinary share special item 1 292 261 12 13 earnings per ordinary share 1 292 250 17 18 ebitda 5500 4990 10 11 depreciation amortization 1173 1115 5 6 1 net income attributable shareholder fresenius se co kgaa detailed overview special item please see reconciliation table page 44 special item reported group corporate segment 46 management report financing mix fresenius group line group structure financing fresenius medical care rest fresenius group con commercial paper 4 ducted separately joint financing facility equityneutral mutual guarantee fresenius kabi fresenius helios convertible bond 6 fresenius vamed business segment financed prima financial rily fresenius se co kgaa order avoid liability 6 senior note 50 structural subordination schuldschein loan 8 syndicated loan 26 financing fresenius meet financing need combination dec 31 2016 14780 million operating cash flow generated business segment short mid longterm debt addition bank group main debt financing instrument shown loan important financing instrument include issuance chart including financing activity related senior note schuldschein loan convertible bond acquisition quirónsalud slight shift commercial paper program receivable securitization within financing mix program sufficient financial cushion assured fresenius financing activity past fiscal year group unused syndicated bilateral credit line addi mainly related acquisition idc salud holding slu tion fresenius se co kgaa fresenius medical care quirónsalud total purchase price 576 billion ag co kgaa maintain commercial paper program 536 billion debtfinanced 400 million paid fresenius medical care receivable securitization program form new fresenius se co kgaa share issued offer additional financing option authorized capital following financing activity another main objective fresenius group financing carried strategy optimize weightedaverage cost capital employing balanced mix equity debt due october 2016 2013 senior credit agreement company diversification within health care sector increased 12 billion incremental facility management report strong market position business segment global consist incremental revolving credit facility 300 growing noncyclical market predictable sustain million incremental term loan 900 million able cash flow generated allow reasonable due 2020 incremental facility disbursed proportion debt ie use comprehensive mix january 31 2017 financial instrument capital increase may also consid ered exceptional case ensure longterm growth example finance major acquisition 2016 2015 2014 2013 2012 ebitda margin 1 189 184 176 191 200 ebit margin 1 149 143 136 150 159 return sale tax noncontrolling interest 1 129 121 110 121 125 1 2012 2015 special item detailed overview special item please see reconciliation table page 44 special item reported group corporate segment management report economic report 47 december 2016 fresenius se co kgaa placed 10 maturity profile fresenius group billion schuldschein loan tranche five seven financing facility 1 ten year fixed variable interest rate fund million ing schuldschein loan took place january 31 4800 2017 4400 january 2017 fresenius finance ireland plc issued 4000 3600 senior note aggregate volume 26 billion 3200 split four tranche maturity five year 700 2800 million coupon 0875 issue price 99732 2400 seven year 700 million coupon 1500 issue price 2000 99875 10 year 700 million coupon 2125 1600 1200 issue price 99359 15 year 500 million cou 800 pon 3000 issue price 99275 senior 400 note drawn newly established fresenius 0 european medium term note emtn program 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 also january 2017 fresenius se co kgaa issued 1 december 31 2016 major financing instrument pro forma quirónsalud acquisition 26 billion senior note 12 billion senior credit 500 million equityneutral convertible bond due 2024 agreement incremental facility 10 billion schuldschein loan 500 million equityneutral convertible bond bond bear interest issued price 10100 initial conversion price 1070979 represents 45 premium fresenius reference share price 738606 concurrently december 2016 fresenius medical care extended placement bond fresenius purchased maturity receivable securitization program call option share fully hedge risk high repay u 800 million december 2019 ment obligation instrument result issuance new share upon conversion bond chart show maturity profile due successful closing longterm financing fresenius group management report acquisition quirónsalud december 2016 fresenius se co kgaa fresenius medical care january 2017 bridge facility fresenius se co kgaa ag co kgaa maintain commercial paper program place since september 2016 10 billion shortterm debt voluntarily terminated arranged small issued december 31 2016 178 million fresenius group bank amount 375 billion se co kgaas commercial paper program utilized fresenius medical care ag co kgaas commercial addition measure related acquisition quirón paper program 476 million outstanding salud following financing activity general corporate fresenius group drawn 44 billion bilat purpose took place 2016 eral syndicated credit line addition decem ber 31 2016 group approximately 34 billion march 2016 fresenius u finance ii inc issued unused credit line available including committed credit schuldschein loan aggregate volume line 28 billion credit facility generally u 400 million tranche five seven year used covering working capital need excep fixed floating interest rate tion syndicated credit agreement fresenius se co kgaa fresenius medical care usually unsecured 48 management report december 31 2016 fresenius se co kgaa cash flow million fresenius medical care ag co kgaa including sub sidiaries complied covenant debt arrange 3866 292 ments 3574 1603 detailed information fresenius group financing found page 136 144 note information financing requirement 2017 included outlook section page 59 1971 1223 effect offbalancesheet financing instrument financial position liability fresenius involved offbalancesheet transaction 748 could significant impact financial position expense income result operation liquidity investment asset liability capitalization cash flow change operating capex net cash flow acquisition cash flow working cash flow acqs dividend acqs liquidity analysis capital dividend dividend 2016 key source liquidity operating cash flow cash inflow financing activity including short mid longterm debt cash flow operation influ funding mostly provided syndicated credit facility enced profitability business fresenius fresenius se co kgaa fresenius medical care net working capital especially account receivable cash well senior note schuldschein loan convertible inflow financing activity generated shortterm bond fresenius convinced existing credit facili borrowing commercial paper program tie inflow senior note issuance well oper drawing bilateral bank credit agreement additionally ating cash flow additional source shortterm fund receivables fresenius medical care account receiv ing sufficient meet company foreseeable liquidity management report able securitization program sold mid longterm need financial position fiveyear overview million 2016 2015 2014 2013 2012 operating cash flow 3574 3327 2585 2320 2438 sale 123 120 111 114 126 working capital 1 6839 6090 5448 4571 4470 sale 235 220 235 225 232 investment property plant equipment net 1603 1462 1323 1047 952 cash flow acquisition dividend 1971 1865 1262 1273 1486 sale 68 68 54 63 77 1 trade account receivable inventory less trade account payable payment received account management report economic report 49 dividend investment operating cash flow depreciation general partner supervisory board propose amortization million fiveyear overview dividend increase annual general meeting 2016 3574 3327 dividend 062 per share proposed increase 3172 13 total dividend distribution increase 2754 2585 14 343 million 2015 300 million cash flow analysis 2438 2320 2450 cash flow increased 11 3866 million 2015 3469 1621 1512 million change working capital 292 million 1345 1173 2015 142 million mainly due business expansion oper 1007 1073 1115 926 ating cash flow increased 7 3574 million 2015 937 843 776 3327 million despite u 100 million discretionary cash 517 contribution fresenius medical care pension plan asset united state cash flow margin 123 2012 2013 2014 2015 2016 2015 120 operating cash flow sufficient investment acquisition operating cash flow meet financing need investment activity excluding depreciation amortization acquisition whereby cash used capital expenditure 1628 million proceeds sale property plant equipment 25 million 2015 1489 million fresenius medical care shareholder dividend 27 million respectively paid third party 270 million primarily relating cash flow acquisition dividend 1971 fresenius medical care payment offset million 2015 1865 million sufficient finance dividend 76 million fresenius se co kgaa group dividend 738 million group dividend con received shareholder fresenius medical care net sisted dividend payment 300 million sharehold acquisition expenditure 485 million financed er fresenius se co kgaa payment 244 million cash flow management report cash flow statement summary million 2016 2015 change margin earnings tax 2694 2297 17 depreciation amortization 1173 1115 5 change pension provision 1 57 102 cash flow 3866 3469 11 133 change working capital 292 142 106 operating cash flow 3574 3327 7 123 property plant equipment 1628 1489 9 proceeds sale property plant equipment 25 27 7 cash flow acquisition dividend 1971 1865 6 68 cash used acquisition proceeds disposal 485 32 dividend 738 639 15 cash flow acquisition dividend 748 1194 37 cash provided used financing activity without dividend paid 238 1343 82 effect exchange rate change cash cash equivalent 25 18 39 change cash cash equivalent 535 131 detailed cash flow statement shown consolidated financial statement 50 management report cash used financing activity without dividend pay investment region ments 238 million 2015 1343 million 2016 predominantly characterized reduction debt region 6 due strong free cash flow refinancing measure asiapacific 6 cash cash equivalent increased 535 million 1579 million december 31 2016 december 31 north america 41 europe 47 2015 1044 million cash cash equivalent posi tively influenced currency translation effect 25 mil lion 2015 18 million 2016 1621 million investment acquisition 2016 fresenius group provided 2547 million 2015 2029 million investment acquisition investment fresenius helios acquisition spending mainly property plant equipment increased 1621 mil purchase 100 share klinikum niederberg lion 2015 1512 million 56 sale 2015 55 ggmbh germany well acquisition outpatient well depreciation level 1173 million facility serf basis enabling expansion preserving company value long term total 926 million main investment property plant equipment invested acquisition 2015 517 million total follows capital expenditure 2016 64 invested property plant equipment 36 spent acquisition optimization expansion production facility pri table show distribution investment marily north america europe fresenius medical acquisition business segment chart right show care fresenius kabi primarily europe north regional breakdown america asia cash outflow acquisition primarily related modernization existing equipping new dialysis following business segment clinic fresenius medical care management report fresenius medical care invested mainly acquisition new building modernization hospital fresenius dialysis clinic expansion care coordi helios accounting 352 million significant nation business individual project hospital schleswig duis fresenius kabi invested primarily acquisition burg pforzheim wiesbaden u production facility portfolio seven iv drug investmentsacquisitions business segment thereof property plant thereof million 2016 2015 equipment acquisition change total fresenius medical care 1705 1244 931 774 37 67 fresenius kabi 436 389 322 114 12 17 fresenius helios 390 376 352 38 4 15 fresenius vamed 11 15 11 0 27 1 corporate 5 5 5 0 0 0 total 2547 2029 1621 926 26 100 management report economic report 51 investment acquisition asset liability million 2016 2015 change investment property asset liability structure plant equipment 1621 1512 7 total asset group rose 8 46447 million thereof maintenance 54 48 dec 31 2015 42959 million constant currency thereof expansion 46 52 increase 6 increase mainly driven busi investment property plant equipment ness expansion currency translation effect latter sale 56 55 resulted increase balance sheet total 09 acquisition 926 517 79 billion inflation significant impact asset total investment acquisition 2547 2029 26 fresenius 2016 current asset increased 11799 million dec 31 2015 10479 million within current asset trade account investment property plant equipment 273 million receivable increased 10 5052 million dec 31 2015 made 2017 continue major ongoing invest 4596 million 63 day average day sale outstanding ment project reporting date investment previous year level 61 day obligation mainly hospital fresenius helios well inventory rose 12 3189 million dec 31 2015 investment expand optimize production facility 2860 million scope inventory 2016 58 day fresenius medical care fresenius kabi project dec 31 2015 55 day ratio inventory total asset financed operating cash flow increased 69 dec 31 2015 67 noncurrent asset increased 7 34648 million acquisition idc salud holding slu dec 31 2015 32480 million constant currency quirónsalud increase 5 addition property plant equipment september 5 2016 fresenius helios announced sign goodwill effect goodwill amount ing purchase agreement acquire 100 share 22774 million dec 31 2015 21523 million proven capital idc salud holding slu quirónsalud spain sustainable increased mainly due acquisition total purchase price 576 billion made fiscal year 2016 due currency translation effect management report seller private equity group cvc capital part fiscal year 2016 addition goodwill acqui ners víctor madera founder ceo quirónsalud sitions 692 million please see page 131 ff note member quirónsaluds management board quirón information salud spain largest private hospital operator cover shareholder equity including noncontrolling inter full spectrum inpatient outpatient care est rose 13 20420 million dec 31 2015 18003 approval relevant antitrust authority received million constant currency shareholder equity including december 22 2016 transaction closed noncontrolling interest rose 11 group net income january 31 2017 quirónsalud consolidated feb ruary 1 2017 52 management report attributable fresenius se co kgaa increased sharehold 1162 million liability due one year er equity 1593 million equity ratio including 12843 million dec 31 2015 13607 million noncontrolling interest 440 december 31 2016 group net debt decreased 4 5 constant cur dec 31 2015 419 rency 13201 million dec 31 2015 13725 million liability equity side balance sheet show net debt equity ratio including noncontrolling inter solid financing structure total shareholder equity includ est gearing 65 dec 31 2015 76 ing noncontrolling interest cover 59 noncurrent asset return equity tax equity attributable dec 31 2015 55 shareholder equity noncontrolling shareholder fresenius se co kgaa decreased interest longterm liability cover noncurrent asset 127 dec 31 2015 130 1 return total asset 65 inventory tax noncontrolling interest increased longterm liability decreased 2 16299 million 58 2015 55 1 december 31 2016 dec 31 2015 16661 million group roic increased 850 2 2015 826 1 shortterm liability increased 16 8544 million group rooa 1013 2 2015 1011 1 within posi dec 31 2015 7348 million tion invested capital goodwill 228 billion sig group major accrual major signifi nificant effect calculation roic important cance individual item take account approximately 62 goodwill group debt remained nearly unchanged 14780 mil attributable strategically significant acquisition lion dec 31 2015 14769 million constant currency national medical care 1996 renal care group helios decrease 2 relative weight balance sheet kliniken 2006 app pharmaceutical 2008 liberty dia 32 dec 31 2015 34 approximately 52 lysis holding 2012 hospital rhönklinikum ag group debt denominated u dollar liability due 2014 significantly strengthened competitive less one year 1937 million dec 31 2015 position fresenius group asset liability fiveyear overview million 2016 2015 2014 3 2013 3 2012 3 management report total asset 46447 42959 39788 32663 30558 shareholder equity 1 20420 18003 15483 13260 12758 total asset 1 44 42 39 41 42 shareholder equity 1 noncurrent asset 59 55 52 54 57 debt 14780 14769 15345 12709 10922 total asset 32 34 39 39 36 gearing 65 76 92 73 2 79 1 including noncontrolling interest 2 pro forma excluding advance made amount 218 billion fiduciary agreement acquisition hospital rhönklinikum ag 3 adjusted due debt issuance cost restatement u gaap standard asu 201503 1 015 special item 2 2 pro forma acquisition detailed overview special item please see reconciliation table page 44 special item reported group corporate segment management report economic report 53 summary show roic rooa business segment corporate rating credit quality fresenius assessed regularly roic rooa reviewed leading rating agency moody standard 2016 2015 2016 2015 poor fitch july 2016 rating agency fitch fresenius medical care 1 78 69 104 96 upgraded corporate credit rating fresenius bb fresenius kabi 2 104 106 127 132 bbb stable outlook standard poor moody fresenius helios 2 81 77 84 81 fresenius vamed 3 105 111 raised fresenius rating investmentgrade status 2015 group 1 2 85 83 101 101 1 2016 pro forma acquisition table show company rating respective 2 2015 special item 3 roic invested capital insignificant due prepayment cash cash equivalent outlook december 31 2016 rating fresenius se co kgaa 2016 fresenius group return invested capital dec 31 2016 dec 31 2015 roic substantially exceeded cost capital wacc standard poor weighted average cost capital fresenius medical corporate credit rating bbb bbb care 51 wacc business segment outlook stable stable 59 moody corporate credit rating baa3 baa3 outlook stable stable currency interest risk management fitch nominal value foreign currency hedging contract corporate credit rating bb b bb 2635 million december 31 2016 con outlook stable stable tract market value 7 million nominal value interest rate hedging contract 647 million contract market value 3 million please see risk report page 68 f note page 162 169 detail management report fiveyear overview financing key figure dec 31 2016 2 dec 31 2015 1 dec 31 2014 1 2 dec 31 2013 3 dec 31 2012 1 2 debt ebitda 27 29 37 27 28 net debt ebitda 4 23 6 27 32 25 26 net debt ebitda 5 24 7 27 34 25 25 ebitda net interest 95 83 68 67 58 1 efore special item b 2 pro forma acquisition 3 pro forma excluding advance made amount 218 billion fiduciary agreement acquisition hospital rhönklinikum ag special item 4 ltm average exchange rate net debt ebitda 5 net debt yearend exchange rate ebitda ltm average exchange rate 6 pro forma quirónsalud acquisition net debt ebitda 31 7 pro forma quirónsalud acquisition net debt ebitda 32 54 management report overall assessment care technical advance driven also still business situation insufficient access health care developing emerging country aboveaverage growth time group management report prepared opportunity u market asia management board continued assess development latin america also africa efficient health care sys fresenius group positive demand prod tems appropriate reimbursement structure ucts service continues grow steadily around world evolve time country economic condi tions improve strengthen activity outlook region introduce product portfolio market successively management report contains forwardlooking statement expansion regional presence fastgrow including statement future sale expense invest ing market asiapacific latin america africa ments well potential change health care sector especially offer potential strengthen market competitive environment financial situation position china instance offer excellent growth statement made basis expectation opportunity longterm infusion assessment management board regarding event nutrition therapy iv drug medical device could affect company future basis fresenius kabi also fresenius medical care midterm planning forwardlooking statement dialysis plan roll additional product subject matter course risk uncertainty assump therapy existing portfolio country tions factor actual result including yet offer comprehensive range acquisition financial position profitability fresenius could largest private hospital operator spain quirón therefore differ materially positively negatively salud give fresenius helios presence outside germany expressly implicitly assumed described growth opportunity spain arise exploiting syn statement information please see opportu ergies expansion construction hospital nities risk report page 61 ff consolidation potential highly fragmented spanish private hospital market particular management report general midterm outlook broadening service business fresenius outlook fresenius group coming year con medical care opportunity extend new market tinues positive able treat patient supply expand market share arise country open customer reliably continuously striving optimize cost private dialysis provider allows cooperation adjust capacity improve product mix public private provider publicprivate part well expand product service business nerships whether private company offer dial expect effort increase earnings coming ysis treatment form depends health year addition good growth opportunity fresenius care system country operate presented following factor legal framework addition dialysis product treatment dialysis patient fresenius medical care sustained growth market oper see significant growth potential future medical ate fresenius still see good opportunity benefit service related dialysis expanding coordi growing health care need arising aging nation care include eg vascular care service population growing demand comprehensive laboratory service hospitalist intensivist service fresenius helios extensive nationwide hospital management report overall assessment business situation outlook 55 network based platform fresenius helios aim also exploiting opportunity potential within develop offer innovative integrated care offering operation costmanagement efficiency patient care improved enhancement measure include plan costefficient exchange knowledge experience best practice production furtheroptimized procurement process fresenius helios quirónsalud cross outlook take account event known time selling quirónsaluds facility occupational risk pre annual financial statement prepared could vention within spanish hospital network offer addi influence operating performance 2017 beyond sig tional growth opportunity nificant risk discussed risk report past broadening product business fresenius utmost achieve possible exceed medical care see renal pharmaceutical growth target driver complement dialysis portfolio add horizontal expansion portfolio offer future market growth potential line strategic goal expect consolidation process continue among com growing trend offering integrated care petitors market europe asiapacific latin fresenius kabi plan expand iv drug product america consequently expect opportu business develop generic drug formulation nities u penetrate new market expanding ready launch time market formation directly regional presence extending product portfolio patent branded product expire also new market open fresenius medical care suc develop new formulation nonpatented drug cessively roll product service portfolio especially develop readytouse product espe emerging country addition fresenius medical care cially convenient safe including example prefilled continues expand care coordination business ser syrinx readytouse solution freeflex infu vice related dialysis care coordination fresenius sion bag medical care address need dialysis patient even development innovative product therapy comprehensively create potential expand fresenius kabi plan introduce product already market position region addition innovation offered outside united state country well management report bestinclass quality reliability convenience also aim roll product portfolio interna product therapy key factor dial tionally especially fastgrowing market asiapacific ysis business expect home therapy gain latin america market share expanded importance leading growth potential fresenius launch new product field iv drug medical care home dialysis corresponding tech medical device infusion therapy clinical nutri nologies product continue major focus tion well transfusion technology r activity addition fresenius kabi devel broad hospital network across germany oping new dosage form product fresenius helios able develop new patient care model selective acquisition besides retaining organic sale addition acquisition opportunity expected growth basis business continue arise german hospital market increasing num utilize opportunity grow making small mid ber privately insured patient spain opening sig sized acquisition expand product portfolio nificant opportunity private operator like quirónsalud strengthen regional presence fresenius vamed expecting grow life cycle ppp project area regard project service business moreover company intends fur ther expand position followup order well enter new target market 56 management report health care sector market driven development infrastructure establish health care sector considered widely indepen ment health care system growing number dent economic cycle demand especially life chronically ill patient overproportional growth expected saving lifesustaining product service expected asia latin america eastern europe middle east increase given medically needed africa fact large part world population population aging moreover medical advance large life region underscore strong growth poten number disease still difficult cure tial entire spectrum dialysis service product incurable expected remain growth driver overall factor aging population grow emerging country availability basic health ing number people suffering diabetes hyperten care growing demand highquality medical treat sion ailment often preceding terminal kidney fail ment increasing percapita income increase individu ure contributing toward continued growth dialysis al increasingly cope illness associated market age expectancy dialysis patient also rising lifestyle disease thanks ongoing advance treatment quality ri hand expert estimate ﬁnancial ing standard living especially emerging country constraint public sector could result pricing market care coordination open additional pressure slowdown revenue company growth opportunity fresenius medical care health care industry country experiencing signiﬁ information provided page 36 ff cant ﬁnancing problem health care sector due management report strained public finance situation especially industrial ized country increased pressure encourage saving market generic iv drug clinical expected health care cost constitute large portion nutrition infusion therapy medical budget device transfusion technology 1 increasingly important company increase expect global market generic iv drug clinical patient benefit improve treatment quality offer nutrition infusion therapy medical device transfusion preventive therapy addition especially product technology grow approximately 4 5 2017 therapy medically also economically market generic iv drug europe united management report advantageous increasing importance state expected grow 7 9 2017 demand generic drug likely grow signifi dialysis market cantly lower price comparison originator drug price global dialysis market expected grow 4 growth dynamic continue driven originator constant exchange rate 2017 drug going offpatent well original offpatent pro number dialysis patient worldwide expected duct offered steady price due unique selling rise approximately 6 2017 although signiﬁcant proposition factor working opposite direction regional difference remain united state japan price erosion original offpatent drug generic drug country central western europe already market prevalence already relatively high forecast patient growth 2 expected clinical nutrition growth region 0 4 economically weaker market europe 2017 however given ﬁnancial con region growth rate even higher straints country effort contain cost 1 arket data refers fresenius kabis addressable market subject annual volatility due currency fluctuation patent expiry original drug iv drug market among thing source company research management report outlook 57 health care sector pursued undiminished contin effect since helios group well prepared quality ued high growth potential projected asiapaciﬁc latin based remuneration thanks clear focus quality america africa expect growth 10 transparency medical outcome individual country despite higher revenue expectation hospital expect market infusion therapy europe rather pessimistic respect economic situa remain prior year level 2017 besides slightly tion 2017 according krankenhausbarometer 2016 decreasing blood volume substitute market due restriction survey german hospital institute dki quarter imposed use product continuous price 24 hospital expect economic situation pressure tenderdriven standardsolutions business improve whereas 36 expect worsen moreover invest expected affect growth outside europe also expect ment need growing government support declin market infusion therapy remain prior year ing rheinischwestfälisches institut für wirtschafts level 2017 whereby latin america expected grow forschung rwi forecast hospital respond 8 economic pressure joining together network worldwide market medical device transfusion bundling service network offer opportunity indi technology expected grow 4 2017 vidual hospital reduce cost example purchasing anticipate privatization consolidation hospital market continue german hospital market expect acute care hospital market germany expect private hospital market spain grow grow slightly 2017 admission forecast increase 2 3 2017 continuing increase number approximately 1 privately insured patient also open opportuni socalled change value figure relevant tie private operator future important market data increase reimbursement hospital treatment example nationwide health care spending bed den 2017 set 250 addition hospital funding sity indicates spanish health care system lagging system provides various increase reduction behind eu country also provides oppor acute hospital tunities establishment new hospital addition 2016 hospital accept 25 discount fragmented private hospital market expected see management report surplus service agreed advance health insurance consolidation company starting 2017 discount replaced socalled fixed cost degression discount surplus service market project service 35 50 exact amount discount negotiated hospital health care hospital health insurance company facility reduction 65 continues apply surplus service 2017 expect worldwide demand project agreed upon service hospital health care facility grow care supplement replace extra charge low singledigit rate invoiced hospital treatment beginning 2017 central european market established health intended support care hospital granted based care system expect solid growth demand proj cost care individual hospital funding vol ect service hospital health care facility ume 2017 around 500 million expect overall continue grow due demographic change effect increase discount helios earnings rising investment modernization need public health neutral 2017 facility focus service ranging mainte beginning 2018 medical outcome factor nance repair medical hospital equipment facility amount funding purpose federal joint com mittee define quality indicator end 2017 specific financial impact helios cannot cur rently quantified however expect adverse rwi krankenhaus rating report 2013 source company research rheinischwestfälisches institut für wirtschaftsforschung rwi 58 management report management technical operation total oper group financial target ational management infrastructure process optimization target 2017 1 fiscal year 2016 1 especially within framework publicprivate partnership sale growth ppp model additional growth opportunity presented constant currency 15 17 29471 increasing number nonmedical service net income 2 growth constant currency 17 20 1560 outsourced public facility private service provider capital expenditure 6 sale 1633 emerging market anticipate overall dynamic profitdriven proposal development growth market africa latin america dividend dividend policy 13 per share southeast asia initially driven demand 1 data according ifrs 2 net income attributable shareholder fresenius se co kgaa efﬁcient needsoriented medical care china middle east growth driven development infrastruc ture creation new care service well research sale earnings business segment training facility 2017 expect sale earnings development business segment shown group sale earnings fresenius group business segment financial target business segment report solely accordance ifrs starting fiscal target 2017 1 fiscal year 2016 1 year 2017 hence following outlook show 2016 figure fresenius medical care well target 2017 according ifrs detail sale growth 2 please also see page 27 constant currency 8 10 16570 net income 2 3 growth constant currency 7 9 1144 group midterm target fresenius kabi sale growth organic 5 7 6007 target 2020 1 ebit growth sale 2 43 47 bn constant currency 5 7 1171 net income 24 27 bn fresenius helios management report 2 3 sale growth organic 3 5 4 5843 4 1 data according ifrs current ifrs rule 2 comparable exchange rate including small midsize acquisition sale 86 bn 5 6 5843 4 3 net income attributable shareholder fresenius se co kgaa 1020 ebit 1070 5 7 683 4 fresenius vamed sale growth organic 5 10 1160 end fiscal year 2020 group sale expected ebit growth 5 10 69 reach 43 47 billion group net income expected 1 1 data according ifrs increase 24 27 billion 2020 2 effect agreement u department veteran affair justice excluded 2017 expect increase group sale 15 3 net income attributable shareholder fresenius medical care ag co kgaa 4 helios kliniken germany excluding quirónsalud 17 constant currency project group net income 1 5 quirónsalud 11 month consolidated increase 17 20 constant currency 6 thereof quirónsalud 25 billion 7 thereof quirónsalud 300 320 million 1 net income attributable shareholder fresenius se co kgaa management report outlook 59 fiscal year 2017 fresenius medical care expects sale fresenius kabi primarily invest expanding main grow 8 10 constant currency net income taining production facility well introducing new attributable shareholder fresenius medical care manufacturing technology fresenius helios pri ag co kgaa expected increase 7 9 con marily investing new building modernizing stant currency effect agreement u equipping existing hospital newly acquired department veteran affair justice excluded hospital fresenius kabi expects organic sale growth 5 regional focus group investment spending 7 ebit growth constant currency 5 7 europe north america account fresenius helios expects organic sale growth 3 55 35 respectively remainder 5 sale 86 bn thereof quirónsalud 25 bn 1 2 invested asia latin america africa 30 total ebit expected increase 1020 1070 million fund invested germany thereof quirónsalud 300 320 million 2 assume return operating asset rooa 2017 fresenius vamed expects achieve organic return invested capital roic level sale growth 5 10 ebit growth 5 10 2016 due acquisition quirónsalud financing procurement 2017 expect continued strong cash flow cash continue optimizing procurement management flow margin 10 12 2017 price term especially quality key factor addition unused credit line syndicated securing earnings growth bilateral credit facility bank provide u suffi based development financial real cient financial cushion market assume price fluctuation continue 2017 refinancing activity limited due well despite tension easing commodity market balanced maturity profile short medium term end 2017 expect group net debt ebitda 3 within bottom half fresenius selfimposed target research development range 25 30 r activity continue play key role secur management report concluded debt financing acquisition idc ing group longterm growth innovation salud holding slu quirónsalud spain largest private new therapy hospital operator january 2017 plan increase group r spending 2017 approximately 5 product sale reinvested investment research development 2017 expect invest 6 sale property marketoriented research development strict plant equipment 50 capital expenditure timetomarket management process crucial suc planned invested fresenius medical care 20 cess new product continually review r result fresenius kabi 25 fresenius helios remai using clearly defined milestone innovative idea product ning fund intended investment expan development therapy high level quality sion group headquarters fresenius medical care continue provide basis future marketleading posi investment primarily used expansion pro tions given continued costcontainment effort duction capacity optimizing production cost estab health care sector costefficiency combined strong qual lishment new dialysis clinic ity focus acquiring evergreater importance product development improvement treatment concept therapy 1 helios kliniken germany excluding quirónsalud 3 quirónsalud consolidated 11 month 3 calculated expected annual average exchange rate net debt ebitda without large unannounced acquisition 60 management report fresenius medical care continue expand planned change human resource global r product platform home dialysis well asso social area ciated technology product focal point number employee group continue rise activity continue expand range innovative future result expected expansion antic product technology future react growth ipate number employee increase approxi opportunity also aim best meeting demand mately 270000 1 december 31 2016 232873 number integrated care employee expected increase business seg infusion nutrition therapy generic iv drug ments approximately 55 located europe approx primary focus area development fresenius kabi imately 30 north america approximately 15 particular concentrating position offer asiapacific latin america africa corresponding generic drug formulation promptly upon expiration patent originator drug also work dividend ing expand portfolio include additional readytouse dividend increase provided fresenius last product example prefilled syrinx readytouse 23 year show impressive continuity dividend policy solution freeflex infusion bag aim align dividend earnings per share growth fresenius kabi portfolio medical device make special item thus broadly maintains payout contribution safe effective application infusion ratio 20 25 based positive earnings fore solution clinical nutrition continue develop cast expect offer shareholder earningslinked new product improve existing one segment dividend transfusion technology focusing development work device disposable enable safe efficient userfriendly production blood product treat ment specific disease including autoimmune disease management report 1 figure includes 27600 quirónsalud employee take account approximately 7400 contract employee independent doctor management report opportunity risk report 61 opportunity risk report risk management fresenius group exposed number risk due supervisory board complexity dynamic business risk inevitable consequence entrepreneurial activity audit committee opportunity exploited supervisory board ingness take risk provider product service severely management board chronically ill relatively independent economic cycle diversification four business segment operate different segment health care mar group controlling ket global footprint minimize group risk profile experience well strong market posi risk management information system tion serve solid basis reliable assessment risk status report time continue take advantage wideranging opportunity sustainable growth adhoc reporting relevant change risk profile expansion health care market offer fresenius new risk group risk management risk controlling control system opportunity management business segment group segment managing opportunity ongoing integral part cor porate activity aimed securing company longterm success way explore new prospect con solidate improve already achieved responsibility risk management process organization management fresenius group monitoring risk business segment decentralized regional structure enables u recog assigned follows management report nize analyze trend requirement opportunity often fragmented market focus action accord using standardized process risk situation evalu ingly maintain regular contact dialogue research ated regularly compared specified requirement group scientific institution keep close watch negative development emerge response initi market competitor order identify opportunity ated early stage within group opportunity synergy exploited manager responsible required report continuous communication involving exchange relevant change risk profile management information knowhow business segment board without delay anticipated future opportunity fresenius group market kept constant observation close discussed outlook starting page 54 contact maintained customer supplier institution policy allow u swiftly identify risk management react change business environment fresenius risk management system risk management system supported group risk management continuous process identifying con level business segment risk controlling trolling managing risk key tool solid corporate measure management information system governance fresenius risk management system closely linked corporate strategy opportunity recognized risk management system 62 management report detailed monthly quarterly report used identify assumption estimate relevance analyze deviation actual versus planned business externally reported group segment result discussed development addition risk management system includes intensively department responsible preparing control system consists organizational safeguarding group consolidated financial statement matter measure well internal control audit also reviewed discussed quarterly supervisory identify significant risk early stage coun board audit committee teract one individually control mechanism automated manual functionality effectiveness risk management reconciliation procedure precaution put place system reviewed regularly management board assure financial reporting reliable trans internal auditing department conclusion arising action correctly accounted consolidated entity audit taken account ongoing refinement report according groupwide standard deter system allow prompt reaction change environ mined head office regularly adjusted allow ment system thus far proved effective control change made accounting regulation con system also regularly reviewed management board solidation proposal supported system internal auditing department moreover external context reference made comprehensive consolidation auditor review whether control system set internal group balance prevent abuse take care management board suitable early identification maintain strict separation function management con risk would put continued existence company trol evaluation also help ensure risk danger insight gained audit regarding direct impact financial reporting identified con internal financial reporting control taken account trols place minimize moreover change continued development system accounting principle monitored employee involved fresenius ensured scope focus financial reporting instructed regularly compre organizational structure system identifying assessing hensively external expert specialist engaged controlling risk developing countermeasure necessary treasury tax controlling legal depart avoidance risk aligned suitably ments involved supporting preparation finan companyspecific requirement properly cial statement finally information provided verified management report functional however absolute certainty department responsible preparing enable risk fully identified controlled consolidated financial statement fresenius medical care subject control sec internal financial reporting control tion 404 sarbanesoxley act numerous measure internal control assure correct ness reliability accounting process financial risk area reporting thus preparation annual financial statement consolidated financial statement management report general economic risk risk compliance applicable principle fourtier report general operating framework ing process especially promotes intensive discussion present development global economy present ensures control financial result reporting significant risk fresenius group 2017 level ie largely expect overall economic growth continue fresenius affected small extent general local entity economic fluctuation expect demand lifesaving region lifesustaining product service continue business segment grow furthermore fresenius striving firm balance group business main region established emerging market financial data key figure reported discussed compared regular monthly basis prioryear figure budget latest forecast addition parameter management report opportunity risk report 63 risk situation business segment also depends payment amount subject annual adjustment based development market countryspecific political increase cost market basket certain health legal financial condition therefore monitored care item service less productivity adjustment evaluated carefully particularly current macroeconomic esrd ppss quality improvement program qip environment applies example country affect medicare payment based performance budget problem result sovereign debt crisis facility set quality measure dialysis facility particular regard account receivable also fail achieve established quality standard could pay applies possible impact business activity ments particular year reduced 2 based resulting decision united kingdom leave year performance underlying quality measure reviewed european union extended amended annually cm material applies particular initiative new u failure fresenius medical care achieve minimum administration possibly increase import duty potential client quality standard qip could materially change current health care program possible adversely affect business financial condition result reduction corporate tax operation fresenius medical care mitigated impact esrd risk health care sector pps legislative initiative referenced risk related change health care market two broad measure first work medical director major importance fresenius group main risk treating physician make clinical protocol change financing health care system corresponding used treating patient consistent qip good reimbursement system well development new clinical practice negotiates pharmaceutical acquisition product therapy cost saving addition fresenius medical care achieved greater efficiency better patient outcome introduc financing health care ing new initiative improve patient care upon initiation reimbursement system dialysis increasing percentage patient using home largely regulated business environment change therapy achieving additional cost reduction law also respect reimbursement major clinic management report impact business sucess applies especially working health care provider group also known united state large portion sale gener esrd seamless care organization escos cm plan ated change government reimbursement test new comprehensive esrd care model payment system particular example reimbursement care delivery seek deliver better health outcome dialysis treatment could considerable impact esrd patient lowering cm cost cm allows dialy business 2016 approximately 32 fresenius medical si clinic physician form called ecso care sale united state attributable u fed comprehensive esrd care model escos achieve eral health care benefit program medicare program minimum quality threshold generate reduc medicaid cm reduction reimbursement rate reim tions cmss cost care certain threshold bursed service could result significantly lower sale esrd patient covered esco receive share operational result cost saving escos include dialysis chain effective 2011 medicare implemented endstage renal 200 facility required share risk cost disease esrd prospective payment system esrd pps increase reimburse cm share increase expanded scope product service covered model commenced october 1 2015 includes six bundled rate resulted lower reimbursement per organization initial agreement period model treatment previous system esrd pps last three year 64 management report addition fresenius medical care currently take part monitor legislative change intensively also various valueoriented program bundled payment work together governmental health care institution care improvement program bpci medicare result acquisition spanish private ho advantage chronic special need plan macsnp well pital chain quirónsalud fresenius helios operation claim payment negotiation insurer side germany first time quirónsalud operates hospi bpci fresenius medical care ability receive addi tals ppp contract publicprivate partnership tional payment fresenius medical care able deliver part public health system spain com quality care cost lower certain established pany thus given responsibility certain area benchmark also risk incurring financial pen health care citizen spain statutory health alties fresenius medical care successful insurance quirónsalud receives compensation service fresenius medical care fail perform required form per caput lump sum remuneration bpci initiative agreement cm cm specific service rendered quirónsalud lose may among remedy terminate right participate concession operate hospital ppp contract renego bpci program whole part tiations public private insurance company resulted new u administration expected revise even worse condition hospital able repeal affordable care act time stance compensate lower reimbursement rate cutting cm towards kind program could well differ cost could material adverse effect net previous administration develop asset financial position result operation ments could impact program unpredictable way reduction health care spending could also negatively future affect pricing fresenius kabi product furthermore portion dialysis care business change law reimbursement method could united state currently reimbursed private insurer affect scope payment service well managed care organization organization enforce insurance coverage product business could reduction reimbursement would significantly significant adverse impact asset liability reduce revenue earnings product ser financial position result operation generally vice fresenius medical care fresenius medical aim counter possible regulatory risk management report care privately insured dialysis patient rely charitable enhanced performance cost reduction support cover insurance premium could shortly forced switch state health insurance recent development new product therapy effort u restrict away option introduction new product service charitable financing successful resulting development new technology competitor could render lower reimbursement rate could substantial negative one product service less competitive impact fresenius medical care operating result even obsolete thus significant negative impact applies hospital market germany future sale price product range ser drg system diagnosis related group intended vice includes introduction generic patented increase efficiency hospital reducing health drug competitor may impact sale care spending company constantly monitor legislative operational result development patient largely assigned hospital cooperation medical doctor scientist allows public health pension insurer therefore important u identify support relevant technological innovation fresenius helios contract hospital keep abreast development alternative treatment insurer health care institution maintained method enable u evaluate adjust cor porate strategy necessary management report opportunity risk report 65 operating risk audited fda public authority deficiency business operation around world exposed detected complaint filed company required number risk extensive regulation remedy example following inspection include among others prior year u production facility grand island facility kalyani india quality safety efficacy medical pharma noncompliance requirement ceutical product supply therapy authority production facility supplier operation hospital manufacturing facility could lead regulatory action warning product laboratory recall production interruption monetary sanction planning construction equipping management delay new product approval regulatory health care facility action could adversely affect ability generate sale rate accurate reporting billing govern result significant expense ment thirdparty reimbursement potential risk arising startup labeling designation pharmaceutical product new production site introduction new tech marketing nologies countered careful planning regular compensation medical director financial analysis continual progress review production capaci arrangement physician referral source tie manufacturing plant could adversely affected event technical failure natural disa fresenius fails comply law regulation may ters regulatory ruling supply disruption eg raw give rise number legal consequence including mone material tary administrative penalty increased compliance cost performing medical treatment patient ho exclusion governmental program complete pitals rehabilitation clinic dialysis clinic subject partial curtailment authorization conduct business inherent risk example disruption process involve could material adverse effect risk patient clinic addition opera business financial condition result operation tional risk example regarding hygiene sterile condi tions counteract risk strict operating proce management report significant risk operation fresenius group dures continual personnel training patientoriented described following section working procedure furthermore constantly striving improve standard patient treatment production product service quality management system compliance product manufacturing regulation performance risk associated fresenius vameds ensured quality management system project business countered professional project structured accordance internationally recognized management control proven system tailored quality standard iso 9001 taking account large number business activity identifying evaluating mini national international regulation imple mizing risk system consists organizational mented internal standard quality work proce measure standard pricingin risk prepar dure manual regular internal external audit car ing quotation risk assessment accepting order ried group production site distribution company regular project controlling continual risk assessment dialysis clinic audit test compliance regu lations area management administration production clinical service patient satisfaction production facility comply good manufacturing practice gmp market supply facility 66 management report update avert risk default financial measure competition taken checking creditworthiness rule safe growing competition among thing induced guarding prepayment letter credit secured reentry competitor u market generic credit iv drug production halt could materially affect development new product therapy always future pricing sale product service adversely carry risk target might achieved might introduction generic patented drug competi take longer planned regulatory authority either tor may impact sale operational result grant delay product approval iv drug product also crucial new product continually brought generally health care market characterized market timely manner product development process price pressure including tender competition controlled basis detailed project roadmaps effort contain cost factor could result lower tight focus achievement specific milestone sale adversely affect business financial position defined target called question countermeasure operational result initiated united state almost fresenius kabi injectable pharmaceutical product sold customer procurement arrangement group purchasing organization gpo procurement side counter risk mainly distributor majority hospital undertake con involve possible price increase availability raw tract gpo choice purchasing need material good appropriately selecting working currently fewer five gpo control large majority together supplier longterm framework sale united state hospital customer fresenius agreement certain purchasing segment bundling kabi derives large percentage revenue united volume within group state small number gpo purchasing medicare bundled reimbursement system pay agreement important maintain ment erythropoietin stimulating agent esas gener business relationship fresenius kabi need reli ally included bundled rate interruption supply able supplier comprehensive highquality product material increase utilization acquisition cost line remain pricecompetitive comply regulation management report esas could materially affect sale profitability adversely u food drug administration fda gpo 2015 patent certain esas expired enables u also purchasing agreement manufacturer diversify procurement source reduce risk bidding process product highly competitive arising supply interruption price increase agreement fresenius gpo united counter risk poorquality purchased raw mate state terminated short medium notice main rial semifinished product component mainly requir customer area transfusion technology plasma ing supplier meet strict quality standard addi company blood center four major plasma tion certification external institute regular supplier company serving united state blood center audit includes exhaustive evaluation advance united state consolidating response bloodsaving sample regular quality control purchase high effort hospital effect pricing quality product proven safety suitability qualified supplier conform specification payment default standard rule assess creditworthiness new customer order limit risk late payment default customer also conduct followup assessment review credit line ongoing basis monitor receivables management report opportunity risk report 67 outstanding existing customer assess risk detailed project roadmaps tight focus achieve default particularly applies country budgetary ment specific milestone defined target called problem country exposed political risk 2016 question countermeasure initiated worked status receivables taking measure factoring risk integration acquisition acquisition integration company carry risk personnel adversely affect asset liability financial company address potential shortage qualified position result operation fresenius following personnel externally utilizing personnel marketing acquisition acquired company structure must inte measure internally offering comprehensive personnel grated clarifying legal question contractual obliga development program also seek retain employ tions marketing patient service logistics must also ee introducing lifework time account various area unified integration phase key manager leave furthermore employee entitled attractive fringe company course ongoing business pro benefit part bonus using targetgroupspecific cesses relationship customer employee measure fresenius address overall shortage spe harmed addition changeofcontrol clause may cialized hospital personnel thereby recruit qualified ded claimed integration process may prove difficult icated specialized personnel thus ensuring high require time resource expected risk standard treatment quality time supporting arise operation newly acquired company training young employee seek commitment fresenius regarded insignificant unaware fresenius result measure risk personnel acquisition may also prove less beneficial initially considered significant expected future acquisition may strain finance management business moreover conse risk associated research quence acquisition fresenius may become directly development indirectly liable toward third party claim third development new product therapy always party may turn nonassertable carry risk ultimate goal might achieved counter risk acquisition detailed inte management report might take longer planned regulatory approval gration roadmaps strict integration project manage new product requires comprehensive costintensive preclin ment countermeasure initiated good time ical clinical study furthermore risk deviation expected development regulatory authority either grant delay product risk also apply acquisition spanish approval addition adverse effect product private hospital chain quirónsalud fresenius helios may discovered regulatory approval registration may aforementioned countermeasure con lead partial complete withdrawal market tinue taken due either regulatory action voluntary decision addition risk hospital operated stop marketing product fresenius group spread quirónsalud via ppp contract quirónsalud lose risk widely conducting development activity various concession operate hospital ppp contract product segment also counteract risk research renegotiations public private insurance company development project regularly analyzing assess resulted worse condition hospital ing development trend examining progress research able compensate lower reimbursement rate project also strictly comply legal regulation cutting cost could material adverse effect clinical chemicalpharmaceutical research devel net asset financial position result operation opment iv drug also crucial new product continually brought market timely manner product development process controlled basis 68 management report information technology risk financial risk company process growing ever complex result fresenius group steady growth increasing currency interestrate risk internationalization correspondingly dependence international operation fresenius group expose information communication technology u variety currency risk addition financing system used structure procedure increasingly business expose u certain interest rate risk harmonize internationally intensifies failure use derivative financial instrument part risk manage system could temporarily lead interruption ment avoid possible negative impact risk part business thus cause serious damage loss however limit nonexchangetraded market sensitive data noncompliance data protec able instrument used exclusively hedge operation tion law regulation standard could damage com trading speculative purpose transaction petitive position reputation entire company conducted bank high rating fresenius counter risk various security mea fresenius group foreign exchange risk manage sures control audit addition counter ment based policy approved management risk constant investment hardware software board defines target organization handling well improving system knowhow potential risk risk management process particular guideline covered detailed contingency plan regularly assign responsibility risk determination execution improved tested redundant system maintained hedging transaction regular reporting risk man key system system communication agement responsibility coordinated infrastructure password system place minimize management structure residual business process organizational risk tampering unauthorized group decision use derivative financial access addition company guideline regulating instrument interest rate management taken close granting access authorization compliance consultation management board hedging trans rule monitored also conduct operational action using derivative carried corporate securityrelated audit treasury department fresenius group apart addition increased integration system exception order adhere foreign currency regula management report business process mean cyber attack could tions transaction subject stringent internal con penetrate internal external system attacker could trols policy ensures management board fully cause damage gain sensitive information existing informed significant risk current hedging activity security architecture various security measure dif fresenius group protected large extent ferent level protects system data center access currency interest rate risk december 31 sensitive critical data outside protected data 2016 approximately 66 fresenius group debt center network prevented use secure protocol protected increase interest rate either cryptographic measure addition annual penetration fixedrate financing arrangement interest rate hedge test carried application critical data 34 exposed interest rate risk ratio example patient personnel data slightly affected longterm finance agreement quirónsalud acquisition sensitivity analysis show rise 05 reference rate relevant fresenius would less 10 impact group net income global company fresenius widely exposed translation effect due foreign exchange rate fluctuation exchange rate u dollar euro parti cular importance extensive operation united state translation risk hedged sensitivity management report opportunity risk report 69 analysis show one cent change exchange rate tax regulation resulting tax audit could lead u dollar euro would annualized effect higher tax payment information status tax 120 million group sale 20 million audit found page 126 f note ebit 5 million group net income globally active company production facility debt liquidity main currency area service business fresenius debt 14780 million december 31 revenue cost base largely coincide fresenius group 2016 debt could limit company ability pay divi us cashflowatrisk cfar model order estimate dends arrange refinancing compliance credit quantify transaction risk foreign currency covenant implement corporate strategy financ foreign currency cash flow reasonably expected ing risk could arise fresenius case ongoing arise within following 12 month less hedge general financial market crisis reduce risk form basis analysis currency risk high proportion mid longterm funding december 31 2016 fresenius group cash flow risk balanced maturity profile financing agreement contain 73 million hence probability 95 poten covenant requiring u comply certain financial tial loss relation forecast foreign exchange cash ratio additional financial criterion noncompliance flow next 12 month higher 73 million covenant could result default acceleration detail financial risk found page 162 debt agreement 169 note additional information condition maturity found page 136 ff note page 46 ff recoverability asset management report financial risk could arise acquisition investment property plant equipment intangible asset compliance legal risk assessed careful indepth review assisted external consultant amount intangible asset compliance risk including goodwill product right trade name manage fresenius subject comprehensive government regulation ment contract represents considerable part total control nearly country especially true management report asset fresenius group goodwill intangible united state germany future true asset indefinite useful life carried group spain addition fresenius must comply general consolidated balance sheet tested impairment rule law differ country country could year significant deterioration prospect farreaching legal repercussion fresenius fail future general economic environment could result comply law regulation additional depreciation necessary asset must comply rule regulation depreciated could significant adverse impact particularly monitor safety effectiveness medical asset liability financial position result product service therefore special importance operation information found page 131 ff u compliance program guideline note adhered compliance aim meet expectation partner orient tax business activity generally accepted standard local global corporation fresenius subject numerous tax law regulation code regulation risk arising therefrom identified evaluated ongoing basis fresenius group company subject regular tax audit change 70 management report corporate compliance department report chief risk compliance officer management board member risk environmental risk risk involving legal affair compliance human resource management control system considered accountable establishing implementing com significant pliance guideline procedure compliance officer appointed business segment sup assessment overall risk ported additional compliance officer appointed based basis evaluating overall risk risk management organizational business structure regularly audited management potential risk corporate compliance department support com group include factor beyond control evolution pliance officer business segment regional economy constantly monitored fresenius country level compliance program guideline set risk also include factor immediately within control binding rule conduct employee believe operating risk company anticipates reacts taken adequate measure ensure national appropriately required currently recog international rule observed complied nizable risk regarding future performance appear pres ent longterm material threat group asset legal risk liability financial position result operation risk arise legal dispute continually identified created organizational structure provide analyzed communicated within company condition needed rapidly alert u possible risk situation company health care industry regularly exposed able take suitable countermeasure action breach duty due care product lia bility breach warranty obligation patent infringement risk affecting treatment error claim result high oneyear forecast period claim damage substantial cost legal defense chart beside show significant risk could lead regardless whether claim damage actually justi deviation expected business performance within fied legal dispute also result inability insure oneyear forecast period compared last year risk kind acceptable term future prod change occurred grouping potential effect management report ucts health care industry also subject risk within regulatory environment due initiative recall action could negative effect asset new u administration exposed risk relat liability financial position result operation ing import duty change existing present group health care program regarding reimbursement rate possi information regarding legal matter ongoing ble change patient structure u increase internal compliance review fresenius medical care risk regard reimbursement private health insurance found page 156 161 note scheme fresenius group also involved various legal dispute resulting business operation although possible predict outcome dispute none expected significant adverse impact asset liability financial position result operation group management report opportunity risk report 71 classifying risk qualitative assessment applied first risk affecting 1year forecast period followed quantitative factor scale classifi cation potential impact probability shown potential impact following two table urrencies c high potential impact description impact interest rate significant negative impact high 1year forecast moderate negative impact medium 1year forecast insignificant negative impact egulatory r low 1year forecast lobal economic g environment medium condition uality q constitution financial market eimbursement r rate price probability classification high 66 100 medium 33 66 low 0 33 procurement itigations nformation low l technology probability tax effect mediumterm goal fundamentally risk area risk listed risk low medium high report could lead failing achieve mediumterm target believe following particularly important risk relating quality safety effectiveness product service risk operating risk management report see page 65 f risk arising financing health system potential change reimbursement system risk healthcare sector see page 63 f risk arising regulatory environment com pliance law regulation general economic risk risk general operating framework see page 62 f 72 corporate governance corporate governance declaration report supervisory board management board committed responsible management focused achieving sus tainable increase value company longterm corporate strategy solid financial man agement strict adherence legal ethical business standard transparency corporate communication key factor corporate governance declaration supervisory partner fresenius management se legal corporate board fresenius se co kgaa management body change group manage board general partner fresenius se co kgaa ment supervision structure reporting period fresenius management se management board report chart following page provides overview pursuant section 289a german commercial code group structure hgb corporate management pursuant number article association fresenius se co kgaa 310 german corporate governance code addition legal provision define respon corporate governance company corporate gover sibilities individual corporate body corporate governance nance report corporate governance declaration loaded website see wwwfreseniuscomcorporate corporate governance report published governance website see wwwfreseniuscomcorporategovernance shareholder shareholder uphold right annual general corporate governance meeting exercise voting right every ordi declaration nary share fresenius se co kgaa confers one vote none share carry multiple preferential voting right group management supervision report detail investor relation activity structure corporate body page 86 section fresenius share page 11 group management supervision annual general meeting structure annual general meeting agm held may 13 company legal form kgaa kommanditgesell 2016 frankfurt main approximately 73 share schaft auf aktien partnership limited share annual capital represented general meeting supervisory board general corporate governance corporate governance declaration 73 agm shareholder approved proposal management board supervisory made general partner supervisory board board procedure increase 2015 dividend 25 055 per ordinary responsibility distributed follows fresenius share majority 90 vote cast se co kgaa management board general partner clear majority shareholder elected candidate responsible conducting business fresenius se new supervisory board clear majority 996 co kgaa supervisory board fresenius se co kgaa 995 respectively shareholder approved supervises management company business action management supervisory board 2015 general partner regard certain subject matter legally required voting right exclusion exist general partner general partner management instance sole shareholder else kröner supervisory board freseniusstiftung pertain example appoint general partner fresenius management se represented ment supervisory board fresenius se co kgaa management board manages fresenius se co kgaa approval action general partner responsibility conduct business man member supervisory board selection agement board formulates company strategy discusses auditor guarantee remaining shareholder supervisory board fresenius management se retain sole authority decide matter especially fresenius se co kgaa oversees implementa pertain supervision management tion action decision aligned best document information annual general meet interest fresenius se co kgaa management board ing well voting result available website committed increasing value company wwwfreseniuscomannualgeneralmeeting sustainable basis rule procedure management structure fresenius se co kgaa reduced voting power 1 else krönerfreseniusstiftung free float 100 26 74 annual general meeting annual general meeting fresenius management se fresenius se co kgaa elect elect corporate governance supervisory board supervisory board fresenius management se fresenius se co kgaa supervises supervises appoints board management fresenius management se manages fresenius se co kgaa general partner 1 selected item voting power eg election supervisory board fresenius se co kgaa discharge general partner supervisory board f fresenius se co kgaa election auditor 74 corporate governance board established supervisory board fresenius member management board appointed max management se define activity within board imum period five year following recommendation specifically especially regard individual duty code firsttime appointment period five year responsibility member matter reserved rule principle firsttime appointment rather full management board resolution passed threeyear period full management board meeting management european company se societas europaea board convened required least month fresenius management se supervisory board chaired chairman management board consists six member chairman dr gerd incapacitated chief financial officer krick supervisory board appoints member also incapacitated management board member management board fresenius management se super present senior age however management vise advises management board conducting board meeting usually held twice month person business necessary eg order discus decide chairing meeting decides order item matter concerning management board super agenda dealt form voting visory board meet without management board estab conducted management board pass resolution lished rule procedure following recommendation simple majority vote cast outside meeting number 513 code simple majority member except case supervisory board member fresenius manage mandatory provision law impose stricter requirement ment se found page 197 annual report chairman management board casting vote vote tied chairman incapacitated absent supervisory board fresenius se co kgaa motion deemed rejected vote tied rule supervisory board fresenius se co kgaa supervises procedure management board also govern rela management company business general tions management board supervisory partner supervises business operation ensure corpo board general partner well general rate decision compliant suitable financially sound partner supervisory board fresenius se co kgaa member management board general partner also matter require approval general part appointed supervisory board fresenius man ners supervisory board agement se already explained supervisory management board generally consists seven mem board fresenius se co kgaa bers chairman chief financial officer chief supervisory board fresenius se co kgaa con legal compliance officer labor relation director sists 12 member half member elected chief executive officer four business seg agm proposal member supervisory corporate governance ments ensures full management board board primarily take account knowledge ability kept constantly informed important event plan expert experience required perform task election development measure within business segment proposal provided supervisory board take management board committee owing account company international activity potential con fresenius se co kgaas role operating holding com flicts interest number independent member pany stephan sturm appointed chairman fresenius supervisory board within meaning number 542 management se july 1 2016 succeeds ulf mark code diversity supervisory board fresenius schneider decided leave company effective se co kgaa law requires quota least 30 woman june 30 2016 since july 1 2016 stephan sturm held 30 men mandatory quota met dual role chairman chief financial officer supervisory board election 2016 company supervisory board appoints new chief financial officer interest limit selection qualified candidate management board consists six member general way supervisory board confines gen management board listed page 196 eral declaration intent particularly refrain annual report age limit well regular limit length membership corporate governance corporate governance declaration 75 statutorily required declaration conformity concern strategy supervisory board supervises company ing code accordingly includes justified limitation management taking account auditor report nomination committee instituted election pro review group annual financial statement another im posals shareholder representative activity portant part supervisory board activity work aligned provision law code euro conducted within committee formed accordance pean work council elect employee representative requirement german stock corporation act supervisory board fresenius se co kgaa recommendation code supervisory board includes deems appropriate number independent member supervisory board training education business personal relationship company measure corporate body controlling shareholder party member supervisory board take related latter may give ground material necessary training education measure required merely temporary conflict interest article task keep regularly informed association fresenius se co kgaa regulate detail internal external source latest require regard supervisory board election constitution ments regard supervisory activity super term office meeting resolution right duty visory board time ensures member suitably published website see wwwfreseniuscom qualified keep professional knowledge date corporategovernance develop judgment expertise sup supervisory board fresenius se co kgaa ported appropriately company accordance established rule procedure accordance number number 545 paragraph 2 code various external expert 513 code chairman supervisory board well expert company provide information responsible coordinating activity supervisory important development example strate board chairing meeting representing interest gic orientation company growth market relevant externally supervisory board convene new law precedent change u gaap calendar quarter must convene twice calendar half ifrs accounting auditing standard addition year meeting convened chaired chair company hold onboarding event new member man incapacitated chairperson named supervisory board chairman person chairing meeting decides order member supervisory board fresenius se item agenda dealt form co kgaa found page 194 195 annual voting conducted unless majority report page 186 193 annual report super mandatory law supervisory board pass resolu visory board report main focus activity corporate governance tions simple majority vote submitted voting committee 2016 vote tied chairman casting vote take part voting matter decided supervisory board efficiency evaluation vote deputy chairman shareholder repre supervisory board fresenius se co kgaa deliber sentative ated efficiency evaluation accordance number supervisory board fresenius se co kgaa con 56 code meeting march 2016 duct business accordance provision law reviewed efficiency activity open article association fresenius se co kgaa discussion within full supervisory board company rule procedure management board general specific questionnaire covering salient point self partner fresenius management se continuously informs evaluation served basis discussion among supervisory board corporate development planning thing included organization structuring meeting amount information infor mation provided selfevaluation showed supervisory board assesses organization well work efficient 76 corporate governance cooperation general partner committee rule procedure committee supervisory board fresenius se co kgaa regulated rule procedure supervisory board good corporate governance requires trusting efficient fresenius se co kgaa committee cooperation management supervisory rule procedure board management board general partner member supervisory board committee supervisory board fresenius se co kgaa closely coop listed page 195 annual report erate benefit company open communication essential common goal sustainably increase audit committee company value line corporate governance com audit committee function among thing pliance principle management board general prepare supervisory board approval financial partner supervisory board fresenius se co kgaa statement consolidated financial statement coordinate especially regard supervisory board proposal agm appoint company strategic focus monitoring body super ment auditor financial statement make visory board fresenius se co kgaa also need fully preliminary review proposal allocation dis informed operating performance corporate plan tributable profit also review quarterly report ning well risk situation risk management com published following discussion pliance management board general partner pro management board engages auditor financial vided information full compliance duty statement concludes agreement auditor representative shareholder fee determines main focus audit defines employee may prepare supervisory board meeting sep auditor reporting duty relation supervisory arately applicable member management board fresenius se co kgaa matter within board premeetings employee representative well remit review effectiveness internal control consultation shareholder representative take place system risk management system internal audit regular basis necessary supervisory board meet system compliance without management board since constitutive meeting supervisory board may 13 2016 audit committee consists klaus composition procedure peter müller chairman konrad kölbl dr gerd krick hauke upervisory board committee star rainer stein klauspeter müller independent supervisory board fresenius se co kgaa form two required expertise field stated section permanent committee among member audit 100 5 german stock corporation act aktg well committee consisting five member nomination specialist knowledge experience application corporate governance committee consisting three member committee accounting principle internal control process member elected duration term mem close annual general meeting may 13 2016 ber supervisory board fresenius se co kgaa audit committee consisted prof dr roland berger chair accordance article association fresenius se man konrad kölbl dr gerd krick gerhard roggemann co kgaa member audit committee receive addi rainer stein tional compensation section 13 2 personnel audit committee also examined detail non committee kgaa supervisory board audit service rendered additionally auditor kpmg ag fresenius se co kgaa responsible appointing mem wirtschaftsprüfungsgesellschaft berlin bers management board general partner contract responsibility personnel matter lie supervisory board general partner provision supervisory board fresenius se co kgaa apply analogously committee commit tee hold meeting required meeting convened committee chairman report following supervisory board meeting work respective corporate governance corporate governance declaration 77 nomination committee relevant disclosure corporate nomination committee proposes suitable candidate governance practice supervisory board nomination make general partner represented management board agm election supervisory board member manages company business due care dili shareholder side consists solely shareholder represen gence prudent conscientious company director tatives making proposal nomination committee compliance provision law article asso guided requirement code ciation rule procedure management board since constitutive meeting supervisory board resolution passed full management board may 13 2016 nomination committee consists supervisory board general partner corporate gover dr gerd krick chairman michael diekmann klaus nance practice extending beyond requirement law peter müller close annual general meeting defined fresenius code conduct code con may 13 2016 nomination committee consisted duct contains key principle rule conduct dr gerd krick chairman prof dr roland berger within company relation external partner michael diekmann public published fresenius code conduct website wwwfreseniuscomcompliance mediation committee code conduct binding company employee fresenius se co kgaa mediation commit must complied regarding type business tee provision german codetermination relationship executive regard ensuring compliance act require committee apply partner principle code conduct part manage ship limited share code require rial responsibility committee either compliance joint committee global health care group sustainable success matter defined detail sec business key providing highquality yet affordable tion 13c 1 article association fresenius se healthcare long term compliance ensures sus co kgaa general partner requires approval tainable growth determines corporate culture joint committee 40 consolidated sale consol integral part daytoday work understanding idated balance sheet total consolidated profit compliance basis corporate value reflected affected matter include example dive fresenius code conduct code conduct titure acquisition large investment business unit management board commits without limitation divestiture large business unit asset binding principle rule conduct within company corporate governance fresenius se co kgaa wholly owned company course business include professionalism approval joint committee also required certain honesty integrity relation patient customer legal transaction fresenius se co kgaa affil supplier employee shareholder furthermore iates else krönerfreseniusstiftung code conduct fresenius commits fair competition dr gerd krick michael diekmann member dealing honestly business partner general joint committee member dr dieter schenk public fresenius expects employee manager chairman dr karl schneider appointed comply applicable law regulation well general partner joint committee meet fresenius guideline policy breach toler 2016 ated pursued fresenius business segment implemented code conduct specific business information position held committee member stat reflecting value fresenius code conduct utorily required supervisory board comparable dome tic foreign control body business enterprise found page 194 197 annual report 78 corporate governance compliance management system cm department corporate compliance department report chief compliance officer fresenius se co kgaa member management board responsible legal p r ev e n compliance labor relation compliance steering committee central con risk assessment sultative committee fresenius se co kgaa compli ode conduct c ance topic facilitates exchange relevant gover policy procedure communication training nance function main agenda topic include continuous advice consultation status development group compliance management system important report handling compliance audit compliance initiative investigation review discussion severe case potential misconduct remediation internal control continuous structure remediation action well improvement reporting re presentation compliancerelevant topic ct governance function internal audit planning po te internal audit report nd de comprises following participant fresenius se co kgaa chief compliance officer chief financial officer head legal internal audit corpo rate compliance department business segment provide compliance steering committee annual update organization compliance management system compliance steering business segment appointed chief com committee meeting held every six eight week mini pliance officer charge developing implementing mum six time per year monitoring compliance management system supervisory board fresenius se co kgaa business segment line business structure general partner fresenius management se regularly organization business segment established compli informed least per year compliance within ance responsibility respective organizational level group topic include compliance management local management responsible compliance system current future compliance initiative case corporate governance respective legal entity besides 150 employ relevant ee working fulltime compliance function within fresenius group compliance management system corporate compliance department fresenius fresenius implemented riskbased compliance se co kgaa support compliance function busi management system business segment ness segment standardized tool process fresenius se co kgaa corporate level system con methodology develop group compliance sider market fresenius operating tailored management system global compliance initiative specific requirement business segment developed corporate compliance department compliance management system comprise three pillar fresenius se co kgaa consultation compliance prevent detect respond emphasis placed pre function business segment addition corpo venting act noncompliance occur rate compliance department fresenius se co kgaa noncompliant behavior detected adequate process responsible developing implementing monitoring place respond short notice compliance management system related corporate function fresenius se co kgaa treasury corporate governance corporate governance declaration 79 prevent avoid potential violation beginning fresenius prevention includes thorough risk assessment adequate give top priority training employee including effective policy procedure regular training manager receive relevant compliance training training continuous advice schedule follow riskbased approach new employee compliance risk regularly assessed using standard receive relevant compliance training standardized basis ized methodology business segment fresenius part onboarding process key compliance training se co kgaa risk assessment include 20 group code conduct mandatory compliance risk group depending business structure employee repeated regularly addition management across business segment corruption one focus specific compliance training performed highrisk com risk area fresenius group perspective antitrust pliance area process place ensure every data privacy additional focus risk area employee join relevant compliance training regular dealing health care professional organization basis well public customer worldwide every day living compliance function provide continuous advice model forward thinking health care demand high stan employee compliancerelated question business seg dard honesty integrity interaction ments established compliance responsibility fore compliance anticorruption regulation worldwide organizational level local compliance function pro basis daytoday action business segment vide employee answer case question defined anticorruption measure central element support employee decision daily work locally compliance management system regional divisional compliance function provide guid measure include diligence interacting ance advice local compliance function business business partner worldwide business segment segment corporate compliance function develop global riskbased due diligence process place deter compliance initiative business segment support mine risk related business partner based regional divisional compliance function risk profile implement appropriate mitigation measure compliance initiative corporate compliance department including contractual commitment prevent corruption fresenius se co kgaa support compliance func business partner putting patient first commits u tions business segment required highest standard fair competition data privacy daytoday business detect business segment fresenius se co kgaa compliance organization regularly performs functional compliance function established policy pro review implemented compliance initiative review cedures provide tailored guidance applying held workshop strengthen implemen corporate governance respective code conduct rule practice purpose tation policy rollout procedure advise help employee making right decision employee live value integrity hon daytoday work example transparency guideline esty daytoday business prevent conflict interest doctor helios group compliance cockpit fresenius kabi tool policy compliant transparent interaction place display compliance risk profile legal health care professional fresenius kabi entity tool us objective internal external regular classroom online training respective indicator fresenius kabi review compliance cockpit code conduct company policy general spe entity annually determines required monitoring cific topic anticorruption antitrust help measure entity higher risk profile employee comply applicable rule aim make addition internal audit department fresenius participant aware importance compliant behavior perform independent audit compliance management system auditing business segment group company also including compliancerelevant topic internal audit examines implementation policy procedure 80 corporate governance effectiveness compliance management system respond result review audit reveal potential improve reported otherwise detected compliance violation ment necessary action defined consultation followedup based severity potential miscon responsible management 2016 internal audit compli duct corporate level fresenius se co kgaa ance function performed multiple compliancerelated business segment case potential misconduct review workshop audit business segment across objectively assessed plausibility potential severity world duly followedup ensure violation man compliance function fresenius se co kgaa aged consistent fair comprehensive manner nec business segment support management imple essary investigation performed either internal ment solid control structure order guarantee compliant investigation team external support transaction daytoday business solid control struc assessment potential misconduct reveals tures assure potential case noncompliance avoided change improvement internal control structure detected early relevant control described compli required measure duly implemented man ance policy business segment group level agement close cooperation responsible compli implemented control cash bank trans ance function required targeted remediation action action requiring dual approval complete monitoring defined reduce risk misconduct future money transfer certain threshold guarantee disciplinary action taken required money transfer properly authorized executed order ensure ethical conduct continuously based legitimate purpose internal control form review question current practice try learn integral part established business process employee best practice four business segment focusing enabled act compliance rule regulation different area compliance mean learning potential improvement resulting audit review continuous exchange idea duly implemented compliance function within group aim achieve employee fresenius expected report continuous improvement compliance activity potential case noncompliance law regulation daytoday operation order live commitment internal policy superior responsible com professionalism honesty integrity relation pliance function fresenius code conduct explicitly patient customer supplier employee state employee may incur disadvantage shareholder result reporting potential misconduct therefore noncom pliance may also reported anonymously whistle blower hotlines email address set purpose corporate governance business segment fresenius se co kgaa corporate governance corporate governance declaration 81 risk management control system declaration management board general view responsible handling risk element partner fresenius se co kgaa fresenius manage good corporate governance fresenius systematic ment se supervisory board fresenius se risk management control system allows manage co kgaa german corporate governance code ment board make early identification risk market pursuant section 161 german stock corporation act trend react promptly relevant change risk aktiengesetz profile risk management control system efficiently designed process help enhance company perfor management board general partner fresenius mance risk management reviewed part annual se co kgaa fresenius management se hereafter man audit financial statement control system regu agement board supervisory board fresenius se larly reviewed management board internal co kgaa declare since issuance previous dec audit division information found page 61 laration conformity december 2015 recommenda 62 management report tions government commission german corpo internal audit division support management rate governance code published federal ministry board independent function outside company day justice consumer protection bundesministerium der today operation division assesses internal process justiz und für verbraucherschutz official section objective viewpoint necessary distance federal gazette bundesanzeiger hereafter code goal create added value fresenius thus version may 5 2015 met met help achieve organizational goal improved internal future following recommendation code control optimized business process cost reduction version may 5 2015 met efficiency increase well prevention corruption fresenius medical care ag co kgaa inter code number 423 paragraph 2 sentence 6 nal risk management control system cap regarding specific compensation amount pursuant code number 423 paragraph 2 sentence 6 orporate governance german c compensation amount management board member declaration conformity shall capped overall variable compensa german corporate governance code aim provide tion component transparency investor regard existing regula recommendation met service agree tions covering management monitoring company ments member management board valueenhancing strategy well majority provide cap regarding specific amount com guideline recommendation suggestion respon pensation component accordingly cap corporate governance sible management contained code basic regarding specific amount overall compensation component activity many year extensive infor performanceoriented shortterm compensation mation corporate governance found website variable bonus capped regard stock option wwwfreseniuscomcorporategovernance phantom stock compensation component management board general partner fresenius longterm incentive service agreement member se co kgaa fresenius management se supervi management board provide possibility sory board fresenius se co kgaa issued required limitation cap regarding specific amount intro declaration conformity pursuant section 161 ducing cap regarding specific amount relation german stock corporate act aktg made available stockbased compensation component would con shareholder website company tradict basic idea member management board participating appropriately economic risk opportunity company instead fresenius pursues flexible concept according individ ual case considered event extraordinary devel opments relation stockbased compensation related performance management board supervisory board may cap stockbased compensation 82 corporate governance code number 423 paragraph 4 severance payment cap specific amount overall compensation pursuant code number 423 paragraph 4 con target value comparable value oneyear cluding management board contract care shall taken variable compensation deferrable portion ensure payment made management board oneyear variable compensation deferral oneyear member premature termination contract variable compensation determined basis bonus including fringe benefit exceed value two curve applicable several year respect year compensation severance payment cap com compensation report cannot meet recommendation pensate remaining term service code irrespective thereof fresenius continue agreement severance payment cap shall calculated comprehensively transparently present compen basis total compensation past full sation system amount paid member fiscal year appropriate also expected total com management board compensation report com pensation current fiscal year pensation report include table relating value recommendation met insofar ser benefit granted well allocation year vice agreement member management review follow structure largely also board contain severance payment arrangement specification model table case premature termination contract consequently contain limitation severance code number 512 paragraph 2 sentence 3 age limit payment amount extent uniform severance pay member management board ment arrangement kind would contradict con pursuant code number 512 paragraph 2 sentence 3 cept practiced fresenius accordance ger age limit shall specified member man man stock corporation act aktiengesetz according agement board past fresenius continue service agreement member manage refrain specifying age limit member ment board principle concluded period management board complying recommen appointment would also allow well dation would unduly limit selection qualified balanced assessment individual case didates code number 425 paragraph 3 presentation code number 532 sentence 3 independence compensation report chairman audit committee pursuant code number 425 paragraph 3 presen pursuant code number 532 sentence 3 chairman tation compensation individual member audit committee shall independent pursuant management board compensation report shall code number 542 sentence 2 supervisory board corporate governance present maximum minimum achievable compensa member considered independent particular tion variable compensation component using personal business relation model table presentation compensation granted company executive body controlling shareholder pursuant description model table 1 shall also enterprise associated latter may specify target value comparable value aver cause substantial merely temporary conflict age probability scenario oneyear variable com interest pensation deferrable portion oneyear term prof dr h c roland berger chairman variable compensation deferral audit committee ended annual general fresenius deviation code number 423 para meeting concluded may 13 2016 term graph 2 sentence 6 provide cap regarding specific amount variable compensation compo nents therefore provide cap regarding corporate governance corporate governance declaration 83 chairman audit committee also partner enterprise potential conflict interest number roland berger strategy consultant holding gmbh independent supervisory board member within mean honorary chairman supervisory board roland ing code number 542 diversity berger strategy consultant holding gmbh interest enterprise generally limit tenure prof dr h c berger chairman audit selection qualified candidate supervisory committee fresenius group made use consultancy ser board however confines complying statutory vice provided roland berger strategy consultant requirement particularly refrain specifying gmbh affiliated enterprise management consultancy age limit regular limit length membership roland berger strategy consultant holding gmbh management board supervisory board believe code number 546 paragraph 2 sentence 2 perfor business relation neither constituted substantial mancerelated compensation member longterm conflict interest interfere supervisory board oriented toward sustainable growth task chairman audit committee enterprise ever precaution deviation code number 532 pursuant code number 546 paragraph 2 sentence 2 sentence 3 declared given legal view performancerelated compensation promised regard question independence time member supervisory board shall oriented prof dr hc roland berger withdrew supervisory toward sustainable growth enterprise variable board since election mr klauspeter müller compensation supervisory board member chairman audit committee constitutive meet fresenius se co kgaa multiyear calcu ing supervisory board may 13 2016 rec lation basis thus sense oriented toward ommendation met sustainable growth enterprise instead super visory board receives performancerelated compen code number 541 paragraph 2 paragraph 3 sation component depends dividend pursuant specification concrete objective regarding section 13 paragraph 1 article association composition supervisory board fresenius se co kgaa compensation model consideration making recommendation existence since 1995 continues bring forth competent election body adequate compensation supervisory board pursuant code number 541 paragraph 2 para line law interest shareholder graph 3 supervisory board shall specify concrete objective regarding composition making bad homburg v h december 2016 recommendation competent election body take management board general partner corporate governance objective account objective specified fresenius se co kgaa fresenius management se supervisory board status implementa supervisory board fresenius se co kgaa tion shall published corporate governance report accordance section 161 para 2 aktg number recommendation met composi 310 sentence 3 code declaration tion supervisory board must align interest past declaration published website see enterprise ensure effective supervision wwwfreseniuscomcorporategovernance consultation management board thus matter principle prime importance member suitably qualified discussing recommendation competent election body supervisory board take account international activity 84 corporate governance information met december 31 2020 call proportion corporate governance woman 375 second management level target corresponds proportion december 31 2015 diversity management board belief inclusion management board take diversity account companywide stock option program strong indicator filling executive position fresenius individual qual individual hold leading executive position propor ifications paramount consideration hiring tion woman group top 1200 executive promotion decision mean woman men 302 december 31 2016 comparable qualification suitability information diversity well personnel career opportunity fresenius continue consistently development personnel management included act upon principle course comply group management report page 29 f law equal participation woman men executive position private company public service legal relationship member supervisory board fresenius se co kgaa corporate body law requires quota least 30 woman 30 general partner supervisory board fresenius men mandatory quota met supervisory se co kgaa duty act best interest board election 2016 company performing activity pursue legally stipulated target management board personal interest bestow unjustified benefit others apply fresenius management se fresenius sideline activity transaction company se co kgaa due legal form fresenius se co kgaa member corporate body must reported management board fresenius manage approved supervisory board supervisory board ment se listed stock exchange also fresenius se co kgaa report agm con subject codetermination flicts interest dealt accordance legal requirement manage fresenius se co kgaa report following relation ment board specifies composition two management ship existing fresenius group company level directly management board follows company member supervisory board first management level includes senior vice presi fresenius se co kgaa member supervisory dent vice president employment contract management board fresenius management se held fresenius se co kgaa report directly executive function 2016 member management board decision effec prof dr med michael albrecht member tive january 1 2016 management board set target supervisory board fresenius se co kgaa medical corporate governance met december 31 2020 call director spokesman management board proportion woman 333 first management university hospital carl gustav carus dresden well level target corresponds proportion member supervisory board university hospital december 31 2015 aachen fresenius group maintains business relation second management level includes vice president hospital ordinary course business employment contract fresenius se customary condition co kgaa report directly member first man klauspeter müller member supervisory board agement level decision effective january 1 fresenius management se fresenius se co kgaa 2016 management board set target chairman supervisory board commerz bank ag fresenius group maintains business relationship customary condition michael diekmann corporate governance information corporate governance 85 member supervisory board fresenius manage payment mentioned section legal relation ment se deputy chairman supervisory board ship member corporate body net amount fresenius se co kgaa currently nonexecutive addition vat paid director board director allianz australia ltd consulting service contract 2016 fresenius group paid insurance premium neither directly indirectly supervisory board allianz customary condition member company consultancy service relationship mem fresenius disclosed information related party bers supervisory board company existed 2016 quarterly report page 181 annual regard dr dieter schenk deputy chairman super report visory board fresenius management se dr schenk partner law firm noerr llp entity inter disclosure director dealing nationally acting law firm noerr provided legal advice manager transaction fresenius group 2016 2016 fresenius group paid shareholding 2016 total 09 million law firm noerr 2015 14 july 3 2016 market abuse regulation mar became million corresponds less 05 total applicable instead former section 15a german amount paid fresenius group service legal security trading act wphg regarding director dealing advice 2016 2015 1 amount paid also includes provision art 19 mar regarding manager payment service already provided 2015 transaction applicable therefore person discharging paid 2016 total amount fiscal year 2016 managerial responsibility well person closely asso less 01 million attributable service group ciated shall notify transaction conducted company related business segment fresenius account relating share debt instrument medical care service rendered group company fresenius se co kgaa derivative financial business segment fresenius medical care require instrument linked thereto separate approval supervisory board fresenius manager transaction 2016 disclosed web medical care management ag fresenius medical care site wwwfreseniuscomcorporategovernance ag co kgaa supervisory board fresenius manage pursuant number 62 code ownership share ment se examined mandate closely approved company financial instrument based mandate dr schenk take part voting must disclosed management board supervisory approval made basis written submission board member 1 share issued supervisory board listed individual mandate company held either directly indirectly none corresponding individual invoice 2016 invoice management supervisory board member general corporate governance paid supervisory board gave approval partner supervisory board fresenius se co supervisory board fresenius se co kgaa dealt kgaa directly indirectly hold 1 share amount legal service paid law firm noerr rela issued fresenius related financial instrument tion amount paid law firm member management supervisory board fresenius management se member super visory board fresenius se co kgaa together hold 026 share fresenius se co kgaa outstanding december 31 2016 form share related financial 86 corporate governance instrument stock option fresenius se co financial accounting reporting kgaa stock option plan 025 held member fresenius prepares consolidated financial statement management board fresenius management se 001 accordance united state generally accepted member supervisory board fresenius manage accounting principle u gaap fresenius publicly ment se 001 member supervisory board traded company based member country european fresenius se co kgaa due fact person union required prepare publish consolidated member supervisory board amount financial statement accordance international finan share related financial instrument stock option held cial reporting standard ifrs pursuant section 315a board fresenius se co kgaa fresenius german commercial code hgb largest subsidiary management se total smaller cumulative hold fresenius medical care prepares financial statement ings three board reported herein accordance u gaap therefore publish consol notification shareholding idated financial statement accordance u gaap member management supervisory board statutory consolidated financial statement accor reached exceeded fallen reporting threshold dance ifrs enables u disclose financial stipulated german security trading act result shareholder comparable transpar ent manner starting 2017 fiscal year fresenius transparency communication report solely accordance ifrs company fresenius adheres recommendation number 6 provide additional financial information according u code transparency guaranteed continuous com gaap information provided group manage munication public way able validate ment report page 27 deepen trust given u particular importance leading auditor marcus rohrbach kpmg ag wirt u equal treatment recipient ensure schaftsprüfungsgesellschaft responsible audit market participant receive information consolidated financial statement since 2012 time post important publication website wwwfreseniuscom report detail investor rela tions activity page 11 annual report corporate governance corporate governance information corporate governance 87 compensation report addition pension commitment member compensation report summarizes main element management board compensation system member management effect june 30 2016 dr ulf schneider board fresenius management se general partner resigned management board fresenius manage fresenius se co kgaa regard notably explains ment se received nonperformancebased compensa amount structure compensation paid tion pro rata fiscal year 2016 plus bonus management board well principle determining ever granted stock option phantom stock compensation supervisory board amount fiscal year 2016 participation stock option compensation compensation report part plan provide case mutually agreed resignation management report annual financial statement member exercise stock option within 60 calendar day annual consolidated financial statement fresenius se resignation potentially plus blackout period co kgaa compensation report prepared basis provided waiting period expired performance recommendation german corporate governance target achieved dr ulf schneider took advan code well consideration declaration tage arrangement exercised 227040 stock option resenius se co kgaa december 2016 conformity f following resignation 270000 stock option 80499 also includes disclosure required pursuant phantom stock already assigned forfeited without applicable statutory regulation notably accordance replacement waiting period yet expired german commercial code dr ulf schneiders contractual pension entitlement affected resignation compensation management board design individual element based entire supervisory board fresenius management se following criterion responsible determining compensation man fixed compensation paid 12 monthly install agement board supervisory board assisted ments fiscal year 2016 mr rice powell paid part task personnel committee personnel committee fixed compensation fresenius medical care north composed dr gerd krick dr dieter schenk dr karl america 24 installment moreover member schneider management board received additional benefit consisting objective compensation system enable mainly insurance premium private use company member management board participate reason car special payment rent supplement reim ably sustainable development company business bursement certain charge tuition fee cost reward based duty performance operation intrusion detection system well contribu well success managing company eco tions pension health insurance corporate governance nomic financial position giving due regard peer performancebased compensation also granted environment fiscal year 2016 shortterm cash component one compensation management board year variable compensation compensation component whole performancebased composed three ele longterm incentive effect stock option sharebased ments fiscal year 2016 compensation cash settlement phantom stock postponed payment oneyear variable compensation nonperformancebased compensation fixed compensa amount oneyear variable compensation tion fringe benefit case dependent certain target parameter oriented shortterm performancebased compensation oneyear net income attributable fresenius se co kgaa variable compensation bonus relevant business segment achieved case component longterm incentive effect several member management board functional year variable compensation comprising stock option responsibility entire group member sharebased compensation cash settlement phan mr sturm dr schneider 1 dr götz amount tom stock postponed payment oneyear variable compensation 1 dr ulf schneider resigned management board fresenius management se effective june 30 2016 receives shortterm performancebased compensation 2016 pro rata june 30 2016 accordance contract 88 corporate governance oneyear variable compensation based entirety oriented net income attributable fresenius se respective net income attributable fresenius se co kgaa co kgaa deduction noncontrolling interest well deduction noncontrolling interest mr henriksson net income tax extraordinary income dr de meo approximately half amount expenditure vamed group mr rice powell receives oneyear variable compensation depends development compensation exclusively fresenius medical care net income attributable fresenius se co kgaa furthermore supervisory board may grant member remainder development net income management board discretionary bonus extraordi business segment case deduction non nary performance controlling interest respective member fiscal year 2016 2015 amount cash management board responsible approximately half payment management board general partner amount oneyear variable compensation dr wastler fresenius se co kgaa consisted following shortterm cash compensation nonperformancebased performancebased without longterm compensation compensation incentive component fixed compensation fringe benefit 2 bonus thousand 2016 2015 2016 2015 2016 2015 2016 2015 stephan sturm 850 600 43 109 1773 1142 2666 1851 dr ulf schneider june 30 2016 550 1100 72 143 875 1712 1497 2955 dr francesco de meo 600 600 23 22 1250 1242 1873 1864 dr jürgen götz 460 460 37 70 928 869 1425 1399 mat henriksson 600 600 149 185 1250 1239 1999 2024 rice powell 1 1242 1239 121 342 2403 1032 3 3766 2613 dr ernst wastler 500 500 72 85 775 707 1347 1292 total 4802 5099 517 956 9254 7943 14573 13998 1 r rice powell received compensation fresenius medical care fresenius se co kgaa held around 3082 total subscribed capital member management board fresenius management se compensation included compensation report fresenius group 2 includes insurance premium private use company car contribution pension health insurance well benefit 3 amount contains discretionary bonus mr rice powell amount 541 thousand 2015 fiscal year fiscal year 2016 oneyear variable compensation annually converted pro rata variable compensation excluding payment mr rice powell amounted 6851 component based multiyear assessment order thousand equal total oneyear variable compen also take account negative development within sation assessment period done way matu corporate governance ensure overall system compensation rity yearly oneyear variable compensation earned member management board oriented towards variable basis postponed discretion super longterm sustained corporate development compen visory board either pro rata basis entirety sation system provides share longterm variable two year time ensured payment compensation component least equal amount made member management board expira half total variable compensation component granted tion multiyear period subsequent adjust respective member management board ment net income adjusted extraordinary effect mean ensuring minimum ratio favor compen attributable fresenius se co kgaa deduction sation component oriented towards long term noncontrolling interest decisive assessing oneyear expressly provided supervisory board may determine variable compensation beyond amount equal tolerance oneyear variable compensation paid rule range 10 made ii amount net income corporate governance information corporate governance 89 attributable fresenius se co kgaa adjusted extraor exercise stock option phantom stock dinary effect two relevant subsequent year resenius se co kgaa subject granted ltip 2013 f substantially less net income attributable several condition expiry fouryear waiting fresenius se co kgaa adjusted extraordinary effect period observance vesting period achievement deduction noncontrolling interest respective specified performance target continuance service preceding fiscal year event aforementioned con employment relationship vested stock option ditions payment missed minor exercised within period four year vested phantom partial extent supervisory board may resolve corre stock settled march 1 year following end sponding pro rata payment converted portion waiting period oneyear variable compensation interest payable amount cash settlement pursuant phan converted oneyear variable compensation claim tom stock plan 2013 based volumeweighted average time first arises time effective payment market price share fresenius se co kgaa way oneyear variable compensation con three month preceding exercise date verted pro rata entirety genuine variable com respective performance target reached pensation component multiyear assessment basis adjusted consolidated net income company net also participates negative development income attributable shareholder company relevant assessment period increased minimum 8 per year comparison fiscal year 2016 portion oneyear variable previous year within waiting period adjustment compensation converted component based foreign currency effect performance target also multiyear assessment achieved average annual growth rate adjusted fiscal year 2016 benefit ltip 2013 consolidated net income company fouryear fresenius se co kgaa mr rice powell benefit waiting period least 8 adjusted foreign currency ltip 2016 fresenius medical care ag co kgaa effect respect one four reference granted another component longterm incentive period within waiting period neither adjusted con effect benefit consist one hand share solidated net income company increased mini based compensation cash settlement phantom stock mum 8 per year comparison previous year hand stock option basis adjustment foreign currency effect average stock option plan 2013 fresenius se co kgaa annual growth rate adjusted consolidated net income mr rice powell performance share basis company fouryear waiting period resenius medical care ag co kgaa ltip ltip 2016 f least 8 adjusted foreign currency effect respective 2013 available member management granted stock option phantom stock forfeited corporate governance board executive accordance division prorata basis according proportion perfor power stock corporation law grant member mance target achieved within waiting management board made supervisory board period ie one fourth two fourth three fourth fresenius management se grant executive completely made management board number stock principle ltip 2013 fresenius se co kgaa option phantom stock management board mem ltip 2016 fresenius medical care ag co kgaa bers granted determined supervisory board described detail note 33 note supervisory board due discretion provided fresenius group sharebased compensation plan generally management board member receive member management board excep amount stock option phantom stock excep tion dr ulf schneider 2 mr rice powell tion chairman management board receives granted entitlement sharebased compensation double respective amount stock option phan cash settlement phantom stock equiva tom stock time grant participant ltip lent value 100 thousand per management board member 2013 may elect whether wish receive stock option fiscal year 2016 regard performance tar phantom stock ratio 75 25 ratio 50 50 get waiting period condition pertain phantom stock granted ltip 2013 apply 2 dr ulf schneider resigned management board fresenius management se effective june 30 2016 90 corporate governance fiscal year 2016 2015 number value twice number period july 1 2016 stock option issued value sharebased compensa became chairman management board stated value tion cash settlement phantom stock performance correspond fair value time grant namely share value postponed performancebased value 1531 2015 1476 per stock option f resenius compensation shown following table se co kgaa exercise price granted stock option number stock option granted member fresenius se co kgaa 6602 2015 6064 management board ltip 2013 fiscal year 2016 higher value comparison 2015 well higher exer basically unchanged compared 2015 however cise price reflect excellent fresenius share price devel dr ulf schneider receive stock option opment phantom stock 2016 fiscal year due fact fair value phantom stock granted member left company june 30 2016 stephan sturm management board fiscal year 2016 corre received regular number stock option phantom sponds value time grant 6431 2015 5870 stock pro rata period june 30 2016 per phantom stock fresenius se co kgaa u 8506 regular member management board per performance share fresenius medical care ag co kgaa granted first time longterm incentive component postponed sharebased payment compensation oneyear variable cash settlement stock option 1 compensation phantom stock total number value thousand value thousand value thousand value thousand 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 stephan sturm 101250 45000 1550 664 0 0 613 762 2163 1426 dr ulf schneider june 30 2016 0 90000 0 1328 0 0 0 1424 0 2752 dr francesco de meo 67500 67500 1033 996 0 0 442 430 1475 1426 dr jürgen götz 67500 45000 1033 664 0 0 442 762 1475 1426 mat henriksson 45000 45000 689 664 0 0 786 762 1475 1426 rice powell 0 149400 0 2244 0 0 2415 2 941 2415 3185 dr ernst wastler 67500 45000 1033 664 0 0 442 762 1475 1426 total 348750 486900 5338 7224 0 0 5140 5843 10478 13067 1 tock option granted 2016 2015 fresenius se co kgaa stock option plan mr rice powell received stock option fresenius medical care stock option plan 2 performance share share based award fresenius medical care ag co kgaa corporate governance end fiscal year 2016 member manage stock fresenius se co kgaa well 19852 ment board held total 1294530 2015 1030920 performance share granted first time 17853 stock option fresenius se co kgaa 344793 2015 2015 24124 phantom stock fresenius medical 465318 fresenius medical care ag co kgaa care ag co kgaa held total 262524 2015 237911 phantom corporate governance information corporate governance 91 development status stock option management board fiscal year 2016 shown following table stephan dr francesco dr jürgen mat rice dr ernst sturm de meo götz henriksson powell 1 wastler total 2 option outstanding january 1 2016 number 305280 242640 135000 213000 465318 135000 1030920 average exercise price 3317 3902 4355 3683 5588 4355 3802 option granted fiscal year number 101250 67500 67500 45000 0 67500 348750 exercise price 6602 6602 6602 6602 0 6602 6602 option exercised fiscal year number 85140 0 0 0 64500 0 85140 average exercise price 2376 n n n 3441 n 2376 average stock price 7000 n n n 7299 n 7000 option forfeited fiscal year number 0 0 0 0 56025 0 0 average exercise price n n n n 4976 n n option outstanding december 31 2016 number 321390 310140 202500 258000 344793 202500 1294530 average exercise price 4601 4489 5104 4193 6089 5104 4650 average remaining life year 526 520 610 480 476 610 540 range 2611 2611 3310 2376 4268 3310 2376 exercise price 6602 6602 6602 6602 7699 6602 6602 exercisable option december 31 2016 number 85140 85140 0 78000 102018 0 248280 average exercise price 2611 2611 n 2521 4738 n 2583 1 mr rice powell hold stock option fresenius medical care stock option plan 2 stock option fresenius se co kgaa excluding stock option mr rice powell following table show total compensation management board general partner fresenius se co kgaa year 2016 2015 cash compensation total compensation without longterm longterm including longterm incentive component incentive component incentive component corporate governance thousand 2016 2015 2016 2015 2016 2015 stephan sturm 2666 1851 2163 1426 4829 3277 dr ulf schneider june 30 2016 1497 2955 0 2752 1497 5707 dr francesco de meo 1873 1864 1475 1426 3348 3290 dr jürgen götz 1425 1399 1475 1426 2900 2825 mat henriksson 1999 2024 1475 1426 3474 3450 rice powell 3766 2613 2415 3185 6181 5798 dr ernst wastler 1347 1292 1475 1426 2822 2718 total 14573 13998 10478 13067 25051 27065 92 corporate governance stock option entitlement sharebased com 2016 2015 stated following table value pensation phantom stock exercised shown year 2016 dr ulf schneider include expiry minimum term vesting period value correction expense prior year stock option recognized vesting period expense respec phantom stock expire due resignation tive fiscal year expense attributable fiscal year expense longterm incentive component sharebased compensation cash settlement total expense stock option phantom stock sharebased compensation thousand 2016 2015 2016 2015 2016 2015 stephan sturm 523 365 1047 929 1570 1294 dr ulf schneider june 30 2016 826 729 1850 1482 2676 2211 dr francesco de meo 552 399 932 892 1484 1291 dr jürgen götz 469 365 1039 929 1508 1294 mat henriksson 433 321 986 686 1419 1007 rice powell 593 377 668 1 699 1261 1076 dr ernst wastler 469 365 1039 929 1508 1294 total 2213 2921 3861 6546 6074 9467 1 includes expense performance share share based award fresenius medical care ag co kgaa shortterm performancebased compensation limited contractual pension commitment based former contract amount regard stock option phantom stock employment general partner fresenius se co contractually agreed limitation possibility kgaa management board member dr ernst wastler make possible adequately take account particular pension commitment vamed ag vienna fresenius se extraordinary development relevant co kgaa issued guarantee commitment proportion performance management board management board member mat henriksson compensation system amount fixed individual contractual pension commitment fresenius total compensation member manage kabi ag management board member mr rice powell ment board assessed giving particular regard received individual contractual pension commitment relevant comparison value dax company fresenius medical care management ag furthermore similar company comparable size performance acquired nonforfeitable entitlement participating corporate governance relevant industrial sector pension plan employee fresenius medical care north america fiscal year 2016 participated commitment member usbased 401k saving plan plan generally management board event enables employee united state invest part termination appointment gross income retirement plan regard pen individual contractual pension commitment sion commitment acting management board member management board member mr stephan sturm december 31 fresenius group pension obliga dr francesco de meo dr jürgen götz based tions 31180 thousand december 31 2016 2015 service agreement general partner fresenius 25111 thousand addition pension liability se co kgaa management board member leaving fiscal year 2016 amounted 6069 thousand 2015 5024 june 30 2016 dr ulf schneider individual thousand corporate governance information corporate governance 93 pension commitment follows thousand january 1 2016 addition december 31 2016 stephan sturm 3007 2667 5674 dr francesco de meo 2402 552 2954 dr jürgen götz 2092 441 2533 mat henriksson 4115 579 4694 rice powell 9397 875 10272 dr ernst wastler 4098 955 5053 total 25111 6069 31180 pension commitment provides pension board member compared potential length service survivor benefit depending amount recent age 63 year 65 year mr rice powell fixed compensation 63rd year life 65th year pension commitment dr ernst wastler provides mr rice powell case termination normal pension early retirement pension profes professional occupational incapacity time end sional incapacity pension widow orphan pen ing active work sion normal pension payable earliest age pension starting percentage 30 last fixed 60 year early retirement pension earliest compensation increase every full year service age 55 year pension benefit equivalent management board member 15 percentage point 45 12 per year service based last fixed compensa attainable maximum tion cap 40 widow pension 60 current pension increase according legal requirement orphan pension 20 capped aggregate section 16 german law improve company pension dr ernst wastlers pension entitlement plan betravg time death pension retirement benefit 30 gross amount postretirement income third party set pension benefit occupation management board member management board member mr mat henriksson offset pension professional occupational solely pension commitment fresenius kabi ag incapacity period previous service pension commitment event death one management board resenius remained unaffected service agreement f member widow receives pension equivalent 60 management se beginning january 1 2013 based pension entitlement accruing time death pension policy fresenius company janu addition legitimate biological child deceased manage ary 1 1988 provides retirement incapacity survi corporate governance ment board member individual case biological vors pension set forth deduction child deceased management board member wife income pension benefit widow pension amount adopted deceased management board 60 incapacity retirement pension granted member child receive orphan pension equivalent time death orphan pension amount 10 20 pension entitlement accruing time halforphans 20 orphan incapacity retire death completion vocational training ment pension granted time death total age 25 year however orphan pen entitlement widow orphan limited 100 sion widow pension capped aggregate mr mat henrikssons pension entitlement 90 management board member pension entitlement postemployment noncompetition covenant agreed management board member service member upon management board member cove management board fresenius management se nant becomes applicable management board member mr rice powell member management board receive waiting allowance generally equivalent fresenius medical care management ag end age half respective annual fixed compensation year 63 year 65 year mr rice powell reason respective application noncompetition covenant professional occupational incapacity right maximum two year said pension benefit vest pension payable service agreement management board mem upon occurrence pensionable event reduced pro bers contain explicit provision event rata according actual length service management change control 94 corporate governance miscellaneous fresenius se co kgaa undertook indemnify man member management board received individ agement board member legally permitted extent ual contractual commitment continuation claim may asserted compensation event sickness maximum period course service company affiliated 12 month provided six month sickness group company extent claim exceed related absence insurance benefit may paid liability german law cover obligation deducted continued compensation company purchased director officer insurance event death member management board deductible complying requirement stock cor surviving dependent receive three monthly payment poration law indemnification cover period month death occurred maximum respective member management board however expiry respective employment agree hold office well claim regard termination ment service management board fiscal year 2016 loan advance pay based pension commitment former member ment future compensation component granted management board 1094 thousand paid fiscal member management board fresenius man year 2016 2015 1081 thousand 585 thousand agement se 2015 588 thousand paid dr ben lipps result stephan sturm dr ulf schneider dr francesco de meo chairman management board chairman management board ceo fresenius helios since july 1 2016 june 30 2016 board member since january 1 2005 board member since may 28 2003 board member since january 1 2008 benefit granted 2016 2016 2016 2016 2016 2016 value thousand 2016 min max 2015 2016 min max 2015 2016 min max 2015 fixed compensation 850 850 850 600 550 550 550 1100 600 600 600 600 fringe benefit 43 43 43 109 72 72 72 143 23 23 23 22 total nonperformancebased compensation 893 893 893 709 622 622 622 1243 623 623 623 622 oneyear variable compensation 1 1773 1750 2300 1142 875 600 875 1712 1250 750 1250 1242 multiyear variable compensation component longterm incentive effect 2163 0 n 1426 0 0 n 2752 1475 0 n 1426 thereof postponed oneyear variable compensation 0 0 n 0 0 0 n 0 0 0 n 0 thereof stock option plan 2013 corporate governance part ltip 2013 5year term 1550 0 n 664 0 0 n 1328 1033 0 n 996 thereof phantom stock part ltip 2013 5year term 513 0 n 662 0 0 n 1324 342 0 n 330 thereof phantom stock 100 0 n 100 0 0 n 100 100 0 n 100 total nonperformancebased performancebased compensation 4829 2643 n 3277 1497 1222 n 5707 3348 1373 n 3290 service cost 276 276 276 251 191 191 191 342 300 300 300 273 value benefit granted 5105 2919 n 3528 1688 1413 n 6049 3648 1673 n 3563 1 f oneyear variable compensation target value comparable value board member receive remuneration fresenius management se oneyear variable compensation calculated basis bonus curve valid several year reason allocation oneyear variable remuneration stated 2 amount contains discretionary bonus mr rice powell amount 541 thousand 2015 fiscal year 3 mr rice powell granted stock option phantom stock performance share program fresenius medical care follows 2016 877 thousand share based award new incentive bonus plan 2010 1538 thousand long term incentive program 2016 performance share plan 2016 2015 164 thousand share based award new incentive bonus plan 2010 2244 thousand long term incentive program 2011 stock option plan 2011 777 thousand long term incentive program 2011 phantom stock plan 2011 corporate governance information corporate governance 95 consultancy agreement entered fresenius following table contain disclosure value medical care management ag benefit obligation benefit granted allocation conform person amounted 23183 thousand 2015 structure large degree specification 17835 thousand thereof 5182 thousand relates model table german corporate governance code dr ulf schneider table displaying allocation additionally show alloca tion fiscal year without multiyear variable table displaying value benefit compensation component longterm incentive effect granted allocation illustrates clearly allocation attributed german corporate governance code stipulates spe activity respective year review cific information shall presented compensation allocation result compensation component report pertaining benefit granted year granted previous even several reporting year review well allocation service cost differentiation comparability respective year review model table provided appen development compensation also increased dix german corporate governance code shall used present information dr jürgen götz mat henriksson rice powell dr ernst wastler chief legal compliance officer ceo fresenius kabi ceo fresenius medical care ceo fresenius vamed labor relation director board member since july 1 2007 board member since january 1 2013 board member since january 1 2013 board member since january 1 2008 2016 2016 2016 2016 2016 2016 2016 2016 2016 min max 2015 2016 min max 2015 2016 min max 2015 2016 min max 2015 460 460 460 460 600 600 600 600 1242 1242 1242 1239 500 500 500 500 37 37 37 70 149 149 149 185 121 121 121 342 72 72 72 85 497 497 497 530 749 749 749 785 1363 1363 1363 1581 572 572 572 585 928 700 950 869 1250 750 1250 1239 2050 169 2460 2586 2 775 650 950 707 1475 0 n 1426 1475 0 n 1426 2415 3 0 n 3185 3 1475 0 n 1426 0 0 n 0 0 0 n 0 0 0 n 0 corporate governance 1033 0 n 664 689 0 n 664 1033 0 n 664 342 0 n 662 686 0 n 662 342 0 n 662 100 0 n 100 100 0 n 100 100 0 n 100 2900 1197 n 2825 3474 1499 n 3450 5828 1532 n 7352 2822 1222 n 2718 211 211 211 190 188 188 188 173 741 741 741 570 137 137 137 133 3111 1408 n 3015 3662 1687 n 3623 6569 2273 n 7922 2959 1359 n 2851 96 corporate governance stephan sturm dr ulf schneider dr francesco de meo chairman management board chairman management board ceo fresenius helios since july 1 2016 june 30 2016 board member since january 1 2005 board member since may 28 2003 board member since january 1 2008 allocation value thousand 2016 2015 2016 2015 2016 2015 fixed compensation 850 600 550 1100 600 600 fringe benefit 43 109 72 143 23 22 total nonperformancebased compensation 893 709 622 1243 623 622 oneyear variable compensation 1773 1142 875 1712 1250 1242 multiyear variable compensation component longterm incentive effect 4234 5757 9454 10590 375 9333 thereof postponed oneyear variable compensation 30 49 0 0 108 0 thereof stock option plan 2003 5year term issue 2007 2078 1845 thereof stock option plan 2008 5year term issue 2010 3630 5771 3996 issue 2011 3937 2385 3 4819 3492 issue 2012 6802 3 thereof phantom stock issue 2011 267 267 267 0 0 0 0 0 0 total nonperformancebased performancebased compensation 6900 7608 10951 13545 2248 11197 service cost 276 251 191 342 300 273 allocation including multiyear variable compensation compo nents longterm incentive effect 7176 7859 11142 13887 2548 11470 allocation year review including multiyear variable compensation component longterm incentive effect 2942 2102 1688 3297 2173 2137 1 amount contains discretionary bonus mr rice powell amount 541 thousand 2015 fiscal year mr rice powell allocation stock option fresenius medical care stock option program corporate governance 2 2016 598 thousand share based award new incentive bonus plan 2010 issue 2012 2043 thousand stock option plan 2006 issue 2009 446 thousand stock option plan 2006 issue 2010 186 thousand long term incentive program 2011 phantom stock plan 2011 issue 2011 2015 485 thousand share based award new incentive bonus plan 2010 issue 2011 2123 thousand stock option plan 2006 issue 2008 3 allocation relates stock option dr ulf schneider exercised resignation management board june 30 2016 accordance condition participation stock option plan corporate governance information corporate governance 97 dr jürgen götz mat henriksson rice powell dr ernst wastler chief legal compliance officer ceo fresenius kabi ceo fresenius medical care ceo fresenius vamed labor relation director board member since july 1 2007 board member since january 1 2013 board member since january 1 2013 board member since january 1 2008 2016 2015 2016 2015 2016 2015 2016 2015 460 460 600 600 1242 1239 500 500 37 70 149 185 121 342 72 85 497 530 749 785 1363 1581 572 585 928 869 1250 1239 2403 1032 1 775 707 267 5993 65 1878 3273 2 2608 2 267 11030 0 0 65 0 0 0 992 1525 2792 2493 353 3723 3500 3523 267 267 0 0 0 0 0 0 0 0 1692 7392 2064 3902 7039 5221 1614 12322 211 190 188 173 741 570 137 133 1903 7582 2252 4075 7780 5791 1751 12455 1636 1589 2187 2197 4507 3183 1484 1425 corporate governance 98 corporate governance compensation supervisory board operation intrusion detection system amount compensation supervisory board determined 14 thousand fresenius se co kgaa provides annual general meeting subject provi member supervisory board insurance coverage sion contained section 13 article association adequate amount relating function excess fresenius se co kgaa member supervisory equal management board board shall receive fixed compensation 13 thousand member supervisory board fresenius se full fiscal year co kgaa time member supervisory member audit committee fresenius se board general partner fresenius management se co kgaa receive additional 10 thousand receives remuneration service supervisory chairman committee 10 thousand resenius management se remuneration shall board f full fiscal year remuneration increase 10 reduced half applies respect percentage point three time dividend paid additional part remuneration chairman one ordinary share year gross dividend according deputy time chairman resolution annual general meeting exceeds 36 one deputy supervisory board fresenius amount equal subscribed capital divided management se deputy chairman super number nonpar value share residual amount inter visory board fresenius se co kgaa time polated general meeting resolve higher remunera chairman supervisory board fresenius man tion view annual result increased amount shall agement se shall receive remuneration service applicable chairman receives twice amount deputy chairman supervisory board fresenius deputy chairman one half time se co kgaa according section 7 article asso amount supervisory board member member ciation fresenius se co kgaa remuneration supervisory board receive appropriate compensation supervisory board fresenius management se charged cost travel accommodation incurred connection fresenius se co kgaa duty member supervisory board includ fiscal year 2016 2015 compensation ing applicable valueadded tax additionally capac member supervisory board fresenius se ity chairman supervisory board fresenius man resenius management se excluding expense co kgaa f agement se dr krick reimbursed cost reimbursement including compensation committee service follows corporate governance corporate governance information corporate governance 99 compensation variable total fixed compensation committee service compensation compensation fresenius se fresenius fresenius se fresenius fresenius se fresenius co kgaa management se co kgaa management se co kgaa management se thousand 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 dr gerd krick 13 13 13 13 10 10 20 20 237 210 237 210 530 476 michael diekmann since may 20 2015 13 8 6 4 0 0 0 0 237 129 119 65 375 206 dr dieter schenk 0 0 19 19 0 0 10 10 0 0 356 315 385 344 niko stumpfögger 19 19 0 0 0 0 0 0 356 315 0 0 375 334 prof dr med michael albrecht 13 13 0 0 0 0 0 0 237 210 0 0 250 223 prof dr h c roland berger may 13 2016 2 7 2 6 7 20 0 0 44 104 44 105 99 242 dr kurt bock since may 13 2016 0 0 8 0 0 0 0 0 0 0 151 0 159 0 dario ilossi may 13 2016 5 13 0 0 0 0 0 0 87 210 0 0 92 223 konrad kölbl 13 13 0 0 10 10 0 0 237 210 0 0 260 233 stefanie lang since may 13 2016 8 0 0 0 0 0 0 0 151 0 0 0 159 0 frauke lehmann since may 13 2016 8 0 0 0 0 0 0 0 151 0 0 0 159 0 prof dr med iris löwfriedrich since may 13 2016 8 0 0 0 0 0 0 0 151 0 0 0 159 0 klauspeter müller 7 7 6 6 13 0 0 0 118 104 119 105 263 222 dieter reuß may 13 2016 5 13 0 0 0 0 0 0 87 210 0 0 92 223 gerhard roggemann may 13 2016 5 13 0 0 4 10 0 0 87 210 0 0 96 233 oscar romero de paco since may 13 2016 8 0 0 0 0 0 0 0 151 0 0 0 159 0 dr karl schneider 0 0 13 13 0 0 10 10 0 0 237 210 260 233 stefan schubert may 13 2016 5 13 0 0 0 0 0 0 87 210 0 0 92 223 hauke star since may 13 2016 8 0 0 0 6 0 0 0 150 0 0 0 164 0 rainer stein 13 13 0 0 10 10 0 0 237 210 0 0 260 233 total 153 145 67 61 60 60 40 40 2805 2332 1263 1010 4388 3648 corporate governance director officer insurance ffiliates co kgaa well representative body fresenius se co kgaa taken consequential loss germany elsewhere policy applies throughout liability insurance policy insurance excess world run end june 2017 policy cov amount basis member management board er legal defense cost member representative supervisory board general partner fresenius se body claim made relevant dam resenius se co kgaa supervisory board f age paid covered policy 100 consolidated financial statement table content consolidated financial statement 101 consolidated statement income 104 consolidated statement change equity 101 consolidated statement comprehensive income 106 consolidated segment reporting 102 consolidated statement financial position 108 note 103 consolidated statement cash flow financial statement consolidated financial statement consolidated statement income consolidated statement comprehensive income 101 fresenius se co kgaa consolidated statement income million note 2016 2015 sale 4 29083 27626 cost sale 5 19955 19092 gross profit 9128 8534 selling general administrative expense 8 4301 4195 research development expense 500 464 operating income ebit 4327 3875 interest income 9 96 255 interest expense 9 678 868 income income tax 3745 3262 income tax 10 1051 965 net income 2694 2297 less noncontrolling interest 11 1101 939 net income attributable shareholder fresenius se co kgaa 1593 1358 earnings per share 12 292 250 fully diluted earnings per share 12 290 248 following note integral part consolidated financial statement fresenius se co kgaa consolidated statement comprehensive income million note 2016 2015 net income 2694 2297 comprehensive income loss foreign currency translation 27 29 544 869 cash flow hedge 27 29 23 63 change fair value available sale financial asset 27 29 actuarial gain loss defined benefit pension plan 24 27 78 95 income tax related component comprehensive income loss 27 1 76 comprehensive income net 488 951 financial statement total comprehensive income 3182 3248 comprehensive income attributable noncontrolling interest subject put provision 203 221 comprehensive income attributable noncontrolling interest subject put provision 1142 1270 comprehensive income attributable shareholder fresenius se co kgaa 1837 1757 following note integral part consolidated financial statement 102 consolidated financial statement fresenius se co kgaa consolidated statement financial position asset december 31 million note 2016 2015 cash cash equivalent 13 1579 1044 trade account receivable less allowance doubtful account 14 5052 4596 account receivable loan related party 13 78 inventory 15 3189 2860 current asset 16 1966 1901 total current asset 11799 10479 property plant equipment 17 8138 7428 goodwill 18 22774 21523 intangible asset 18 1571 1510 noncurrent asset 16 1605 1479 deferred tax 10 560 540 ii total noncurrent asset 34648 32480 total asset 46447 42959 liability shareholder equity december 31 million note 2016 2015 trade account payable 1315 1291 shortterm account payable related party 57 9 shortterm accrued expense shortterm liability 19 20 4979 4691 shortterm debt 21 847 202 shortterm debt related party 6 4 current portion longterm debt capital lease obligation 21 611 607 current portion senior note 22 473 349 shortterm accrual income tax 256 195 total shortterm liability 8544 7348 longterm debt capital lease obligation less current portion 21 5048 5502 senior note less current portion 22 6941 7267 convertible bond 23 854 838 longterm accrued expense longterm liability 19 20 1205 955 pension liability 24 1155 1078 longterm accrual income tax 221 221 deferred tax 10 875 800 b total longterm liability 16299 16661 financial statement total liability 24843 24009 ii noncontrolling interest subject put provision 25 1184 947 noncontrolling interest subject put provision 25 7917 7068 subscribed capital 26 547 546 capital reserve 26 3125 3095 reserve 26 8307 7014 accumulated comprehensive income 27 524 280 b total fresenius se co kgaa shareholder equity 12503 10935 iii total shareholder equity 20420 18003 total liability shareholder equity 46447 42959 following note integral part consolidated financial statement consolidated financial statement consolidated statement financial position consolidated statement cash flow 103 fresenius se co kgaa consolidated statement cash flow january 1 december 31 million note 2016 2015 operating activity net income 2694 2297 adjustment reconcile net income cash cash equivalent provided operating activity depreciation amortization 16 17 18 1173 1115 gain sale investment divestiture 2 2 34 change deferred tax 10 10 73 loss sale fixed asset 5 1 change asset liability net amount business acquired disposed trade account receivable net 14 274 303 inventory 15 304 451 current noncurrent asset 16 14 51 account receivable payable related party 55 6 trade account payable accrued expense shortterm longterm liability 19 20 194 695 accrual income tax 37 23 net cash provided operating activity 3574 3327 investing activity purchase property plant equipment 17 1628 1489 proceeds sale property plant equipment 25 27 acquisition investment net cash acquired net purchase intangible asset 2 31 675 396 proceeds sale investment divestiture 2 190 364 net cash used investing activity 2088 1494 financing activity proceeds shortterm debt 21 985 260 repayment shortterm debt 21 351 349 proceeds longterm debt capital lease obligation 21 387 281 repayment longterm debt capital lease obligation 21 1101 985 proceeds issuance senior note 22 0 269 repayment liability senior note 22 350 729 change account receivable securitization program 21 112 262 proceeds exercise stock option 33 76 173 dividend paid 738 639 change noncontrolling interest 25 1 3 exchange rate effect due corporate financing 5 2 net cash used financing activity 976 1982 effect exchange rate change cash cash equivalent 25 18 financial statement net increase decrease cash cash equivalent 535 131 cash cash equivalent beginning reporting period 13 1044 1175 cash cash equivalent end reporting period 13 1579 1044 following note integral part consolidated financial statement 104 consolidated financial statement fresenius se co kgaa consolidated statement change equity subscribed capital reserve number capital ordinary share amount amount reserve reserve note thousand thousand million million million december 31 2014 541533 541533 542 3018 5894 proceeds exercise stock option 33 4195 4195 4 110 compensation expense related stock option 33 19 vested subsidiary stock incentive plan 1 dividend paid 26 238 sale noncontrolling interest subject put provision 25 noncontrolling interest subject put provision 25 51 comprehensive income loss net income 1358 comprehensive income loss cash flow hedge 27 29 change fair value available sale financial asset 27 29 foreign currency translation 27 29 actuarial gain defined benefit pension plan 24 27 comprehensive income 1358 december 31 2015 545728 545728 546 3095 7014 proceeds exercise stock option 33 1480 1480 1 44 compensation expense related stock option 33 27 vested subsidiary stock incentive plan 1 dividend paid 26 300 purchase noncontrolling interest subject put provision 25 noncontrolling interest subject put provision 25 40 comprehensive income loss net income 1593 comprehensive income loss cash flow hedge 27 29 change fair value available sale financial asset 27 29 foreign currency translation 27 29 actuarial loss defined financial statement benefit pension plan 24 27 comprehensive income 1593 december 31 2016 547208 547208 547 3125 8307 consolidated financial statement consolidated statement change equity 105 accumulated total fresenius noncontrolling com se co kgaa interest total prehensive shareholder subject put shareholder income loss equity provision equity note million million million million december 31 2014 119 9335 6148 15483 proceeds exercise stock option 33 114 59 173 compensation expense related stock option 33 19 7 26 vested subsidiary stock incentive plan 1 3 4 dividend paid 26 238 250 488 sale noncontrolling interest subject put provision 25 0 45 45 noncontrolling interest subject put provision 25 51 118 169 comprehensive income loss net income 1358 793 2151 comprehensive income loss cash flow hedge 27 29 25 25 21 46 change fair value available sale financial asset 27 29 foreign currency translation 27 29 325 325 439 764 actuarial gain defined benefit pension plan 24 27 49 49 17 66 comprehensive income 399 1757 1270 3027 december 31 2015 280 10935 7068 18003 proceeds exercise stock option 33 45 31 76 compensation expense related stock option 33 27 19 46 vested subsidiary stock incentive plan 1 2 3 dividend paid 26 300 260 560 purchase noncontrolling interest subject put provision 25 0 5 5 noncontrolling interest subject put provision 25 40 86 126 comprehensive income loss net income 1593 928 2521 comprehensive income loss cash flow hedge 27 29 3 3 11 14 change fair value available sale financial asset 27 29 foreign currency translation 27 29 293 293 212 505 actuarial loss defined financial statement benefit pension plan 24 27 52 52 9 61 comprehensive income 244 1837 1142 2979 december 31 2016 524 12503 7917 20420 following note integral part consolidated financial statement 106 consolidated financial statement fresenius se co kgaa consolidated segment reporting business segment fresenius medical care fresenius kabi million 2016 2015 change 2016 2015 1 change sale 16181 15086 7 6007 5950 1 thereof contribution consolidated sale 16158 15062 7 5956 5903 1 thereof intercompany sale 23 24 4 51 47 9 contribution consolidated sale 56 55 20 21 ebitda 3084 2744 12 1479 1446 2 depreciation amortization 701 647 8 255 257 1 ebit 2383 2097 14 1224 1189 3 net interest 366 353 4 149 184 19 income tax 618 560 10 323 306 6 net income attributable shareholder fresenius se co kgaa 1123 928 21 716 669 7 operating cash flow 1933 1767 9 991 913 9 cash flow acquisition dividend 1019 923 10 668 589 13 total asset 25552 23298 10 11125 10395 7 debt 8132 7942 2 5155 5234 2 capital expenditure gross 931 859 8 322 352 9 acquisition gross investment 774 385 101 114 37 research development expense 147 126 17 353 336 5 employee per caput balance sheet date 116120 110242 5 34917 33195 5 key figure ebitda margin 191 182 246 243 ebit margin 147 139 204 200 depreciation amortization sale 43 43 42 43 operating cash flow sale 119 117 165 153 rooa 104 96 127 132 1 cost efficiency program 2 integration cost disposal gain two helios hospital 3 cost efficiency program integration cost disposal gain two helios hospital 4 underlying ebit include cost efficiency program integration cost disposal gain two helios hospital region europe north america million 2016 2015 change 2016 2015 change sale 10839 10557 3 13735 12621 9 financial statement contribution consolidated sale 38 38 47 46 ebit 902 888 2 2691 2337 15 depreciation amortization 483 467 3 549 521 5 total asset 16865 15986 5 24314 22480 8 capital expenditure gross 763 672 14 671 615 9 acquisition gross investment 346 241 44 444 213 108 employee per caput balance sheet date 119434 114753 4 72803 68859 6 consolidated financial statement consolidated segment reporting 107 fresenius helios fresenius vamed corporate fresenius group 2016 2015 2 change 2016 2015 change 2016 2015 3 change 2016 2015 change 5843 5578 5 1160 1118 4 108 106 2 29083 27626 5 5843 5578 5 1122 1077 4 4 6 33 29083 27626 5 0 0 38 41 7 112 112 0 0 0 20 20 4 4 0 0 100 100 877 831 6 80 75 7 20 106 81 5500 4990 10 195 191 2 11 11 0 11 9 22 1173 1115 5 682 640 7 69 64 8 31 115 73 4327 3875 12 37 48 23 2 3 33 28 25 12 582 613 5 100 108 7 21 16 31 11 25 56 1051 965 9 543 483 12 45 44 2 834 766 9 1593 1358 17 622 618 1 27 53 49 1 24 104 3574 3327 7 273 347 21 16 42 62 5 36 86 1971 1865 6 8701 8430 3 1108 988 12 39 152 74 46447 42959 8 1406 1282 10 176 161 9 89 150 159 14780 14769 0 352 277 27 11 11 0 5 13 62 1621 1512 7 38 99 62 4 100 0 8 100 926 517 79 0 0 0 2 100 500 464 8 72687 69728 4 8198 8262 1 951 878 8 232873 222305 5 150 149 69 67 189 184 1 2 117 115 59 57 149 143 1 2 33 34 09 10 40 40 106 111 23 47 123 120 84 81 105 111 101 101 4 consolidated segment reporting business segment integral part note following note integral part consolidated financial statement asiapacific latin america africa fresenius group 2016 2015 change 2016 2015 change 2016 2015 change 2016 2015 change 2928 2779 5 1223 1297 6 358 372 4 29083 27626 5 financial statement 10 10 4 5 1 1 100 100 587 511 15 98 79 24 49 60 18 4327 3875 12 95 85 12 39 36 8 7 6 17 1173 1115 5 3591 3108 16 1479 1225 21 198 160 24 46447 42959 8 98 109 10 79 106 25 10 10 0 1621 1512 7 122 53 130 14 10 40 0 0 926 517 79 22441 20257 11 16283 16498 1 1912 1938 1 232873 222305 5 consolidated segment reporting region integral part note following note integral part consolidated financial statement 108 consolidated financial statement table content note 109 general note 136 21 debt capital lease obligation 109 1 principle 142 22 senior note 109 group structure 144 23 convertible bond 109 ii basis presentation 144 24 pension similar obligation 110 iii summary significant accounting policy 151 25 noncontrolling interest 120 iv critical accounting policy 152 26 fresenius se co kgaa shareholder equity 122 2 acquisition divestiture investment 154 27 comprehensive income loss 124 note consolidated statement income 156 note 124 3 special item 156 28 commitment contingent liability 124 4 sale 162 29 financial instrument 124 5 cost sale 169 30 supplementary information capital management 124 6 cost material 170 31 supplementary information consolidated 124 7 personnel expense statement cash flow 125 8 selling general administrative expense 171 32 note consolidated segment reporting 125 9 net interest 173 33 sharebased compensation plan 125 10 tax 181 34 related party transaction 127 11 noncontrolling interest 181 35 subsequent event 127 12 earnings per share 182 note accordance german commercial code hgb 128 note consolidated statement financial position 182 36 compensation management board 128 13 cash cash equivalent supervisory board 128 14 trade account receivable 183 37 auditor fee 128 15 inventory 183 38 corporate governance 129 16 current noncurrent asset 183 39 proposal distribution earnings 130 17 property plant equipment 184 40 responsibility statement 131 18 goodwill intangible asset 134 19 accrued expense 135 20 liability financial statement consolidated financial statement general note 109 general note center quirónsalud treat approximately 320000 inpa tients approximately 94 million outpatient annually 1 principle hospital spain operates total approximately 6600 bed group structure fresenius vamed manages project provides service fresenius global health care group product ser hospital health care facility worldwide vice dialysis hospital outpatient medical care portfolio range along entire value chain proj addition fresenius group focus hospital operation ect development planning turnkey construction via also manages project provides service hospi maintenance technical management total operational tals health care facility worldwide besides management activity parent company fresenius se co kgaa fresenius se co kgaa owned 3082 sub bad homburg v h operating activity split scribed capital fresenius medical care ag co kgaa following legally independent business segment fmcag co kgaa end fiscal year 2016 fiscal year 2016 fresenius medical care management ag general partner fmcag co kgaa wholly owned subsidiary fresenius medical care fresenius se co kgaa structure fresenius fresenius kabi se co kgaa right give fresenius se co kgaa fresenius helios ability direct relevant activity hence fresenius vamed earnings fmcag co kgaa therefore fmcag co kgaa fully consolidated consolidated financial statement fresenius medical care world largest integrated pro fresenius group vider product service individual renal dis fresenius se co kgaa continued hold 100 eas december 31 2016 fresenius medical care management company business segment fresenius treating 308471 patient 3624 dialysis clinic along kabi fresenius kabi ag well fresenius helios core business company seek expand range fresenius vamed held fresenius proserve medical service field care coordination gmbh december 31 2016 fresenius proserve fresenius kabi offer infusion therapy intravenously gmbh fresenius se co kgaa hold 100 helios administered generic drug clinical nutrition seriously kliniken gmbh 77 stake vamed ag addition chronically ill patient hospital outpatient fresenius se co kgaa hold interest company environment company also leading supplier medi holding function regarding real estate financing insur cal device transfusion technology product ance well fresenius netcare gmbh offer fresenius helios germany largest hospital operator service field information technology end 2016 helios group operated 112 hospital reporting currency fresenius group euro thereof 88 acute care hospital including 7 maximum care order make presentation clearer amount hospital berlinbuch duisburg erfurt krefeld schwerin mostly shown million euro amount 1 million wiesbaden wuppertal 24 postacute care clinic rounding marked fresenius helios treat 52 million patient per year thereof approximately 13 million inpatient operates ii basis presentation financial statement approximately 35000 bed accompanying consolidated financial statement following closing acquisition quirónsalud prepared accordance united state generally january 31 2017 fresenius helios also largest private accepted accounting principle u gaap hospital operator spain quirónsalud offer full spectrum fresenius se co kgaa stock exchange listed com inpatient outpatient care 43 hospital 39 outpatient pany domicile member state european center around 300 occupational risk prevention 110 consolidated financial statement union fulfills obligation prepare publish consol item property plant equipment inventory acquired idated financial statement accordance interna group entity also eliminated deferred tax tional financial reporting standard ifrs applying section asset liability recognized temporary difference 315a german commercial code hgb simultaneously resulting consolidation procedure fresenius group voluntarily prepares publishes noncontrolling interest subject put provision recog consolidated financial statement accordance u gaap nized liability equity consolidated state due requirement fresenius medical care ag ment financial position noncontrolling interest subject co kgaa report accordance u gaap put provision comprised interest noncontrolling socalled pooling agreement shareholder consolidated equity group entity may 2016 annual general meeting fresenius profit loss attributable noncontrolling sharehold medical care ag co kgaa rescinded obligation pre er separately disclosed consolidated statement pare report u gaap financial statement therefore income noncontrolling interest subject put provision fresenius group managed solely accordance acquired entity valuated fair value ifrs starting 2017 fiscal year longer pro associated company fresenius se vide consolidated financial statement according u gaap co kgaa significant exercisable influence generally voluntarily hold 20 less 50 voting order improve readability various item aggre right consolidated using equity method invest gated consolidated statement financial position ments classified associated company consolidated statement income item recorded acquisition cost fair value respectively shown separately note provide useful information reader consolidated financial statement b composition group consolidated statement financial position classi consolidated financial statement include material fied basis maturity asset liability company fresenius se co kgaa legal consolidated statement income classified using cost effective control includes variable interest entity ofsales accounting format resenius group deemed primary vies f beneficiary iii summary significant accounting fresenius medical care entered various arrange policy ments certain legal entity whereby entity equity principle consolidation holder lack power direct activity signifi financial statement consolidated entity cantly impact entity performance obligation prepared using uniform accounting method acquisi absorb expected loss receive expected residual return tions company accounted applying purchase legal entity arrangement entity method vie fresenius medical care determined capital consolidation performed offsetting invest primary beneficiary therefore ments subsidiary underlying revaluated equity fully consolidated fresenius medical care provided date acquisition identifiable asset liabili following service vies management tie subsidiary well noncontrolling interest financing product supply generated approximately recognized fair value remaining debit balance 227 million us251 million 223 million us247 mil financial statement investment subsidiary plus noncontrol lion sale 2016 2015 respectively fresenius ling interest revaluated equity recognized good medical care provided funding vie loan tested least year impairment account receivable 179 million u 188 million significant intercompany sale expense income 180 million us196 million 2016 2015 respec receivables payable eliminated profit loss tively relating vies 2016 fresenius medical care consolidated financial statement general note 111 consolidated asset amount 242 million u 255 fiscal year 2016 following fully consolidated million liability amount 232 million u 245 german subsidiary fresenius group apply million 10 million u 10 million equity 2015 exemption provided section 264 3 264b respec 248 million u 270 million asset 225 million u 245 tively german commercial code hgb million liability 23 million u 25 million equity consolidated due firsttime implementation name company registered office accounting standard update 201502 2016 number corporate fresenius biotech beteiligungs gmbh bad homburg v h entity consolidated vies decreased prior year fresenius immobilienverwaltungs figure adjusted accordingly see note 1iiiff recent pro gmbh co objekt friedberg kg bad homburg v h nouncements applied interest held share fresenius immobilienverwaltungs gmbh co objekt st wendel kg bad homburg v h holder consolidated vies reported noncontrolling fresenius immobilienverwaltungs interest consolidated statement financial position gmbh co objekt schweinfurt kg bad homburg v h fresenius vamed participates project entity fresenius netcare gmbh bad homburg v h set longterm defined period time fresenius proserve gmbh bad homburg v h fps immobilien verwaltungs specific purpose constructing operating thermal cen gmbh co reichenbach kg bad homburg v h ters project entity qualify vie proserve krankenhaus beteiligungs fresenius vamed primary beneficiary based gesellschaft mbh co kg münchen fresenius kabi cash flow analysis involved party project enti fresenius hemocare gmbh bad homburg v h tie generated approximately 114 million sale 2016 fresenius hemocare beteiligungs gmbh bad homburg v h 2015 110 million vie finance mainly fresenius kabi ag bad homburg v h debt profit participation right investment grant fresenius kabi deutschland gmbh bad homburg v h asset liability relating vie material fresenius kabi logistik gmbh friedberg fresenius kabi fresenius vamed made payment vies vermögensverwaltung gmbh bad homburg v h contractually stipulated today perspective due mc medizintechnik gmbh alzenau contractual situation fresenius vamed exposed medi1one medical gmbh waiblingen material risk loss vies fresenius helios helios agneskarllkrankenhaus gmbh bad schwartau consolidated financial statement 2016 included helios aokklinik bad em gmbh bad em addition fresenius se co kgaa 2477 2015 2323 helios aukammklinik wiesbaden gmbh wiesbaden fully consolidated company 33 2015 31 company helios beteiligungs aktiengesellschaft berlin accounted equity method 2016 helios bördeklinik gmbh oschersleben bode material change scope consolidated enti helios care gmbh berlin helios fachkliniken tie except mentioned note 2 acquisition hildburghausen gmbh hildburghausen divestiture investment helios hanseklinikum stralsund gmbh stralsund complete list investment fresenius se helios kid pflege gmbh geesthacht co kgaa registered office 61352 bad homburg v h helios klinik berching gmbh berching helios klinik bergischland gmbh wuppertal elsekrönerstraße 1 registered commercial register helios klinik blankenhain gmbh blankenhain local court bad homburg v h b11852 helios klinik bleicherode gmbh bleicherode submitted electronic federal gazette financial statement helios klinik für herzchirurgie electronic company register karlsruhe gmbh karlsruhe helios klinik geesthacht gmbh geesthacht helios klinik hagen ambrock gmbh hagen helios klinik hattingen gmbh hattingen helios klinik hohenstücken gmbh brandenburg helios klinik jerichower land gmbh burg helios klinik leezen gmbh leezen 112 consolidated financial statement name company registered office c classification fresenius helios certain item consolidated financial statement helios klinik leisnig gmbh leisnig 2015 reclassified conform presentation helios klinik lengerich gmbh lengerich helios klinik schkeuditz gmbh schkeuditz 2016 helios klinik schloss pulsnitz gmbh pulsnitz deferred tax classified current helios klinik schloss schönhagen gmbh damp december 31 2015 reclassified noncurrent helios klinik schwedenstein january 1 2016 accordance accounting standard pulsnitz gmbh pulsnitz helios klinik volkach gmbh volkach update 201517 financial accounting standard board helios klinik wipperfürth gmbh wipperfürth accounting standard codification topic 740 income tax helios klinik zerbst anhalt gmbh zerbst balance sheet classification deferred tax helios kliniken breisgauhochschwarzwald gmbh müllheim helios kliniken gmbh berlin sale recognition policy helios kliniken bad grönenbach gmbh bad grönenbach sale service recognized amount estimated helios kliniken mansfeldsüdharz gmbh sangerhausen receivable reimbursement arrangement helios kliniken taunus gmbh bad schwalbach third party payors sale recognized date service helios klinikum aue gmbh aue related product provided customer obli helios klinikum bad saarow gmbh bad saarow gated pay helios klinikum berlinbuch gmbh berlin helios klinikum erfurt gmbh erfurt product sale recognized title product helios klinikum gotha gmbh gotha ohrdruf pass customer either time shipment helios klinikum krefeld gmbh krefeld upon receipt customer upon term helios klinikum meiningen gmbh meiningen clearly define passage title product return helios klinikum pirna gmbh pirna typical return provision recognized event helios klinikum schwelm gmbh schwelm helios klinikum siegburg gmbh siegburg return required appropriate reduction sale helios klinikum uelzen gmbh uelzen cost sale account receivable made sale pre helios klinikum wuppertal gmbh wuppertal sented net discount allowance rebate helios ostseeklinik damp gmbh damp business segment fresenius vamed sale long helios parkklinikum leipzig gmbh leipzig term production contract recognized using percent helios privatkliniken gmbh bad homburg v h ostseebad age completion poc method accounting condi helios rehaklinik ahrenshoop gmbh ahrenshoop tions met sale recognized calculated helios rehaklinik damp gmbh damp percentage cost already incurred based esti helios rehakliniken bad berleburg gmbh bad berleburg mated total cost contract milestone laid helios rehakliniken gmbh damp heliosservice gmbh berlin contract percentage completion profit helios spital überlingen gmbh überlingen recognized earnings production contract helios st elisabethkrankenhaus accounted using poc method measured reliably bad kissingen gmbh bad kissingen expected excess total contract cost total helios st josefshospital gmbh bochum helios versorgungszentren gmbh berlin contract revenue contract recognized expense helios versorgungszentrum immediately bad saarow gmbh bad saarow tax assessed governmental authority financial statement helios vogtlandklinikum plauen gmbh plauen incurred result sale transaction e g sale tax helios weißeritztalkliniken gmbh freital herzzentrum leipzig gmbh leipzig excluded sale related sale reported klinik kipfenberg gmbh neurochirur net basis gische und neurologische fachklinik kipfenberg ostsee resort damp gmbh damp poliklinik helios klinikum buch gmbh berlin senioren und pflegeheim erfurt gmbh erfurt verwaltungsgesellschaft endoklinik mbh hamburg consolidated financial statement general note 113 e government grant h capitalized interest fresenius group primarily receives governmental funding fresenius group includes capitalized interest part hospital germany finance building medical cost asset directly attributable acqui equipment public sector grant recognized sition construction manufacture qualifying asset reasonable assurance respective condition fiscal year 2016 2015 interest 4 million met grant received initially grant 5 million based average interest rate 464 recorded liability soon asset acquired 448 respectively recognized component grant offset acquisition cost expense cost asset related grant recognized income period related cost occur income tax current tax calculated based earnings f research development expense fiscal year accordance local tax rule research independent planned investigation respective tax jurisdiction expected executed addi taken prospect gaining new scientific techni tional tax payment tax refund prior year cal knowledge understanding development techni also taken account cal commercial implementation research result deferred tax asset liability recognized occurs start commercial production use future consequence attributable temporary difference research development expense expensed financial statement carrying amount existing incurred asset liability respective tax basis deferred tax recognized certain consolidation g impairment procedure affecting net income attributable shareholder fresenius group review carrying amount prop fresenius se co kgaa deferred tax asset also include erty plant equipment intangible asset non claim future tax reduction arise current asset impairment whenever event change likely expected usage existing tax loss available circumstance indicate carrying amount carryforward recognition deferred tax asset asset may recoverable recoverability asset net operating loss utilization based measured comparing carrying amount asset budget planning fresenius group implemented future net cash flow directly associated asset tax strategy asset considered impaired impairment rec deferred tax computed using enacted adopted tax ognized amount carrying amount exceeds rate relevant national jurisdiction amount fair value asset fresenius group us dis recovered tax rate valid future counted cash flow approach method appropriate adopted till date statement financial posi assess fair value longlived asset disposed tion considered sale reported lower carrying amount fair value realizability carrying amount deferred tax less cost sell depreciation ceased asset reviewed date statement financial position assessing realizability deferred tax asset management considers whether likely portion deferred tax asset real financial statement ized ultimate realization deferred tax asset depen dent upon generation future taxable income period temporary difference tax loss carryforwards become deductible management considers expected reversal deferred tax liability projected future taxable income making assessment 114 consolidated financial statement longer likely sufficient taxable trade account receivable income available allow benefit part trade account receivable stated nominal value entire deferred tax asset utilized carrying amount less allowance doubtful account allowance deferred tax asset reduced certain extent estimate comprised customerspecific evaluation regard reduction reversed date extent becomes ing payment history current financial stability probable sufficient taxable profit available applicable countryspecific risk receivables fresenius group policy asset uncertain due one year time time account receiv tax position recognized extent likely able reviewed change historic collection expe tax recovered also fresenius group rience ensure appropriateness allowance policy recognize interest penalty related tax position income tax expense n inventory inventory comprised asset held sale j unrecognized tax benefit normal course business finished good pro recognition measurement tax position taken cess production sale work process consumed expected taken tax return requires two step production process rendering service raw approach fresenius group determines whether material purchased component likely tax position sustained upon inventory stated lower acquisition examination including resolution related appeal manufacturing cost determined using average first litigation process based technical merit firstout method net realizable value manufacturing position threshold met tax position measured cost comprised direct cost production material largest amount tax benefit 50 overhead including depreciation charge likely realized upon settlement recognized consolidated financial statement available sale financial asset investment equity instrument debt instrument k earnings per share fund share classified available sale financial asset basic earnings per share computed dividing net measured fair value fresenius group regularly income attributable shareholder fresenius se co kgaa review objective substantial evidence occurs would weightedaverage number ordinary share indicate impairment financial asset portfolio standing year diluted earnings per share include financial asset testing recoverability asset effect potentially dilutive instrument ordinary possible impairment loss recorded consolidated share would outstanding fiscal year statement financial position gain loss available equitysettled award granted fresenius sale financial asset recognized directly con fresenius medical care stock option plan result solidated statement equity financial asset dis dilutive effect posed considered impaired case impairment accumulated net loss retrieved l cash cash equivalent consolidated statement equity recognized con cash cash equivalent comprised cash fund solidated statement income shortterm liquid investment original maturity financial statement three month time deposit security consolidated financial statement general note 115 p property plant equipment useful life trade name acquired purchase property plant equipment stated acquisition method business combination recognized reported manufacturing cost less accumulated depreciation signifi apart goodwill recorded acquisition cost cant improvement capitalized repair maintenance goodwill intangible asset indefinite useful life cost extend useful life asset amortized tested impairment annually charged expense incurred depreciation property event becomes known could trigger impairment plant equipment calculated using straightline impairment test method estimated useful life asset ranging perform annual impairment test goodwill 3 50 year building improvement fresenius group identified several reporting unit deter weightedaverage life 16 year 2 15 year mined carrying amount assigning asset lia machinery equipment weightedaverage life bilities including existing goodwill intangible asset 11 year reporting unit reporting unit usually defined one level segment level based region q intangible asset finite useful life nature business activity 4 reporting unit identi intangible asset finite useful life patent prod fied segment fresenius medical care fresenius uct distribution right noncompete agreement tech kabi respectively europe latin america asiapacific nology well license manufacture distribute sell north america according regional organizational pharmaceutical drug amortized using straightline structure segment fresenius helios consists 10 report method respective useful life residual val ing unit managed central division ues reviewed impairment see note 1 iii g impair segment fresenius vamed consists 2 reporting unit proj ment useful life patent product distribution right ect business service business least year range 5 20 year average useful life 13 year fresenius group compare fair value reporting useful life customer relationship vary 6 15 unit reporting unit carrying amount fair value year average useful life 10 year noncompete agree reporting unit determined using discounted cash flow ments finite useful life useful life ranging approach based upon cash flow expected gener 2 25 year average useful life 6 year technology ated reporting unit case fair value finite useful live 15 year license manufacture reporting unit less carrying amount difference distribute sell pharmaceutical drug amortized first recorded impairment fair value contractual license period intangible asset goodwill amortized individual estimated useful life evaluate recoverability separable intangible 3 15 year asset indefinite useful life fresenius group com loss value lasting nature recorded pares fair value intangible asset impairment carrying amount intangible asset fair value deter mined using discounted cash flow approach r goodwill intangible asset method appropriate indefinite useful life recoverability goodwill separable intan resenius group identified intangible asset indefi f gible asset indefinite useful life recorded group nite useful life based analysis consolidated statement financial position verified financial statement relevant factor foreseeable limit period result fresenius group record impairment asset expected generate net cash inflow loss 2016 2015 group identified intangible asset indefinite 116 consolidated financial statement excess net fair value identifiable asset according character fresenius group classifies liability cost badwill still existing reassessing financial instrument following class cash purchase price allocation recognized immediately cash equivalent asset recognized carrying amount lia profit loss bilities recognized carrying amount derivative hedging purpose well asset recognized fair value liability lease recognized fair value noncontrolling interest subject leased asset assigned fresenius group based put provision recognized fair value risk reward approach finance lease recognized relationship class category well property plant equipment measured receipt reconciliation consolidated statement finan date present value lease payment long cial position shown tabular form note 29 financial fair value lower leased asset depreciated instrument straightline useful life doubt fresenius group potential obligation purchase whether title asset pass later stage noncontrolling interest held third party certain opportune purchase option asset depreciated consolidated subsidiary obligation lease term shorter impairment loss rec form put provision exercisable thirdparty ognized recoverable amount lower amor owner discretion within specified period outlined tized cost leased asset specific put provision put provision exercised finance lease liability measured present fresenius group would required purchase value future lease payment recognized part thirdparty owner noncontrolling interest financial liability appraised fair value time exercise estimate property plant equipment rented fair value noncontrolling interest subject put provi fresenius group accounted purchase cost depre sion fresenius group recognizes higher net book ciation calculated using straightline method value multiple earnings based historical earnings leasing time expected residual value development stage underlying business factor additionally put provision valued financial instrument external valuation firm external valuation esti financial instrument contract give rise mate fair value using combination discounted cash financial asset one entity financial liability equity flow multiple earnings revenue depending instrument another entity market condition estimated fair value purchase sale financial asset accounted noncontrolling interest subject put provision trading day fresenius group make use also fluctuate discounted cash flow implicit fair value option allows financial asset finan multiple earnings revenue noncontrol cial liability classified fair value profit ling interest subject put provision may ultimately loss upon initial recognition settled could vary significantly fresenius group current following category according international estimate accounting standard 39 financial instrument recognition derivative financial instrument primarily include measurement relevant fresenius group foreign currency forward contract interest rate swap loan receivables financial liability measured amor recognized fair value asset liability consol financial statement tized cost available sale financial asset well financial idated statement financial position change fair liability asset measured fair value consolidated value derivative financial instrument classified fair value statement income category immaterial hedge corresponding underlying asset lia existing fresenius group financial instrument bilities recognized periodically earnings effective reclassified fiscal year 2016 portion change fair value cash flow hedge recog nized accumulated comprehensive income loss shareholder equity secured underlying transaction consolidated financial statement general note 117 realized see note 29 financial instrument ineffec past event probable obligation settled tive portion cash flow hedge recognized current earn future amount reliably estimated ings change fair value derivative accrual warranty complaint estimated based designated hedging instrument recognized periodically historical experience earnings tax accrual include obligation current year derivative embedded host contract accounted prior year separate derivative economic characteristic risk closely related host contract x pension liability similar obligation host contract held trading designated fresenius group recognizes underfunded status fair value profit loss embedded derivative defined benefit plan measured difference measured fair value change fair value recog fair value plan asset present value nized income statement benefit obligation liability funded status fresenius group us december 31 measure u liability ment date measuring funded status plan liability generally stated present value change funded status plan resulting actu mally corresponds value product service arial gain loss prior service cost credit delivered general policy shortterm liability recognized component net periodic benefit measured repayment amount cost recognized accumulated comprehen sive income loss net tax year occur v legal contingency fresenius group us corridor method ordinary course fresenius group operation recognition actuarial gain loss actuarial gain fresenius group involved litigation arbitration adminis loss exceed corridor 10 present value trative procedure investigation relating various defined benefit obligation spread expected aspect business fresenius group regularly analyzes average remaining working life employee participat current information claim probable loss ing plan adjusted fluctuation provides accrual matter including estimated actuarial gain loss prior service cost sub legal expense consulting service connection sequently recognized component net periodic benefit matter appropriate fresenius group utilizes cost realized internal legal department well external resource assessment making decision regarding need debt issuance cost loss accrual fresenius group considers degree debt issuance cost related recognized debt liability probability unfavorable outcome ability presented consolidated statement financial position make reasonable estimate amount loss direct deduction carrying amount debt filing suit formal assertion claim liability cost amortized term disclosure suit assertion necessarily related obligation indicate accrual loss appropriate w accrued expense financial statement accrual tax obligation recognized present obligation third party arising 118 consolidated financial statement z sharebased compensation plan professional liability claim coverage fmc line standard sharebased payment ag co kgaa assumes responsibility incurred claim fresenius group us modified prospective transition predetermined amount third party insur method transition method 2016 2015 ance applies reported liability year represent esti fresenius group recognized compensation cost mated future payment anticipated expense claim sharebased payment subsequent january 1 2012 incurred reported incurred reported based grantdate fair value estimated based historical experience existing claim activity measurement date fair value cashsettled phantom experience includes rate claim incidence stock granted member management board number claim severity cost combined indi executive employee fresenius group except vidual claim expectation estimate reported amount fresenius medical care cashsettled performance share granted member management board bb foreign currency translation executive employee fresenius medical care calculated reporting currency euro substantially asset using monte carlo simulation corresponding liability liability foreign subsidiary use functional cur based measurement date fair value accrued rency euro translated yearend exchange vesting period phantom stock performance share rate income expense translated annual plan average exchange rate fiscal year adjustment due measurement date fair value cashsettled phantom foreign currency translation fluctuation excluded stock granted member management board net earnings reported accumulated com executive employee fresenius medical care calculated prehensive income loss addition translation adjust using binomial model corresponding liability based ments certain intercompany borrowing measurement date fair value accrued vesting longterm nature also reported accumulated period phantom stock plan comprehensive income loss gain loss arising translation foreign aa selfinsurance program currency position well arising elimination insurance program professional product foreign currency intercompany loan recorded general liability auto liability worker compensation claim general administrative expense far medical malpractice claim largest subsidiary considered foreign equity instrument fiscal year fresenius medical care ag co kgaa fmcag co kgaa 2016 immaterial gain resulted translation located north america partially selfinsured exchange rate main currency affecting foreign currency translation developed follows yearend exchange rate average exchange rate dec 31 2016 dec 31 2015 2016 2015 u dollar per 10541 10887 11069 11095 chinese renminbi per 73202 70608 73522 69733 japanese yen per 1234 13107 1201967 13431 financial statement brazilian real per 34305 43117 38561 37004 pound sterling per 08562 07340 08195 07259 argentinean peso per 167182 141340 163342 102706 swedish krona per 95525 91895 94689 93535 russian ruble per 643 806736 741446 680720 consolidated financial statement general note 119 cc fair value hierarchy fresenius group applied following standard threetier fair value hierarchy defined financial far relevant fresenius group business accounting standard board accounting standard codifica first time tion topic 820 fair value measurement disclosure november 2015 financial accounting standard classifies asset liability recognized fair value based board fasb issued accounting standard update 201517 input used estimating fair value level 1 asu 201517 fasb accounting standard codification asc defined observable input quoted price active topic 740 income tax balance sheet classification market level 2 defined input quoted price deferred tax focus reducing complexity active market directly indirectly observable classifying deferred tax balance sheet asu 201517 level 3 defined unobservable input little eliminates current requirement organization market data exists therefore requiring company present deferred tax liability asset current non develop assumption threetier fair value hierar current classified balance sheet requires classifi chy used note 24 pension similar obligation cation deferred tax asset liability noncurrent note 29 financial instrument update effective fiscal year interim period within year beginning december 15 2016 earlier dd use estimate adoption permitted fresenius group adopted preparation consolidated financial statement con asu march 31 2016 accordance asu 201517 formity u gaap requires management make esti deferred tax recorded december 31 2015 within mate assumption affect reported amount current asset liability reclassified non asset liability disclosure contingent asset current asset liability amount 438 million liability date consolidated financial statement 61 million respectively result deferred tax reported amount income expense netting noncurrent asset liability adjusted reporting period actual result could differ amount 211 million estimate estimate discretionary decision required february 2015 fasb issued accounting standard particular position trade account receivable update 201502 asu 201502 fasb asc topic 810 con deferred tax asset pension liability well solidation amendment consolidation analysis examining recoverability goodwill focus clarifying guidance related evaluation var iou type legal entity limited partnership limited ee receivables management liability corporation certain security transaction con entity fresenius group perform ongoing eval solidation update effective fiscal year interim uations financial situation customer gener period within year beginning december 15 2015 ally require collateral customer fresenius group implemented asu 201502 supply product provision service approximately full retrospective basis information given regard 18 17 fresenius group sale earned variable interest entity vies segment subject regulation governmental health care pro fresenius medical care year 2015 based gram medicare medicaid administered united vies 2016 see note 1 iii b composition group state government 2016 2015 respectively financial statement ff recent pronouncement applied resenius group prepared consolidated financial f statement december 31 2016 conformity u gaap applied fiscal year beginning janu ary 1 2016 u gaap applied earlier vol untary basis 120 consolidated financial statement gg recent pronouncement yet applied sale volume cost determining discounted cash fresenius group longer voluntarily prepare flow fresenius group utilizes every reporting unit u gaap financial statement starting fiscal year approved threeyear budget projection year 4 10 interim period within year beginning january 1 corresponding growth rate remaining year 2017 therefore new u gaap standard applied growth rate 0 4 fresenius medical care 3 future financial statement fresenius group fresenius kabi 1 fresenius helios fresenius exception asu 201517 fresenius group vamed growth rate main reporting unit apply new u gaap standard earlier fresenius medical care fresenius kabi north amer ica carrying amount goodwill december 31 2016 iv critical accounting policy 10927 million 3941 million respectively 1 opinion management fresenius group 3 respectively projection 10 year po following accounting policy topic critical sible due historical experience stability consolidated financial statement present economic envi fresenius group business largely independent ronment influence judgment well uncer economic cycle discount factor determined tainties affect also important factor wacc respective reporting unit fresenius considered looking present future operating earn medical care wacc consisted basic rate 514 ings fresenius group wacc business segment fresenius kabi con sisted basic rate 593 2016 respectively recoverability goodwill intangible asset basic rate adjusted countryspecific risk rate indefinite useful life appropriate factor reflect higher risk associated amount goodwill nonamortizable intangible cash flow recent material acquisition asset indefinite useful life represents considerable appropriately integrated within reporting unit part total asset fresenius group decem 2016 wacc tax reporting unit ber 31 2016 december 31 2015 carrying amount fresenius medical care ranged 512 1588 23004 million 21750 million respectively waccs tax reporting unit fresenius kabi represented 50 51 respectively total asset ranged 593 1438 business segment impairment test goodwill nonamortizable intan fresenius helios fresenius vamed wacc tax gible asset indefinite useful life performed least 593 countryspecific adjustment occur year event occur circumstance change waccs tax main reporting unit fresenius would indicate carrying amount might impaired medical care fresenius kabi north america impairment test 512 593 respectively fair value report determine possible impairment asset ing unit less carrying amount difference fair value reporting unit compared carrying recorded impairment fair value goodwill amount fair value reporting unit determined first increase wacc tax 05 percentage using estimated future cash flow unit discounted point would resulted recognition weightedaverage cost capital wacc specific impairment loss 2016 reporting unit estimating discounted future cash flow additional sensitivity analysis carried involves significant assumption especially regarding future reporting unit latin america increase wacc financial statement reimbursement rate sale price number treatment reporting unit fresenius medical care latin america carrying amount goodwill december 31 2016 consolidated financial statement general note 121 89 million 1 percentage point would led rec c allowance doubtful account ognition impairment loss 47 million increase trade account receivable significant asset allow wacc 061 percentage point would led ance doubtful account significant estimate made fair value equal carrying amount increase management trade account receivable 5052 mil wacc reporting unit fresenius kabi latin america lion 4596 million 2016 2015 respectively net carrying amount goodwill december 31 2016 171 allowance approximately 66 receivables derive million 2 percentage point would led recog business segment fresenius medical care mainly nition impairment loss 43 million increase relate dialysis care business north america wacc 151 percentage point would led fair major debtor debtor group trade account value equal carrying amount ceivable u medicare medicaid health care pro prolonged downturn health care industry gram 18 private insurer united state lower expected increase reimbursement rate 11 december 31 2016 fresenius price higher expected cost providing group significant risk concentration due inter health care service manufacture product could national heterogeneous customer structure adversely affect estimated future cash flow certain allowance doubtful account 700 million country segment future adverse change reporting 650 million december 31 2016 december 31 unit economic environment could affect discount rate 2015 respectively decrease estimated future cash flow allowance estimate comprised customer decline reporting unit economic environment could specific evaluation regarding payment history current result impairment charge goodwill intangi financial stability applicable countryspecific risk ble asset indefinite useful life could materially overdue receivables fresenius group opinion adversely affect fresenius group future operating result analysis result wellfounded estimate allowance doubtful account time time fresenius group b legal contingency review change collection experience ensure fresenius group involved several legal matter arising appropriateness allowance ordinary course business outcome valuation allowance calculated specific circum matter may material effect financial posi stance indicate amount collectible tion result operation cash flow fresenius effort collect receivable including use outside group detail please see note 28 commitment con source required allowed exhausted tingent liability appropriate management review receivable deemed fresenius group regularly analyzes current informa uncollectible considered bad debt written tion claim probable loss provides accru deterioration aging receivables collection al matter including estimated expense legal difficulty could require fresenius group increase service appropriate fresenius group utilizes inter estimate allowance doubtful account additional nal legal department well external resource expense uncollectible receivables could significant assessment making decision regarding need negative impact future operating result loss accrual fresenius group considers degree probability unfavorable outcome ability make financial statement reasonable estimate amount loss filing suit formal assertion claim disclosure suit assertion necessarily indicate accrual loss appropriate 122 consolidated financial statement selfinsurance program furthermore third quarter 2015 fresenius medial insurance program professional product care sold european marketing right certain renal general liability auto liability worker compensation pharmaceutical joint venture vifor fresenius medical claim medical malpractice claim largest subsidiary care renal pharma transaction resulted aftertax fresenius medical care ag co kgaa located north gain 100 million u 111 million america partially selfinsured professional liability claim detail regarding accounting policy fresenius kabi selfinsurance program please see note 1 iii aa self resenius kabi spent 114 million acquisition 2016 f insurance program including acquisition u pharmaceutical manufac turing plant line seven iv drug 2 acquisition divestiture investment 2015 fresenius kabi spent 37 million acquisition mainly related purchase 100 share acquisition divestiture investment medi1one medical gmbh germany purchase fresenius group made acquisition investment share fresenius kabi bidiphar jsc vietnam purchase intangible asset 926 million 517 mil february 16 2015 fresenius kabi sold german lion 2016 2015 respectively amount 675 oncology compounding business september 30 2015 million paid cash 251 million assumed obli fresenius kabi also sold compounding business au gations 2016 tralia transaction resulted book gain imma terial amount respectively fresenius medical care 2016 fresenius medical care spent 774 million acquisi fresenius helios tions mainly acquisition dialysis clinic well 2016 fresenius helios spent 38 million acquisition purchase medical technology company focusing mainly purchase 100 share klinikum treatment lung cardiac failure niederberg ggmbh germany purchase patient clinic 2015 fresenius medical care spent 385 million acqui sitions mainly purchase dialysis clinic acquisition idc salud holding slu loan associated company third quarter 2015 quirónsalud fresenius medical care sold dialysis service business january 31 2017 fresenius helios closed acquisi venezuela transaction resulted aftertax loss 24 tion 100 share capital idc salud holding slu million u 269 million quirónsalud spain largest private hospital operator quirónsalud consolidated february 1 2017 536 billion total purchase price amount 576 billion already financed mean different debt instrument paid cash see note 21 debt capital lease obligation 22 senior note 23 convertible bond balance 400 million paid form financial statement consolidated financial statement general note 123 6108176 new share fresenius se co kgaa issued impact fresenius group january 31 2017 authorized capital excluding consolidated financial statement subscription right resulting acquisition due relatively short interval closing fiscal year 2016 acquisition accounted date acquisition reporting date purchase applying purchase method accordingly price allocation yet completed based first internal consolidated starting date acquisition analysis fresenius group expects opening balance excess total acquisition cost fair value sheet quirónsalud include goodwill 35 billion net asset acquired 903 million 307 million tangible asset 12 billion well net asset 13 bil 2016 2015 respectively lion 2016 quirónsalud generated sale 25 billion purchase price allocation yet finalized ebitda1 461 million acquisition current year based preliminary pur quirónsaluds network comprised 43 hospital 39 chase price allocation recognized goodwill 692 mil outpatient center 300 occupational risk prevention lion intangible asset 211 million center located economically important area spain goodwill 586 million attributable acquisition company 35000 employee offer full fresenius medical care 5 million fresenius kabis spectrum inpatient outpatient care acquisition acquisition 101 million acquisition fresenius fresenius helios strengthens position europe largest helios private hospital operator goodwill asset representing future economic benefit arising asset acquired business com 2015 fresenius helios spent 99 million acquisition bination individually identified separately mainly purchase 49 minority interest recognized goodwill arises principally due fair value helios kreiskrankenhaus gotha ohrdruf gmbh sub placed established stream future cash flow versus sequent purchase price payment acquisition building similar business patient facility purchase 94 share acquisition completed 2016 included lungenklinik diekholzen ggmbh germany consolidated statement first time full year con tributed following amount development sale fresenius vamed earnings 2015 fresenius vamed spent 4 million acquisition mainly participation expansion thermal spa million 2016 austria sale 210 ebitda 7 ebit 20 corporate net interest 11 2015 segment corporate includes con net income attributable solidation intercompany transaction amount shareholder fresenius se co kgaa 21 8 million acquisition increased total asset fresenius group 977 million financial statement 1 special item primarily relating transaction 124 consolidated financial statement note consolidated 5 cost sale statement income cost sale comprised following 3 special item million 2016 2015 net income attributable shareholder fresenius se cost service 14905 13929 manufacturing cost product co kgaa year 2016 amount 1593 million related good 4513 4637 include special item cost longterm production contract 535 524 net income attributable shareholder fresenius se cost sale 2 2 co kgaa year 2015 amount 1358 million cost sale 19955 19092 included special item relating fresenius kabis efficiency program integration acquired rhön hospital 6 cost material divestment two helios hospital fiscal year 2014 cost material comprised cost raw material led additional disposal gain 2015 supply purchased component cost purchased special item following impact consol service idated statement income 2015 million 2016 2015 net income cost raw material supply attributable purchased component 6572 6466 shareholder fresenius cost purchased service 1027 1027 million ebit se co kgaa cost material 7599 7493 earnings 2015 adjusted 3958 1423 cost fresenius kabis efficiency program 105 89 7 personnel expense integration cost cost sale selling general administrative expense acquired rhön hospital 12 10 disposal gain divestment research development expense included personnel two helios hospital 34 34 expense 11671 million 10862 million 2016 earnings 2015 according u gaap 3875 1358 2015 respectively personnel expense comprised following 4 sale sale activity follows million 2016 2015 wage salary 9367 8732 social security contribution cost retirement million 2016 2015 pension social assistance 2304 2130 sale service 19918 18558 thereof retirement pension 334 321 less patient service bad debt provision 389 369 personnel expense 11671 10862 sale product related good 8950 8851 sale longterm production contract 597 577 fresenius group annual average number employee sale 7 9 function shown sale 29083 27626 2016 2015 sale analysis business segment region shown production 37589 37143 financial statement service 158970 151903 segment information page 106 107 administration 19673 19078 sale marketing 10236 10041 research development 2500 2180 total employee per caput 228968 220345 consolidated financial statement note consolidated statement income 125 8 selling general administrative 10 tax expense selling expense 916 million 2015 915 million income tax mainly included expenditure sale personnel 459 income income tax attributable following million 2015 444 million geographic region general administrative expense amounted 3385 million 2015 3280 million related expendi million 2016 2015 tures administrative function attributable research germany 791 698 international 2954 2564 development production selling total 3745 3262 2016 operating income 329 million 2015 303 million operating expense 147 million 2015 224 million included selling general income tax expense benefit 2016 2015 consisted administrative expense following current deferred income 9 net interest million tax tax tax net interest 582 million included interest expense 2016 germany 130 5 135 678 million interest income 96 million main international 911 5 916 portion interest expense resulted fresenius total 1041 10 1051 group financial liability recognized fair value consolidated statement income see note 29 2015 financial instrument main portion interest income germany 197 32 165 resulted valuation call option connection international 841 41 800 total 1038 73 965 convertible bond fresenius se co kgaa valuation derivative embedded convertible bond fresenius medical care ag co kgaa see note 23 reconciliation expected actual income tax convertible bond expense shown following table expected corpo rate income tax expense computed applying ger man corporation tax rate including solidarity surcharge effective trade tax rate income income tax respective combined tax rate 307 fiscal year 2016 2015 305 million 2016 2015 computed expected income tax expense 1148 995 increase reduction income tax resulting item recognized tax purpose 55 50 tax rate differential 7 35 taxfree income 36 63 financial statement tax prior year 32 26 change valuation allowance deferred tax asset 24 40 noncontrolling interest 106 99 5 19 income tax 1051 965 effective tax rate 281 296 126 consolidated financial statement deferred tax net operating loss tax effect temporary difference loss car expiration net operating loss follows ried forward prior year gave rise deferred tax asset liability december 31 presented fiscal year million 2017 26 million 2016 2015 2018 32 2019 36 deferred tax asset 2020 67 account receivable 31 29 2021 29 inventory 108 95 2022 36 current asset 44 9 2023 33 noncurrent asset 94 80 2024 22 accrued expense 445 474 2025 18 shortterm liability 39 47 2026 thereafter 35 liability 39 41 total 334 benefit obligation 225 230 loss carried forward prior year 352 324 deferred tax asset valuation allowance 1377 1329 total remaining operating loss 685 million less valuation allowance 152 128 mainly carried forward unlimited period deferred tax asset 1225 1201 based upon level historical taxable income deferred tax liability projection future taxable income management account receivable 28 41 fresenius group belief likely inventory 30 32 fresenius group realize benefit deductible current asset 106 90 difference net existing valuation allowance noncurrent asset 1099 1030 december 31 2016 accrued expense 30 10 shortterm liability 165 169 liability 82 89 unrecognized tax benefit deferred tax liability 1540 1461 fresenius se co kgaa subsidiary subject net deferred tax 315 260 tax audit germany united state regular basis ongoing tax audit jurisdiction consolidated statement financial position net germany fresenius se co kgaa subsid amount deferred tax asset liability included iaries tax year 2006 2013 currently follows audit tax authority fresenius group recognized million 2016 2015 recorded current proposed adjustment audit deferred tax asset 560 540 period consolidated financial statement fiscal year deferred tax liability 875 800 2014 2016 open audit net deferred tax 315 260 fresenius kabi usa audit action fiscal year 2012 concluded regard federal tax december 31 2016 fresenius medical care currently tax audit progress two fresenius recognized deferred tax liability approximately 70 bil kabi usa relevant federal state partly com financial statement lion undistributed earnings foreign subsidiary pleted proposed adjustment deemed immaterial earnings considered indefinitely reinvested fiscal year 2013 2016 open audit regard federal tax consolidated financial statement note consolidated statement income 127 united state fresenius medical care fiscal year 11 noncontrolling interest 2013 2016 open audit fresenius medical care december 31 noncontrolling interest net income holding inc also subject audit various state jurisdic fresenius group follows tions number audit progress various year open audit various state jurisdiction million 2016 2015 expected result federal state income tax audit noncontrolling interest fresenius medical care 776 641 recognized consolidated financial statement noncontrolling interest subsidiary fresenius se co kgaa number fresenius vamed 10 10 country outside germany united state also noncontrolling interest business segment subject tax audit fresenius group estimate fresenius medical care 276 256 effect tax audit material consolidated fresenius kabi 36 30 financial statement fresenius helios 2 1 following table show change unrecognized fresenius vamed 1 1 total noncontrolling interest 1101 939 tax benefit year 2016 million 2016 fiscal year 2016 fresenius medical care ag co kgaa balance january 1 2016 260 paid dividend noncontrolling interest amount increase unrecognized tax benefit prior period 59 169 million 2015 163 million decrease unrecognized tax benefit prior period 37 increase unrecognized tax benefit current period 9 change related settlement tax authority 20 12 earnings per share foreign currency translation 3 following table show earnings per share including balance december 31 2016 274 excluding dilutive effect stock option issued 2016 2015 included balance december 31 2016 269 mil numerator million net income attributable lion unrecognized tax benefit would affect shareholder effective tax rate recognized fresenius group cur fresenius se co kgaa 1593 1358 less effect dilution due rently position forecast timing magnitude fresenius medical care share 1 change unrecognized tax benefit income available fresenius group policy recognize interest ordinary share 1593 1357 denominator number share penalty related tax position income tax expense weightedaverage number fiscal year 2016 fresenius group recognized ordinary share outstanding 546395188 543893874 gain 6 million interest penalty fresenius potentially dilutive ordinary share 3689472 4266418 group total accrual 24 million tax related inter weightedaverage number ordinary est penalty december 31 2016 share outstanding ssuming dilution 550084660 548160292 basic earnings per share 292 250 fully diluted earnings per share 290 248 financial statement 128 consolidated financial statement note consolidated 14 trade account receivable statement financial position december 31 trade account receivable follows 13 cash cash equivalent million 2016 2015 december 31 cash cash equivalent follows trade account receivable 5752 5246 less allowance doubtful account 700 650 trade account receivable net 5052 4596 million 2016 2015 cash 1492 992 time deposit security trade account receivable due within one year maturity 90 day 87 52 total cash cash equivalent 1579 1044 following table show development allow ance doubtful account fiscal year december 31 2016 december 31 2015 ear million 2016 2015 marked fund 61 million 57 million respectively allowance doubtful account beginning year 650 545 included cash cash equivalent change valuation allowance recorded fresenius group operates multicurrency notional consolidated statement income 431 431 pooling cash management system fresenius group writeoffs recovery amount previously writtenoff 400 353 met condition offset balance within cash pool foreign currency translation 19 27 reporting purpose december 31 2016 86 million allowance doubtful account december 31 2015 106 million cash balance end year 700 650 equivalent amount overdraft balance offset thereof 46 million related fresenius medical care following table show aging analysis trade account receivable allowance doubtful account 3 3 6 6 12 month month month 12 month million overdue overdue overdue overdue overdue total trade account receivable 3371 1091 403 315 572 5752 less allowance doubtful account 118 112 48 113 309 700 trade account receivable net 3253 979 355 202 263 5052 15 inventory resenius group obliged purchase company f december 31 inventory consisted following approximately 1119 million raw material pur chased component fixed term 575 million million 2016 2015 committed december 31 2016 2017 term raw material purchased component 667 602 agreement run one eight year advance payment work process 620 526 customer 420 million 2015 564 million financial statement finished good 2044 1839 less reserve 142 107 offset inventory exclusively related inventory net 3189 2860 longterm construction contract consolidated financial statement note consolidated statement financial position 129 16 current noncurrent asset december 31 current noncurrent asset comprised following 2016 2015 thereof thereof million shortterm shortterm equity investment 644 0 592 0 tax receivables 332 302 375 352 insurance recovery fresenius medical care 209 209 202 202 prepaid expense 156 91 143 80 advance made 125 112 138 79 prepaid rent insurance 77 77 74 74 asset 501 365 444 327 nonfinancial asset net 2044 1156 1968 1114 derivative financial instrument 408 41 375 39 security longterm loan 344 264 339 263 account receivable resulting german hospital law 272 230 265 250 leasing receivables 128 54 112 49 cost report receivable medicare medicaid 120 120 100 100 investment 79 0 61 0 deposit 71 22 60 19 discount 49 49 46 46 asset 56 30 54 21 financial asset net 1527 810 1412 787 asset net 3571 1966 3380 1901 allowance 11 8 10 7 asset gross 3582 1974 3390 1908 equity investment mainly related joint venture approval evidenced letter written granting named vifor fresenius medical care renal pharma ltd authority fresenius helios already received fresenius medical care galenica ltd 2016 item insurance recovery fresenius medical care income 59 million 2015 28 million resulting includes recognized amount relation naturalyte valuation included selling general adminis granuflo agreement principle partially offset trative expense consolidated statement income accrued settlement amount recorded accrued expense security longterm loan included 258 million financial see note 19 accrued expense information see asset available sale december 31 2016 2015 note 28 commitment contingent liability 257 million mainly relating share fund fiscal year 2016 depreciation immaterial account receivable resulting german hospital amount 2015 depreciation recognized non law primarily contain approved yet received ear current asset marked subsidy fresenius helios operation financial statement 130 consolidated financial statement 17 property plant equipment december 31 acquisition manufacturing cost well accumulated depreciation property plant equipment consisted following acquisition manufacturing cost foreign change currency entity reclassifi million jan 1 2016 translation consolidated addition cation disposal dec 31 2016 land land facility 536 3 5 7 11 1 561 building improvement 5388 96 64 228 348 56 6068 machinery equipment 6665 102 39 668 152 242 7384 machinery equipment rental equipment capital lease 185 3 1 20 1 18 192 construction progress 1074 21 7 654 567 5 1184 property plant equipment 13848 225 116 1577 55 322 15389 depreciation foreign change currency entity reclassifi million jan 1 2016 translation consolidated addition cation disposal dec 31 2016 land land facility 11 0 1 1 13 building improvement 2386 48 4 325 1 41 2723 machinery equipment 3953 56 4 640 2 209 4434 machinery equipment rental equipment capital lease 66 1 16 6 77 construction progress 4 0 4 property plant equipment 6420 105 982 256 7251 acquisition manufacturing cost foreign change currency entity reclassifi million jan 1 2015 translation consolidated addition cation disposal dec 31 2015 land land facility 524 2 4 13 7 536 building improvement 4863 189 1 109 288 60 5388 machinery equipment 5907 161 4 613 206 218 6665 machinery equipment rental equipment capital lease 171 5 3 8 1 1 185 construction progress 862 29 1 744 540 20 1074 property plant equipment 12327 386 3 1478 34 306 13848 depreciation financial statement foreign change currency entity reclassifi million jan 1 2015 translation consolidated addition cation disposal dec 31 2015 land land facility 6 3 1 1 11 building improvement 2031 108 3 298 2 46 2386 machinery equipment 3458 94 10 611 16 184 3953 machinery equipment rental equipment capital lease 51 2 15 1 1 66 construction progress 5 0 1 4 property plant equipment 5551 204 10 925 19 231 6420 consolidated financial statement note consolidated statement financial position 131 carrying amount million dec 31 2016 dec 31 2015 land land facility 548 525 building improvement 3345 3002 machinery equipment 2950 2712 machinery equipment rental equipment capital lease 115 119 construction progress 1180 1070 property plant equipment 8138 7428 depreciation property plant equipment year leasing 2016 2015 982 million 925 million respec machinery equipment december 31 2016 2015 tively allocated within cost sale selling general included medical device fresenius medical care administrative expense research development fresenius kabi lease customer patient physician expense depending upon use asset operating lease amount 771 million 720 million respectively 18 goodwill intangible asset december 31 acquisition cost accumulated amortization intangible asset consisted following acquisition cost foreign change currency entity reclassifi million jan 1 2016 translation consolidated addition cation disposal dec 31 2016 goodwill 21523 556 674 18 3 22774 patent product distribution right 713 21 15 9 1 11 748 technology 383 12 67 0 0 0 462 customer relationship 324 9 0 0 0 333 tradenames 221 6 0 0 0 227 software 406 10 1 51 19 13 474 noncompete agreement 322 11 17 0 0 3 347 management contract 6 0 0 0 3 0 3 414 10 19 32 5 7 463 goodwill intangible asset 24312 635 793 110 15 34 25831 financial statement 132 consolidated financial statement amortization foreign change currency entity reclassifi million jan 1 2016 translation consolidated addition cation disposal dec 31 2016 goodwill 0 0 0 0 0 0 0 patent product distribution right 356 11 36 11 392 technology 111 5 0 25 0 0 141 customer relationship 61 3 0 33 1 0 98 tradenames 0 0 0 0 0 0 0 software 248 5 48 1 12 290 noncompete agreement 251 9 0 21 3 278 management contract 0 0 0 0 0 0 0 252 7 0 28 2 2 287 goodwill intangible asset 1279 40 191 4 28 1486 acquisition cost foreign change currency entity reclassifi million jan 1 2015 translation consolidated addition cation disposal dec 31 2015 goodwill 19868 1465 176 13 2 1 21523 patent product distribution right 633 61 4 14 9 713 technology 349 40 0 0 5 1 383 customer relationship 272 30 22 0 0 324 tradenames 202 19 0 0 0 0 221 software 336 12 45 21 8 406 noncompete agreement 281 30 14 2 5 322 management contract 6 0 0 0 0 6 392 19 1 26 18 6 414 goodwill intangible asset 22339 1676 209 98 11 21 24312 amortization foreign change currency entity reclassifi million jan 1 2015 translation consolidated addition cation disposal dec 31 2015 goodwill 0 0 0 0 0 0 0 patent product distribution right 288 25 4 47 0 356 technology 77 9 0 25 0 111 customer relationship 29 3 0 29 0 61 tradenames 0 0 0 0 0 0 0 software 205 7 40 1 5 248 noncompete agreement 212 24 0 20 0 5 251 management contract 0 0 0 0 0 0 0 214 14 29 1 4 252 goodwill intangible asset 1025 82 4 190 0 14 1279 financial statement consolidated financial statement note consolidated statement financial position 133 carrying amount million dec 31 2016 dec 31 2015 goodwill 22774 21523 patent product distribution right 356 357 technology 321 272 customer relationship 235 263 tradenames 227 221 software 184 158 noncompete agreement 69 71 management contract 3 6 176 162 goodwill intangible asset 24345 23033 split intangible asset amortizable nonamortizable intangible asset shown following table amortizable intangible asset dec 31 2016 dec 31 2015 acquisition accumulated carrying acquisition accumulated carrying million cost amortization amount cost amortization amount patent product distribution right 748 392 356 713 356 357 technology 462 141 321 383 111 272 customer relationship 333 98 235 324 61 263 software 474 290 184 406 248 158 noncompete agreement 347 278 69 322 251 71 463 287 176 414 252 162 total 2827 1486 1341 2562 1279 1283 estimated regular amortization expense intangible asset next five year shown following table million 2017 2018 2019 2020 2021 estimated amortization expense 199 191 186 178 169 financial statement 134 consolidated financial statement nonamortizable intangible asset dec 31 2016 dec 31 2015 acquisition accumulated carrying acquisition accumulated carrying million cost amortization amount cost amortization amount tradenames 227 0 227 221 0 221 management contract 3 0 3 6 0 6 goodwill 22774 0 22774 21523 0 21523 total 23004 0 23004 21750 0 21750 amortization intangible asset amounted 191 million administrative expense research development 190 million year 2016 2015 respectively expense depending upon use asset allocated within cost sale selling general carrying amount goodwill developed follows fresenius fresenius fresenius fresenius corporate fresenius million medical care kabi helios vamed group carrying amount january 1 2015 10775 4601 4387 99 6 19868 addition 105 27 57 0 189 disposal 0 1 0 0 0 1 reclassification 0 2 0 0 0 2 foreign currency translation 1091 374 0 0 0 1465 carrying amount december 31 2015 11971 5003 4444 99 6 21523 addition 586 5 101 0 692 disposal 0 0 0 reclassification 3 0 0 0 0 3 foreign currency translation 405 151 0 0 0 556 carrying amount december 31 2016 12965 5159 4545 99 6 22774 december 31 2016 december 31 2016 medical care well 28 million 29 million carrying amount nonamortizable intangible respectively fresenius kabi asset 202 million 198 million fresenius 19 accrued expense december 31 accrued expense consisted following 2016 2015 thereof thereof million shortterm shortterm personnel expense 946 712 876 712 selfinsurance program 328 328 288 288 settlement fresenius medical care 266 266 257 257 litigation risk 49 49 52 52 financial statement warranty complaint 45 44 45 44 accrued expense 640 531 598 485 accrued expense 2274 1930 2116 1838 consolidated financial statement note consolidated statement financial position 135 following table show development accrued expense fiscal year foreign change currency entity reclassifi million jan 1 2016 translation consolidated addition cation utilized reversed dec 31 2016 personnel expense 876 14 19 810 6 706 61 946 selfinsurance program 288 8 0 58 0 7 19 328 settlement fresenius medical care 257 9 0 0 0 0 0 266 litigation risk 52 2 17 1 5 18 49 warranty complaint 45 27 0 18 9 45 accrued expense 598 9 58 435 5 369 96 640 total 2116 42 77 1347 1105 203 2274 accrual personnel expense mainly refer bonus sev medical care recorded current noncurrent erance payment contribution partial retirement share asset see note 16 current noncurrent asset based compensation plan holiday entitlement information see note 28 commitment con item settlement fresenius medical care includes tingent liability accrual related naturalyte granuflo agreement detail regarding accrual selfinsurance pro principle partially offset insurance recovery fresenius gram please see note 1 iii aa selfinsurance program 20 liability december 31 liability consisted following 2016 2015 thereof thereof million shortterm shortterm tax liability 223 223 208 208 account receivable credit balance 194 61 173 55 advance payment customer 87 68 75 65 liability 539 369 532 354 nonfinancial liability 1043 721 988 682 personnel liability 603 599 510 506 invoice outstanding 447 447 450 450 derivative financial instrument 412 47 355 15 debtor credit balance 408 408 378 378 accrued variable payment outstanding acquisition 223 78 51 48 account payable resulting german hospital law 208 203 256 253 bonus discount 183 183 162 162 interest liability 157 157 159 159 leasing liability 122 122 101 101 legal matter advisory audit fee 40 40 62 62 commission 36 35 33 32 liability 28 9 25 5 financial statement financial liability 2867 2328 2542 2171 liability 3910 3049 3530 2853 136 consolidated financial statement account payable resulting german hospital law december 31 2016 total amount longterm primarily contain earmarked subsidy received yet liability 861 million thereof 737 million due spent appropriately fresenius helios amount yet one five year 124 million due five spent appropriately classified liability year statement financial position line item long term accrued expense longterm liability 1205 million also included longterm accrued expense 344 million december 31 2016 21 debt capital lease obligation shortterm debt december 31 shortterm debt consisted following book value million 2016 2015 fresenius se co kgaa commercial paper 178 0 fresenius medical care ag co kgaa commercial paper 476 0 shortterm debt 193 202 shortterm debt 847 202 shortterm debt mainly consists borrowing cer december 31 2016 2015 597 631 tain entity fresenius group line credit respectively commercial bank average interest rate borrowing longterm debt capital lease bligations december 31 longterm debt capital lease obligation net debt issuance cost consisted following million 2016 2015 fresenius medical care 2012 credit agreement 2244 2399 2013 senior credit agreement 1574 2203 schuldschein loan 1186 914 account receivable facility fresenius medical care 165 46 capital lease obligation 146 151 344 396 subtotal 5659 6109 less current portion 611 607 longterm debt capital lease obligation less current portion 5048 5502 maturity longterm debt capital lease obligation shown following table financial statement million 1 year 1 3 year 3 5 year 5 year fresenius medical care 2012 credit agreement 214 2040 0 0 2013 senior credit agreement 211 423 953 0 schuldschein loan 125 401 586 77 account receivable facility fresenius medical care 0 166 0 0 capital lease obligation 18 26 19 83 54 84 174 33 longterm debt capital lease obligation 622 3140 1732 193 consolidated financial statement note consolidated statement financial position 137 aggregate annual repayment applicable listed fresenius medical care 2012 credit agreement longterm debt capital lease obligation year fresenius medical care ag co kgaa fmcag co kgaa subsequent december 31 2016 originally entered syndicated credit facility fresenius medical care 2012 credit agreement us3850 million fiscal year million 5year period large group bank institutional 2017 622 investor collectively lender october 30 2012 2018 877 november 26 2014 fresenius medical care 2012 2019 2263 credit agreement amended increase total credit 2020 1389 2021 343 facility approximately us4400 million extend term subsequent year 193 additional two year october 30 2019 total 5687 following table show available outstanding resenius medical care 2012 credit agree amount f ment december 31 2016 maximum amount available balance outstanding million million revolving credit u u 1000 million 949 u 10 million 10 revolving credit 400 million 400 0 million 0 u term loan u 2100 million 1992 u 2100 million 1992 term loan 252 million 252 252 million 252 total 3593 2254 less financing cost 10 total 2244 2015 maximum amount available balance outstanding million million revolving credit u u 1000 million 918 u 25 million 23 revolving credit 400 million 400 0 million 0 u term loan u 2300 million 2113 u 2300 million 2113 term loan 276 million 276 276 million 276 total 3707 2412 less financing cost 13 total 2399 december 31 2016 fresenius medical care 2012 term loan facility u 2100 million also scheduled credit agreement consisted mature october 30 2019 quarterly repayment u 50 million began january 2015 remaining financial statement revolving credit facility approximately u 1400 mil balance outstanding due october 30 2019 lion comprising u 1000 million revolving facility term loan facility 252 million scheduled mature 400 million revolving facility due october 30 2019 quarterly repayment 6 million payable october 30 2019 began january 2015 remaining balance standing due october 30 2019 138 consolidated financial statement interest credit facility fresenius medical december 31 2016 fmcag co kgaa sub care option rate equal either libor euribor sidiaries compliance covenant applicable plus applicable margin ii base fresenius medical care 2012 credit agreement rate defined fresenius medical care 2012 credit addition december 31 2016 december 31 2015 agreement plus applicable margin december 31 fresenius medical care letter credit outstanding 2016 2015 u dollar denominated tranche amount u 4 million u dollar revolving standing fresenius medical care 2012 credit credit facility included part agreement weightedaverage interest rate 215 balance outstanding date reduce available 172 respectively december 31 2016 borrowing applicable revolving credit facility 2015 euro denominated tranche interest rate 125 138 respectively 2013 senior credit agreement applicable margin variable depends december 20 2012 fresenius se co kgaa various fresenius medical care consolidated leverage ratio subsidiary entered delayed draw syndicated credit ratio consolidated funded debt less cash agreement 2013 senior credit agreement original cash equivalent consolidated ebitda term amount u 1300 million 1250 million since defined fresenius medical care 2012 credit initial funding 2013 senior credit agreement june agreement 2013 additional tranche added furthermore sched addition scheduled principal payment indebtedness uled amortization payment well voluntary repayment outstanding fresenius medical care 2012 credit made january 29 2015 term loan b facility agreement would reduced portion net cash pro 297 million voluntarily prepaid february 12 ceeds received certain sale asset 2015 revolving credit facility term loan obligation fresenius medical care 2012 tranche extended ahead time two year new credit agreement secured pledge capital stock maturity date june 28 2020 february 29 2016 certain material subsidiary favor lender term loan b u 489 million voluntarily prepaid fresenius medical care 2012 credit agreement con october 14 2016 senior credit agreement 2013 tains affirmative negative covenant respect fmc increased incremental term loan 900 mil ag co kgaa subsidiary certain circum lion incremental revolving facility 300 million stance covenant limit indebtedness investment incremental facility used fund acquisition restrict creation lien fresenius medical resenius helios idc salud holding slu quirónsalud f care 2012 credit agreement fmcag co kgaa required incremental facility funded january 31 2017 comply maximum leverage ratio ratio net debt resenius medical care 2012 ebitda additionally f credit agreement provides limitation dividend share buyback similar payment dividend paid subject annual basket 440 million 2017 increase subsequent year additional dividend restricted payment may made subject maintenance maximum leverage ratio default financial statement outstanding balance fresenius medical care 2012 credit agreement becomes immediately due payable option lender consolidated financial statement note consolidated statement financial position 139 following table show available outstanding amount 2013 senior credit agreement december 31 2016 maximum amount available balance outstanding million million revolving credit facility 900 million 900 0 million 0 revolving credit facility u u 300 million 284 u 0 million 0 term loan 933 million 933 933 million 933 term loan u u 689 million 654 u 689 million 654 total 2771 1587 less financing cost 13 total 1574 include incremental facility amount 12 billion funded january 2017 2015 maximum amount available balance outstanding million million revolving credit facility 900 million 900 0 million 0 revolving credit facility u u 300 million 276 u 0 million 0 term loan 1057 million 1057 1057 million 1057 term loan u u 781 million 717 u 781 million 717 term loan b u u 489 million 449 u 489 million 449 total 3399 2223 less financing cost 20 total 2203 december 31 2016 2013 senior credit agreement interest rate borrowing 2013 senior consisted credit agreement rate equal either libor euribor applicable plus applicable margin ii revolving credit facility aggregate principal base rate defined 2013 senior credit agreement amount u 300 million 900 million final plus applicable margin applicable margin variable repayment date june 28 2020 depends leverage ratio defined 2013 term loan facility u 689 million 933 million senior credit agreement together term loan term loan amortizes addition scheduled principal payment indebted repayable quarterly installment final maturity ness outstanding 2013 senior credit agreement june 28 2020 would reduced mandatory prepayment case certain sale asset incurrence certain addi tional indebtedness amount prepaid depending proceeds generated respective transaction financial statement 140 consolidated financial statement 2013 senior credit agreement guaranteed condition covenant include limitation lien sale fresenius se co kgaa fresenius proserve gmbh fresenius asset incurrence debt among item 2013 kabi ag certain u subsidiary fresenius kabi ag senior credit agreement also includes financial covenant obligation 2013 senior credit agreement defined agreement require fresenius se secured pledge capital stock certain material sub co kgaa subsidiary fresenius medical sidiaries fresenius kabi ag since funding incre care subsidiary maintain maximum leverage mental facility february 2014 additionally secured ratio minimum interest coverage ratio pledge capital stock helios kliniken gmbh december 31 2016 fresenius group favor lender compliance covenant 2013 senior credit 2013 senior credit agreement contains number agreement customary affirmative negative covenant certain schuldschein loan december 31 schuldschein loan fresenius group net debt issuance cost consisted following book value million notional amount maturity interest rate 2016 2015 fresenius se co kgaa 2012 2016 108 million april 4 2016 336 0 108 fresenius se co kgaa 2013 2017 51 million aug 22 2017 265 51 51 fresenius se co kgaa 2013 2017 74 million aug 22 2017 variable 74 74 fresenius se co kgaa 2014 2018 97 million april 2 2018 209 97 96 fresenius se co kgaa 2014 2018 76 million april 2 2018 variable 76 76 fresenius se co kgaa 2014 2018 65 million april 2 2018 variable 65 65 fresenius se co kgaa 2012 2018 72 million april 4 2018 409 72 72 fresenius se co kgaa 2015 2018 36 million october 8 2018 107 36 36 fresenius se co kgaa 2015 2018 55 million october 8 2018 variable 55 55 fresenius se co kgaa 2014 2020 106 million april 2 2020 267 105 105 fresenius se co kgaa 2014 2020 55 million april 2 2020 variable 55 55 fresenius se co kgaa 2014 2020 101 million april 2 2020 variable 100 100 fresenius se co kgaa 2015 2022 21 million april 7 2022 variable 21 21 fresenius u finance ii inc 2016 2021 u 309 million march 10 2021 variable 292 0 fresenius u finance ii inc 2016 2021 u 33 million march 10 2021 266 31 0 fresenius u finance ii inc 2016 2023 u 15 million march 10 2023 variable 15 0 fresenius u finance ii inc 2016 2023 u 43 million march 10 2023 312 41 0 schuldschein loan 1186 914 financial statement consolidated financial statement note consolidated statement financial position 141 december 19 2016 fresenius se co kgaa issued account receivable facility 1000 million schuldschein loan tranche 5 7 fresenius medical care 10 year fixed variable interest rate transaction december 6 2016 asset securitization facility closed january 31 2017 proceeds used account receivable facility fresenius medical care general corporate purpose finance acquisition refinanced term expiring december 6 2019 resenius helios idc salud holding slu quirónsalud f available borrowing u 800 million schuldschein loan issued fresenius se co kgaa december 31 2016 outstanding borrowing amount 108 million due april 4 account receivable facility u 175 million 2016 repaid scheduled 166 million 2015 u 51 million 47 million march 10 2016 fresenius u finance ii inc issued amount shown debt issuance cost included schuldschein loan total amount u 400 million fresenius medical care also letter credit outstanding consist fixed floating rate tranche term five account receivable facility amount seven year u 16 million 15 million december 31 2016 u 17 schuldschein loan issued fresenius se co kgaa million 15 million december 31 2015 letter total amount 125 million due credit included part balance august 22 2017 shown current portion longterm standing december 31 2016 however reduce avail debt capital lease obligation consolidated able borrowing account receivable facility statement financial position account receivable facility certain receiv march 2015 fresenius se co kgaa voluntarily ter ables sold nmc funding corp nmc funding minated floating rate tranche schuldschein loan due wholly owned subsidiary fresenius medical care nmc 2016 2018 amount 172 million ahead time funding assigns percentage ownership interest furthermore company made termination offer account receivable certain bank investor investor fixed rate 156 million schuldschein loan term account receivable facility nmc funding maturing april 2016 accepted 48 million retains right time recall outstand respective repayment made april 7 2015 ing transferred interest account receivable con moreover april 2015 new schuldschein loan matur sequently receivables remain consolidated state ities 2018 2022 issued total amount ment financial position proceeds 112 million transfer percentage ownership interest recorded schuldschein loan fresenius se co kgaa longterm debt guaranteed fresenius kabi ag fresenius proserve nmc funding pay interest bank investor calcu gmbh schuldschein loan fresenius u finance ii lated based commercial paper rate particular inc guaranteed fresenius se co kgaa fresenius tranche selected december 31 2016 2015 inter kabi ag fresenius proserve gmbh est rate 100 089 respectively refinancing december 31 2016 fresenius group fee include legal cost bank fee amortized compliance covenant schuldschein term facility loan financial statement 142 consolidated financial statement credit line source liquidity fresenius medical care also issue shortterm note addition financial liability described 1000 million commercial paper program fresenius group maintains additional credit facility december 31 2016 commercial paper program utilized utilized part fresenius medical care ag co kgaa utilized reporting date december 31 2016 additional amount 476 million financial cushion resulting unutilized credit facility additional financing u 800 million pro approximately 34 billion vided using fresenius medical care account receivable syndicated credit facility accounted 25 billion facility utilized amount u 191 portion comprised fresenius medical care 2012 million december 31 2016 credit agreement amount u 1408 million 1336 million 2013 senior credit agreement amount bridge financing facility u 1248 million 1184 million furthermore bilateral december 31 2016 fresenius se co kgaa facility approximately 900 million available loan facility 2750 million outstanding include credit facility certain entity fresenius entered bridge financing facility september 2016 group arranged commercial bank credit purpose acquisition idc salud holding slu facility used general corporate purpose usu quirónsalud original amount 3750 million ally unsecured reduced 1000 million december 2016 following addition fresenius se co kgaa commercial issuance longterm financial instrument form paper program 1000 million shortterm senior note convertible bond january 2017 note issued december 31 2016 commercial bridge financing facility cancelled prematurely without paper program fresenius se co kgaa utilized utilized amount 178 million 22 senior note december 31 senior note fresenius group net debt issuance cost consisted following book value million notional amount maturity interest rate 2016 2015 fresenius se co kgaa 2014 2019 300 million feb 1 2019 2375 299 297 fresenius se co kgaa 2012 2019 500 million apr 15 2019 425 498 497 fresenius se co kgaa 2013 2020 500 million july 15 2020 2875 497 496 fresenius se co kgaa 2014 2021 450 million feb 1 2021 300 445 443 fresenius se co kgaa 2014 2024 450 million feb 1 2024 400 449 450 fresenius u finance ii inc 2014 2021 u 300 million feb 1 2021 425 283 275 fresenius u finance ii inc 2015 2023 u 300 million jan 15 2023 450 281 273 fmc finance vi sa 2010 2016 250 million july 15 2016 550 0 249 fmc finance vii sa 2011 2021 300 million feb 15 2021 525 295 295 fmc finance viii sa 2011 2016 100 million oct 15 2016 variable 0 100 fmc finance viii sa 2011 2018 400 million sept 15 2018 650 397 396 financial statement fmc finance viii sa 2012 2019 250 million july 31 2019 525 244 244 fresenius medical care u finance inc 2007 2017 u 500 million july 15 2017 6875 473 457 fresenius medical care u finance inc 2011 2021 u 650 million feb 15 2021 575 611 590 fresenius medical care u finance ii inc 2011 2018 u 400 million sept 15 2018 650 377 363 fresenius medical care u finance ii inc 2012 2019 u 800 million july 31 2019 5625 757 732 fresenius medical care u finance ii inc 2014 2020 u 500 million oct 15 2020 4125 471 456 fresenius medical care u finance ii inc 2012 2022 u 700 million jan 31 2022 5875 661 639 fresenius medical care u finance ii inc 2014 2024 u 400 million oct 15 2024 475 376 364 senior note 7414 7616 senior note included table unsecured consolidated financial statement note consolidated statement financial position 143 inance bv july 29 2016 original issuer fresenius f demand immediate repayment plus interest decem replaced issuer outstanding senior ber 31 2016 fresenius group compliance note successor issuer fresenius se co kgaa covenant resenius u finance ii inc senior note issued f january 30 2017 fresenius finance ireland plc due july 15 2015 repaid wholly owned subsidiary fresenius se co kgaa issued scheduled refinanced issuance commercial senior note aggregate volume 26 billion paper consist four tranche maturity five seven ten september 25 2015 fresenius u finance ii inc fifteen year proceeds used fund acquisition issued u 300 million senior note maturity idc salud holding slu quirónsalud general seven year senior note coupon 450 corporate purpose issued par proceeds offering used senior note issued fmc finance vi sa refinance commercial paper due july 15 2016 senior note issued senior note fresenius u finance ii inc guar fmc finance viii sa due october 15 2016 anteed fresenius se co kgaa fresenius kabi ag repaid scheduled fresenius proserve gmbh senior note fresenius se senior note issued fresenius medical care u resenius kabi ag fresenius co kgaa guaranteed f finance inc due july 15 2017 proserve gmbh holder right request reclassified shortterm debt shown current por issuer repurchase senior note 101 principal tion senior note consolidated statement finan plus accrued interest upon occurrence change con cial position trol followed decline rating respective senior senior note fresenius medical care u finance note senior note fresenius se co kgaa inc fresenius medical care u finance ii inc fmc finance fresenius u finance ii inc may redeemed prior vii sa fmc finance viii sa wholly owned subsidiary maturity option issuer price 100 fmcag co kgaa guaranteed senior basis jointly plus accrued interest premium calculated pursuant severally fmcag co kgaa fresenius medical care term indenture observance certain holding inc fresenius medical care deutschland notice period gmbh holder right request respec fresenius se co kgaa agreed number cove tive issuer repurchase respective senior note nants provide protection bondholder partly 101 principal plus accrued interest upon occurrence restrict scope action fresenius se co kgaa change control fmcag co kgaa followed subsidiary excluding fresenius medical care ag co decline rating respective senior note issu kgaa fmcag co kgaa subsidiary er may redeem senior note time 100 covenant include restriction debt principal plus accrued interest premium calculated raised mortgaging sale asset entering pursuant term indenture sale leaseback transaction well merger consol fmcag co kgaa agreed number covenant idations company restriction provide protection holder certain lifted automatically rating respective senior circumstance limit ability fmcag co kgaa note reached investment grade event noncom subsidiary among thing incur debt incur lien pliance certain term senior note bondhold engage sale leaseback transaction merge con financial statement er owning aggregate 25 outstanding solidate company sell asset decem senior note entitled call senior note ber 31 2016 fmcag co kgaa subsidiary compliance covenant senior note 144 consolidated financial statement 23 convertible bond december 31 convertible bond fresenius group net debt issuance cost consisted following book value million current notional amount maturity coupon conversion price 2016 2015 fresenius se co kgaa 2014 2019 500 million sept 24 2019 0000 495184 474 464 fresenius medical care ag co kgaa 2014 2020 400 million jan 31 2020 1125 736054 380 374 convertible bond 854 838 fair value derivative embedded convertible fresenius group pension plan structured accor bond fresenius se co kgaa 267 million dance differing legal economic fiscal circum december 31 2016 derivative embedded convert stance country fresenius group currently ible bond fresenius medical care ag co kgaa fmc two type plan defined benefit defined contribution ag co kgaa recognized fair value 95 plan general plan benefit defined benefit plan million december 31 2016 fresenius se co kgaa based portion employee year service fmcag co kgaa purchased stock option call final salary plan benefit defined contribution plan option secure future fair value fluctuation determined amount contribution employee derivative call option also aggregate employer may limited legis fair value 267 million 95 million respectively lation return earned investment december 31 2016 contribution conversion cashsettled increase upon retirement defined benefit plan fresenius fresenius share price fresenius medical care share group required pay defined benefit former employ price conversion price would offset corre ee defined benefit become due defined benefit sponding value increase call option plan may funded unfunded fresenius group derivative embedded convertible bond funded defined benefit plan particular united state call option recognized noncurrent liability norway united kingdom netherlands austria asset consolidated statement financial position unfunded defined benefit plan located germany january 31 2017 fresenius se co kgaa issued france 500 million equityneutral convertible bond due 2024 actuarial assumption generally determine benefit obli convertible bond bear interest issue gations defined benefit plan actuarial calculation price fixed 101 nominal value corresponding require use estimate main factor used annual yield maturity 0142 initial con actuarial calculation affecting level benefit obliga version price 1070979 represents 45 premium tions assumption life expectancy discount rate reference share price fresenius share future salary benefit level fresenius group 738606 proceeds used fund acquisition funded plan asset set aside meet future payment idc salud holding slu quirónsalud general cor obligation estimated return plan asset recog porate purpose nized income respective period actuarial gain financial statement loss generated variation actu 24 pension similar obligation arial assumption difference actual estimated projected benefit obligation return general fresenius group recognizes pension cost related pension liability current future benefit quali fied current former employee fresenius group consolidated financial statement note consolidated statement financial position 145 plan asset year company pension liability major part pension liability relates germany impacted actuarial gain loss december 31 2016 78 pension liability related defined benefit plan fresenius group recognized germany 20 predominantly rest exposed certain risk besides general actuarial risk e g europe north america 55 beneficiary longevity risk interest rate risk fresenius located north america 31 germany remainder group exposed market risk well investment risk throughout rest europe continent case fresenius group funded plan defined 69 pension liability amount 1173 benefit obligation offset fair value plan asset million relate versorgungsordnung der fresenius funded status pension liability recognized con unternehmen established 2016 pension plan 2016 solidated statement financial position defined benefit applies german entity fresenius obligation exceeds fair value plan asset asset group except fresenius helios pension plan 2016 recognized reported asset consolidated updated version pension plan 1988 minor amend statement financial position fair value plan asset ments remaining pension liability relate individual exceeds defined benefit obligation fresenius plan fresenius helios entity germany non group right reimbursement fund right german group entity reduce future payment fund plan benefit generally based employee defined contribution plan fresenius group year service final salary consistent predominant pay defined contribution independent third party practice germany benefit obligation german directed employee employee service life entity fresenius group unfunded german pen satisfies obligation fresenius group sion plan 2016 separate pension fund employee employee retains right contribu fresenius medical care holding inc fmch subsid tions made employee vested portion iary fresenius medical care ag co kgaa defined fresenius group paid contribution upon leaving benefit pension plan employee united state fresenius group fresenius group main defined supplemental executive retirement plan first contribution plan united state quarter 2002 fmch curtailed pension plan curtailment amendment substantially employee defined benefit pension plan eligible participate plan benefit frozen december 31 2016 projected benefit obligation pbo curtailment date additional defined benefit fresenius group 1671 million 2015 1492 future service earned fmch retained million included 532 million 2015 424 million funded employee benefit obligation curtailment date plan asset 1139 million 2015 1068 million year fmch contributes plan covering united state covered pension provision furthermore pension lia employee least minimum amount required bility contains benefit obligation offered sub employee retirement income security act 1974 amended sidiaries fresenius medical care amount 34 mil 2016 fmchs minimum funding requirement u 10 lion 2015 28 million current portion pension million 9 million addition compulsory con liability amount 18 million 2015 18 million tributions fmch voluntarily provided u 101 million 91 recognized consolidated statement financial position million defined benefit plan expected funding within shortterm accrued expense shortterm 2017 u 1 million 1 million financial statement liability noncurrent portion 1155 million 2015 1078 million recorded pension liability 146 consolidated financial statement benefit plan offered subsidiary fresenius pension liability developed follows medical care outside united state germany million 2016 2015 france contain separate benefit obligation total pen benefit obligation beginning sion liability plan 34 million 28 year 1492 1472 change entity consolidated 3 million december 31 2016 2015 respectively foreign currency translation 5 55 consists pension asset 0 thousand 2015 56 thou amendment 0 9 sand recognized noncurrent asset current service cost 53 53 pension liability 2 million 2015 3 million rec prior service cost 3 3 ognized current liability line item shortterm interest cost 45 43 contribution plan participant 3 3 accrued expense shortterm liability non transfer plan participant 5 3 current pension liability 32 million 2015 25 million curtailment settlement 8 11 plan recorded pension liability consoli actuarial loss gain 120 98 dated statement financial position benefit paid 50 39 fresenius group benefit obligation relating fully plan amendment 0 1 partly funded pension plan 694 million benefit obliga benefit obligation end year 1671 1492 thereof vested 1397 1267 tions relating unfunded pension plan 977 million following table show change benefit obliga fair value plan asset beginning tions change plan asset funded status year 424 391 change entity consolidated 0 pension plan pension liability benefit paid shown foreign currency translation 6 32 change benefit obligation represent payment amendment 0 made funded unfunded plan ben actual return cost plan asset 30 8 efits paid shown change plan asset include contribution employer 107 26 benefit payment fresenius group funded benefit contribution plan participant 3 3 plan settlement 8 1 transfer plan participant 5 3 benefit paid 35 22 fair value plan asset end year 532 424 funded status december 31 1139 1068 benefit plan offered subsidiary 34 28 pension liability december 31 1173 1096 financial statement consolidated financial statement note consolidated statement financial position 147 december 31 2016 december 31 2015 fair sensitivity analysis value plan asset exceed benefit obligation increase decrease principal actuarial assumption pension plan 05 percentage point would affect pension liability discount rate plan based upon yield december 31 2016 follows portfolio highly rated debt instrument maturity 05 pp 05 pp mirror plan benefit obligation fresenius group development pension liability million increase decrease discount rate weighted average plan based discount rate 151 175 rate compensation increase 25 25 upon benefit obligation rate pension increase 89 79 following weightedaverage assumption utilized determining benefit obligation december 31 sensitivity analysis calculated based average 2016 2015 duration pension obligation determined decem discount rate 256 315 rate compensation increase 287 290 ber 31 2016 calculation performed isolated rate pension increase 146 165 significant actuarial parameter order show effect fair value pension liability separately mainly change discount factor well inflation sensitivity analysis compensation increase pen mortality assumption used actuarial computation sion increase excludes u pension plan resulted actuarial gain 2016 decreased fair frozen therefore affected change value defined benefit obligation unrecognized actuarial two actuarial assumption loss 616 million 2015 538 million explanatory note december 31 2016 accumulated benefit obligation defined benefit pension plan 1487 million 2015 1371 million following table relates pension plan pro jected benefit obligation accumulated benefit obliga tions excess plan asset million 2016 2015 projected benefit obligation pbo 1671 1492 accumulated benefit obligation abo 1487 1371 fair value plan asset 532 424 financial statement 148 consolidated financial statement pretax change comprehensive income loss relating pension liability year 2016 2015 shown following table foreign currency million jan 1 2016 reclassification 1 addition translation dec 31 2016 actuarial gain loss 538 39 115 2 616 prior service cost 1 2 2 1 transition obligation 0 adjustment related pension liability 539 41 117 2 617 1 effect recognized consolidated statement income foreign currency million jan 1 2015 reclassification 1 addition translation dec 31 2015 actuarial gain loss 634 44 77 25 538 prior service cost 1 2 1 transition obligation 0 0 adjustment related pension liability 634 45 75 25 539 1 effect recognized consolidated statement income tax effect comprehensive income decem defined benefit pension plan net periodic benefit cost ber 31 2016 see note 27 comprehensive income 118 million 2015 116 million comprised loss following component fresenius group expects following amount amortized comprehensive income net million 2016 2015 periodic pension cost year 2017 service cost 53 53 interest cost 45 43 expected return plan asset 21 22 million 2017 amortization unrealized actuarial loss net 39 44 actuarial gain loss 43 amortization prior service cost 2 1 prior service cost 1 amortization transition obligation 0 settlement loss 3 net periodic benefit cost 118 116 net periodic benefit cost allocated personnel expense within cost sale selling general administrative expense well research development expense allocation depends upon area beneficiary employed financial statement consolidated financial statement note consolidated statement financial position 149 following weightedaverage assumption used following table show expected benefit payment determining net periodic benefit cost year ended next 10 year december 31 fiscal year million 2016 2015 2017 43 discount rate 306 285 2018 43 expected return plan asset 472 477 2019 46 rate compensation increase 303 305 2020 51 rate pension increase 162 166 2021 53 2022 2026 321 total expected benefit payment 557 december 31 2016 december 31 2015 weightedaverage duration defined benefit obligation 19 year fair value plan asset category follows december 31 2016 december 31 2015 quoted price active market significant quoted price significant identical observable active market observable asset input identical asset input million level 1 level 2 total level 1 level 2 total category plan asset equity investment 66 83 149 62 59 121 index fund 1 53 83 136 50 59 109 equity investment 13 0 13 12 0 12 fixed income investment 123 215 338 101 164 265 government security 2 40 1 41 43 1 44 corporate bond 3 35 209 244 29 156 185 fixed income investment 4 48 5 53 29 7 36 5 31 14 45 26 12 38 total 220 312 532 189 235 424 1 category mainly comprised lowcost equity index fund actively managed track p 500 p 400 russell 2000 msci emerging market index morgan stanley international eafe index 2 category primarily comprised fixed income investment u government government sponsored entity 3 category primarily represents investment grade bond u issuer diverse industry 4 category mainly comprised private placement bond well collateralized mortgage obligation well cash fund invest treasury obligation directly treasury backed obligation 5 category mainly represents cash money market fund well mutual fund comprised high grade corporate bond method input used measure fair value plan corporate bond bond valued based mar asset follows ket quote date statement financial position index fund valued based market quote cash stated nominal value equal fair value financial statement equity investment valued market price u treasury money market fund well money date statement financial position market mutual fund valued market price government bond valued based market price level 1 market quote level 2 150 consolidated financial statement plan investment policy strategy following schedule describes fresenius group alloca united state tion funded plan fresenius group periodically review assumption allocation allocation target longterm expected return pension plan asset part 2016 2015 allocation assumption review range reasonable expected equity investment 2791 2857 2915 fixed income investment 6361 6245 6142 investment return pension plan whole deter incl real estate 848 898 943 mined based analysis expected future return total 10000 10000 10000 asset class weighted allocation asset range return developed relies forecast include actuarial firm expected longterm rate overall expected longterm rate return asset return significant asset class economic indicator fresenius group amount 468 compounded annually broadmarket historical benchmark expected contribution plan asset fiscal year 2017 expec return correlation volatility asset class ted amount 11 million result expected rate return pension plan asset u pension plan 6 year 2016 defined contribution plan overall investment strategy u pension plan fresenius group total expense defined contribution achieve mix approximately 98 investment plan 2016 139 million 2015 134 million longterm growth income 2 cash cash amount 87 million related contribution fresenius equivalent investment income cash cash equivalent group several public supplementary pension fund used nearterm benefit payment investment employee fresenius helios 44 million related governed investment policy include well diversified contribution u saving plan employee index fund fund targeting index performance fresenius medical care holding inc join target allocation plan asset united state following applicable collective bargaining agreement range around 30 equity 70 longterm fresenius group pay contribution given number u corporate bond investment policy considers employee fresenius helios rheinische zusatzversor time horizon invested fund gungskasse supplementary pension fund five year total portfolio measured public supplementary pension fund together referred custom index reflects asset class benchmark zvk öd complement statutory retirement pension target asset allocation plan policy allow invest given employee multiple participating entity ments security fresenius medical care ag co kgaa insured zvk öds plan multiemployer related party security performance bench plan employee entitled statutory benefit mark separate asset class include p 500 regardless contributed amount index p 400 mid cap index russell 2000 index msci eafe index msci emerging market index barclays capital longcorporate bond index financial statement consolidated financial statement note consolidated statement financial position 151 plan operates payasyouearn system based noncontrolling interest subject put provision changed applying collection rate given part gross remuneration follows paid contribution accounted personnel expense within cost sale selling general admin million 2016 istrative expense amounted 87 million 2016 noncontrolling interest subject put provision january 1 2016 947 2015 84 million thereof 47 million 2015 45 million noncontrolling interest subject payment rheinische zusatzversorgungskasse put provision profit 173 versorgungsanstalt de bundes und der länder zusatz purchase noncontrolling interest subject put provision 85 versorgungskasse wiesbaden supplementary pension dividend payment 178 fund currency effect change 157 disclosure either irrelevant immaterial noncontrolling interest subject put provision december 31 2016 1184 plan supplementary pension fund necessary information cannot obtained zvk öds without undue cost effort 990 noncontrolling interest subject put provision u saving plan employee deposit applied fresenius medical care december 31 2016 75 pay annual maximum u 18000 december 31 2016 2015 put option 50 year old u 24000 50 fresenius aggregate purchase obligation 288 million 237 medical care match 50 employee deposit million respectively exercisable two put option maximum company contribution 3 employee exercised total consideration 1 million 2016 pay fresenius medical care total expense defined 2015 six put option total consideration 2 million contribution plan year ended december 31 2016 2015 44 million 42 million respectively noncontrolling interest subject put provision 25 noncontrolling interest december 31 noncontrolling interest subject put provision fresenius group follows noncontrolling interest subject put provision million 2016 2015 noncontrolling interest fresenius group potential obligation purchase subject put provision noncontrolling interest held third party certain fresenius medical care ag co kgaa 7094 6274 consolidated subsidiary obligation noncontrolling interest subject put provision form put provision exercisable thirdparty vamed ag 55 49 owner discretion within specified period outlined noncontrolling interest subject put provision specific put provision put provision exer business segment cised fresenius group would required purchase fresenius medical care 615 559 part thirdparty owner noncontrolling interest fresenius kabi 89 120 fresenius helios 57 59 appraised fair value time exercise fresenius vamed 7 7 total noncontrolling interest subject put provision 7917 7068 financial statement financial information relating fresenius medical care see consolidated segment reporting page 106 107 152 consolidated financial statement noncontrolling interest subject put provision changed eliminate fractional amount cash contribution follows authorization exercised issue price significantly stock exchange price already million 2016 listed share time issue price fixed final noncontrolling interest subject effect general partner furthermore case capi put provision january 1 2016 7068 tal increase cash contribution proportionate noncontrolling interest subject put provision profit 928 amount share issued exclusion subscription stock option 50 right may exceed 10 subscribed capital purchase noncontrolling interest exclusion subscription right context use subject put provision 5 authorization concerning issuance sale dividend payment 260 currency effect change 126 share fresenius se co kgaa issuance right noncontrolling interest subject authorize bind subscription share put provision december 31 2016 7917 fresenius se co kgaa taken consideration duration authorized capital utili 26 fresenius se co kgaa zation case subscription kind subscription shareholder equity right excluded order acquire company part company participation company subscribed capital authorization granted concerning exclusion development subscribed capital subscription right used fresenius management se january 1 2016 subscribed capital fresenius se extent proportional amount total co kgaa consisted 545727950 bearer ordinary share number share issued exclusion subscription fiscal year 2016 1480421 stock option right exceed 20 subscribed capital exercised consequently december 31 2016 exclusion subscription right context use subscribed capital fresenius se co kgaa consisted authorization concerning issuance sale 547208371 bearer ordinary share share issued share fresenius se co kgaa issuance nonpar value share proportionate amount right authorize bind subscription share subscribed capital 100 per share fresenius se co kgaa taken consideration course acquisition quirónsalud janu duration authorized capital ary 31 2017 6108176 new share fresenius se co kgaa utilization issued authorized capital excluding subscription right new share full dividend entitlement conditional capital fiscal year 2016 following conditional capital exist order fulfill subscription right stock option plan authorized capital fresenius se co kgaa conditional capital stock option december 31 2016 general partner fresenius man plan 2003 conditional capital ii stock option plan 2008 agement se authorized approval super conditional capital iv stock option plan 2013 see visory board may 15 2019 increase fresenius se note 33 sharebased compensation plan co kgaas subscribed capital total amount another conditional capital iii exists authorization financial statement 120960000 single multiple issue new bearer issue option bearer bond convertible bond accord ordinary share cash contribution contribu ingly general partner authorized approval tions kind authorized capital thereof january 31 supervisory board may 15 2019 issue option 2017 6108176 utilized issuance bearer bond convertible bearer bond 6108176 share thereby reducing authorized capital several time total nominal amount 25 billion 114851824 fulfill granted subscription right subscribed subscription right must granted shareholder capital fresenius se co kgaa increased conditionally principle defined case general partner autho 48971202 issuing 48971202 rized consent supervisory board decide new bearer ordinary share conditional capital increase exclusion shareholder subscription right e g consolidated financial statement note consolidated statement financial position 153 shall implemented extent holder long form settlement used cash issued convertible bond cash issued warrant new bearer ordinary share shall participate profit option bond exercise conversion option right start fiscal year issued following table show development conditional capital ordinary share conditional capital fresenius ag stock option plan 2003 5261987 conditional capital ii fresenius se stock option plan 2008 7216907 conditional capital iii option bearer bond convertible bond 48971202 conditional capital iv fresenius se co kgaa stock option plan 2013 25200000 total conditional capital january 1 2016 86650096 fresenius ag stock option plan 2003 option exercised 244402 fresenius se stock option plan 2008 option exercised 1236019 total conditional capital december 31 2016 85169675 december 31 2016 conditional capital composed follows ordinary share conditional capital fresenius ag stock option plan 2003 5017585 conditional capital ii fresenius se stock option plan 2008 5980888 conditional capital iii option bearer bond convertible bond 48971202 conditional capital iv fresenius se co kgaa stock option plan 2013 25200000 total conditional capital december 31 2016 85169675 capital reserve dividend capital reserve comprised premium paid german stock corporation act aktg amount issue share exercise stock option additional dividend available distribution shareholder based paidin capital upon unconsolidated retained earnings fresenius se co kgaa reported statement financial position reserve determined accordance german commercial reserve comprised earnings generated code hgb group entity prior year extent may 2016 dividend 055 per bearer ordinary distributed share approved fresenius se co kgaas sharehold er annual general meeting paid total divi dend payment 300 million financial statement 154 consolidated financial statement 27 comprehensive income loss currency translation foreign subsidiary financial comprehensive income loss comprised statement effect measuring financial instrument amount recognized directly equity net tax resulting fair value well change benefit obligation change component comprehensive income loss 2016 2015 follows total total non non controlling non controlling amount interest controlling interest million tax tax effect tax interest tax cash flow hedge 34 9 25 21 46 change unrealized gain loss 21 3 18 18 realized gain loss due reclassification 13 6 7 21 28 change fair value available sale financial asset foreign currency translation 355 30 325 514 839 actuarial loss defined benefit pension plan 71 22 49 17 66 total change 2015 460 61 399 552 951 cash flow hedge 7 4 3 11 14 change unrealized gain loss 13 1 12 2 14 realized gain loss due reclassification 20 5 15 13 28 change fair value available sale financial asset foreign currency translation 302 9 293 242 535 actuarial gain loss defined benefit pension plan 68 16 52 9 61 total change 2016 241 3 244 244 488 change accumulated comprehensive income loss net tax component 2016 2015 follows actuarial change gain loss fair value defined total total available foreign benefit non non non cash flow sale financial currency pension controlling controlling controlling million hedge asset translation plan interest interest interest balance december 31 2014 109 1 294 305 119 189 70 comprehensive income loss reclassification 18 325 33 376 517 893 amount reclassified accumulated comprehensive income loss 7 0 16 23 35 58 comprehensive income loss net 25 325 49 399 552 951 balance december 31 2015 84 1 619 256 280 741 1021 comprehensive income loss reclassification 12 293 67 214 219 433 amount reclassified accumulated comprehensive income loss 15 0 15 30 25 55 comprehensive income loss net 3 293 52 244 244 488 balance december 31 2016 81 1 912 308 524 985 1509 financial statement consolidated financial statement note consolidated statement financial position 155 reclassification accumulated comprehensive income loss net income 2016 2015 follows amount gain loss r eclassified accumulated comprehensive income loss1 affected line item million 2016 2015 consolidated statement income detail accumulated comprehensive income loss component cash flow hedge interest rate contract 36 37 interest income expense foreign exchange contract 1 16 cost sale selling general foreign exchange contract 3 11 administrative expense foreign exchange contract 1 interest income expense comprehensive income loss 39 42 tax expense benefit 11 14 comprehensive income loss net 28 28 amortization defined benefit pension item prior service cost 2 1 2 transition obligation 0 2 actuarial gain loss defined benefit pension plan 39 44 2 comprehensive income loss 41 45 tax expense benefit 14 15 comprehensive income loss net 27 30 total reclassification period 55 58 1 gain shown negative sign loss positive sign 2 net periodic benefit cost allocated personnel expense within cost sale selling general administrative expense well research development expense financial statement 156 consolidated financial statement note material noteworthy described mat ters described fresenius group belief 28 commitment contingent loss reasonably possible estimable estimate liability loss range loss exposure provided matter described fresenius group belief operating lease rental payment loss probability remote loss range po fresenius group subsidiary lease hospital office sible loss cannot reasonably estimated time manufacturing building well machinery equipment outcome litigation legal matter always diffi various lease agreement expiring date cult predict accurately outcome consis 2106 rental expense recorded operating lease tent fresenius group view merit occur year ended december 31 2016 2015 888 million fresenius group belief valid defense 821 million respectively legal matter pending defending vigor future minimum rental payment noncancellable ously nevertheless possible resolution one operating lease year subsequent december 31 legal matter currently pending threatened 2016 could material adverse effect business result operation financial condition fiscal year million 2017 811 commercial litigation 2018 690 product liability litigation 2019 592 april 5 2013 u judicial panel multidistrict 2020 498 2021 410 litigation ordered numerous lawsuit pending var thereafter 1470 iou federal court alleging wrongful death personal total 4471 injury claim fresenius medical care holding inc fmch certain affiliate relating fmchs acid december 31 2016 future investment commitment concentrate product naturalyte granuflo trans existed year 2022 acquisition contract ferred consolidated pretrial management purpose hospital projected cost 308 million thereof consolidated multidistrict litigation united state 59 million relates year 2017 district court district massachusetts see besides mentioned contingent liability fresenius granuflo naturalyte dialysate product liability amount commitment immaterial litigation case 2013md02428 massachusetts state court st louis city missouri court subsequently legal regulatory matter established similar consolidated litigation case fresenius group routinely involved claim lawsuit filed massachusetts county court st louis city court regulatory tax audit investigation legal see consolidated fresenius case case micv matter arising part ordinary course 201303400o massachusetts superior court middlesex business providing health care service product county lawsuit alleged generally inadequate legal matter fresenius group currently deems labeling warning product caused harm patient addition similar case filed state financial statement court february 17 2016 fmch reached com mittee plaintiff counsel reported court consolidated financial statement note 157 agreement principle settlement potentially case applicable policy including reimbursement fmch liti agreement principle called fmch pay us250 gation defense cost incurred agreement principle million settlement fund exchange release reached affected carrier confirmed substantially plaintiff claim subject fmchs coverage litigation impact commitment fund right void settlement certain condition includ u 220 million settlement plaintiff ing 3 plaintiff rejected settlement certain complaint granuflo naturalyte distribution rejecters met certain criterion subse litigation named combination fresenius medical care ag quently agreed fmch plaintiff committee co kgaa fresenius medical care management ag ordered court plaintiff may enforce settlement fresenius se co kgaa fresenius management se compel payment fmch total case electing defendant addition fmch domestic united participate settlement dismissed court state affiliate agreement principle provides dis prejudice voluntarily involuntarily come comprise missal release claim encompassing european 97 case court entering lone pine order defendant requiring plaintiff pain dismissal four institutional plaintiff filed complaint elected participate settlement submit specific justi fmch affiliate state deceptive practice statute fication satisfactory court complaint resting certain background allegation common including attorney verification certain material factual rep granuflo naturalyte personal injury litigation seek resentations expert medical opinion relating causation ing remedy repayment sum paid fmch attribut fmch may elect void settlement may 10 2017 able granuflo naturalyte product case 97 threshold achieved plaintiff non implicate different legal standard theory liability participation fall suspect pattern incidental change form potential recovery personal injury date likely trial case participating set litigation claim extinguished tlement may resume scheduled discretion personal injury litigation settlement described respective court fmch expects combination four plaintiff attorney general state election participate notice dismissal already sub kentucky louisiana mississippi commercial insur mitted lone pine procedure result confirmation ance company blue cross blue shield louisiana settlement private capacity see state mississippi ex rel hood v fmchs affected insurer agreed fund u 220 fresenius medical care holding inc 14cv152 million settlement fund settlement voided chancery court desoto county state louisiana ex reservation right regarding certain coverage issue caldwell louisiana health service indemnity company among fmch insurer fmch v fresenius medical care airline 2016 civ 11035 usdc accrued net expense us60 million consummation mass commonwealth kentucky ex rel beshear v settlement including legal fee anticipated fresenius medical care holding inc et al 16ci00946 cost circuit court franklin county subsequent agreement principle fmchs insurer aig group initiated action declaratory judg ment new york state court advancing various argument reducing amount coverage obligation fmch financial statement filed action massachusetts state court seeking com pel aig group carrier honor obligation 158 consolidated financial statement litigation potential exposure internal review fresenius medical care holding qui tam complaint fresenius medical care received communication alleging massachusetts conduct country outside united state may february 15 2011 whistleblower relator action violate u foreign corrupt practice act fcpa false claim act fresenius medical care hold antibribery law audit corporate governance ings inc fmch unsealed order united state committee fresenius medical care supervisory board district court district massachusetts served conducting investigation assistance indepen relator see united state ex rel chris drennen v dent counsel fresenius medical care voluntarily advised fresenius medical care holding inc 2009 civ 10179 u security exchange commission sec mass united state intervene initially u department justice doj fresenius medical care case relators complaint first filed seal investigation dialogue sec doj february 2009 alleged fmch sought received ongoing fresenius medical care cooperating reimbursement government payors serum ferritin government investigation multiple form hepatitis b laboratory test conduct identified may result monetary medically unnecessary properly ordered phy penalty sanction fcpa anti sician discovery relators complaint closed may bribery law addition fresenius medical care ability 2015 october 2 2015 united state attorney moved conduct business certain jurisdiction could negatively intervene relators complaint respect impacted fresenius medical care previously recorded certain hepatitis b surface antigen test performed prior nonmaterial accrual identified matter given cur 2011 medicare reimbursement rule test rent status investigation remediation activity changed fmch opposed government motion inter fresenius medical care cannot reasonably estimate range vene remains undecided possible loss may result identified matter final outcome investigation remediation subpoena fresenius vascular care activity october 6 2015 office inspector general fresenius medical care implementing enhancement united state department health human service anticorruption compliance program including internal oig issued subpoena fresenius medical care seeking control related compliance international antibribery information utilization invoicing fresenius law fresenius medical care continues fully committed vascular care facility whole period beginning fcpa antibribery law compliance fresenius medical care acquisition american access care llc aac october 2011 fresenius medical subpoena maryland care cooperating government inquiry august 2014 fresenius medical care holding inc fmch managed united state attorney eastern received subpoena united state attorney district new york allegation aac arising district maryland inquiring fmchs contractual arrange district connecticut florida rhode island relating ments hospital physician including contract utilization invoicing settled 2015 relating management inpatient acute dialysis ser vice fmch cooperating investigation financial statement civil complaint hawaii july 2015 attorney general hawaii issued civil complaint hawaii false claim act alleging conspiracy pursuant certain liberty subsidiary fresenius medical care holding inc fmch overbilled consolidated financial statement note 159 hawaii medicaid liberty epogen administration subpoena new york hawaii medicaid patient period 2006 november 18 2016 fresenius medical care holding 2010 prior time fmchs acquisition inc fmch received subpoena united state liberty see hawaii v liberty dialysis hawaii llc et al attorney eastern district new york seeking docu case 151135707 hawaii 1st circuit state ments information relating operation shiel alleges liberty acted unlawfully relying incorrect medical laboratory inc fmch acquired october unauthorized billing guidance provided liberty 2013 course cooperating investigation xerox state healthcare llc acted hawaii con preparing respond subpoena fmch identified tracted administrator medicaid program reimburse falsification misrepresentation document submitted ment operation relevant period amount shiel salesperson relate integrity certain overpayment claimed state approximately invoice submitted shiel laboratory testing patient us8 million state seek civil remedy interest fine longterm care facility february 21 2017 fresenius penalty liberty fmch hawaii medical care north america initiated termination false claim act substantially excess overpayment employee notification united state attorney fmch filed thirdparty claim contribution indemnifi termination circumstance fmch cannot time cation xerox state false claim act complaint determine scope conduct implicated filed liberty initiated administrative action chal employee termination whether related liability lenging state recoupment alleged overpayment payment penalty false claim act might sum currently owed liberty civil litigation material administrative action proceeding parallel subpoena american kidney fund cm litigation subpoena colorado new york january 3 2017 fresenius medical care holding august 31 november 25 2015 respectively fresenius inc fmch received subpoena united state attor medical care holding inc fmch received subpoena ney district massachusetts inquiring fmchs united state attorney district colorado interaction relationship american kidney eastern district new york inquiring fmchs fund akf including fmchs charitable contribution participation management dialysis facility joint ven fund fund financial assistance patient tures physician partner fmch cooperating insurance premium fmch cooperating investigation investigation december 14 2016 center medicare medicaid service cm published interim final rule ifr subpoena texas dallas titled medicare program condition coverage end june 30 2016 fresenius medical care holding inc stage renal disease facilitiesthird party payment fmch received subpoena united state attorney would amend condition coverage dialysis provider northern district texas dallas seeking information like fresenius medical care north america fmcna use management pharmaceutical including ifr would effectively enabled insurer reject premium velphoro well fmchs interaction davita payment made patient received grant individual healthcare partner inc fmch understands subpoena market coverage akf therefore could isclosed davita relates investigation previously resulted patient losing individual market cov financial statement investigation encompasses davita amgen erage loss individual market coverage sanofi fmch cooperating investigation patient would material adverse impact operating result fmch 160 consolidated financial statement january 25 2017 federal district court texas time time fresenius group party may responding litigation initiated patient advocacy threatened litigation arbitration claim group dialysis provider including fmcna preliminarily assessment arising ordinary course business enjoined cm implementing ifr dialysis patient management regularly analyzes current information includ citizen v burrwell ed texas sherman div prelimi ing applicable fresenius group defense insur nary injunction based cm failure follow appropriate ance coverage necessary provides accrual noticeandcomment procedure adopting ifr pre probable liability eventual disposition matter liminary injunction remain place absence fresenius group like health care provider contrary ruling district appellate court insurance plan supplier conduct operation time extent cm continue intense government regulation scrutiny must comply contest preliminary injunction unclear also unclear regulation relate govern safety effi whether cm elect pursue notice cacy medical product supply marketing comment another rule related topic operation distribution product operation manufacturing charitable assistance program also receiving increased facility laboratory clinic health care facility attention state regulator including state department environmental occupational health safety insurance result may regulatory framework respect development manufacture marketing dis differs state state even absence ifr tribution medical product compliance main similar administrative action insurer expected con tained fresenius group could subject significant tinue take step thwart premium assistance provided adverse regulatory action u food drug admin fresenius medical care patient individual market istration fda comparable regulatory authority outside plan well insurance coverage united state regulatory action could include warn ing letter enforcement notice fda subpoena nevada comparable foreign regulatory authority may require november 2014 fresenius kabi oncology limited fkol fresenius group expend significant time resource received subpoena u department justice order implement appropriate corrective action doj u attorney district nevada subpoena fresenius group address matter raised warning request document connection january 2013 letter enforcement notice satisfaction inspection u food drug administration fda fda comparable regulatory authority outside fkols plant active pharmaceutical ingredient kalyani united state regulatory authority could take additional india inspection resulted warning letter action including product recall injunction fda july 2013 subpoena mark doj criminal distribution product operation manufacturing plant civil investigation connection seek infor civil penalty seizure fresenius group product mation throughout fresenius kabi group criminal prosecution fmch currently engaged ancillary subpoena january 2016 doj requested remediation effort respect one pending fda warn additional historic information data ing letter fresenius kabi respect two pending fda ancilliary subpoena june 2016 november 2016 resenius group must also comply warning letter f doj requested information fresenius kabi law united state including federal antikick usa fresenius kabi ag without changing focus back statute federal false claim act federal stark financial statement investigation fresenius kabi fully cooperates law federal civil monetary penalty law federal governmental investigation foreign corrupt practice act well federal consolidated financial statement note 161 state fraud abuse law applicable law regulation may accountability act health information technology amended enforcement agency court may make economic clinical health act foreign cor interpretation differ fresenius group interpreta rupt practice act among law comparable law tions manner conduct business country enforcement become high priority federal govern physician hospital participant health ment state addition provision care industry also subject large number lawsuit false claim act authorizing payment portion alleging professional negligence malpractice product recovery party bringing suit encourage private liability worker compensation related claim many plaintiff commence whistleblower action virtue involve large claim significant defense cost regulatory environment fresenius group business fresenius group currently subject activity practice subject extensive review suit due nature business expects regulatory authority private party continuing type lawsuit may continue although fresenius audit subpoena inquiry claim litigation relat group maintains insurance level belief ing fresenius group compliance applicable law prudent cannot assure coverage limit ade regulation fresenius group may always quate insurance cover asserted claim suc aware inquiry action begun particularly cessful claim fresenius group sub case whistleblower action initially filed sidiaries excess insurance coverage could material court seal adverse effect upon result operation fresenius group operates many facility handle claim regardless merit eventual outcome could personal health information patient beneficiary material adverse effect fresenius group reputa throughout united state part world tion business decentralized system often difficult maintain fresenius group also claim asserted desired level oversight control thousand lawsuit filed relating alleged patent individual employed many affiliated company infringement business acquired divested fresenius group relies upon management structure regu claim suit relate operation busi latory legal resource effective operation ness acquisition divestiture transaction compliance program direct manage monitor activ fresenius group appropriate asserted ities employee occasion fresenius group claim claim indemnification successful claim may identify instance employee agent delib fresenius group subsidiary could erately recklessly inadvertently contravene fresenius material adverse effect upon business financial group policy violate applicable law action condition result operation claim person may subject fresenius group subsid regardless merit eventual outcome could iaries liability antikickback statute stark material adverse effect fresenius group reputation law false claim act health insurance portability business financial statement 162 consolidated financial statement 29 financial instrument relationship class category well reconciliation statement financial position line item shown following table category financial liability asset financial liability measured fair value measured consolidated available sale loan receivables amortized cost statement income financial asset relating category cash cash ash cash c equivalent equivalent asset trade account receiv current non recognized able incl receivables current financial asset carrying amount loan related party ther current non current financial asset asset hare fund recognized fair value liability rade account payable ongterm capital l recognized hortterm account pay lease obligation carrying amount able related party hortterm debt incl shortterm loan related party ongterm debt l excluding capital lease class obligation enior note onvertible bond c shortterm longterm financial liability liability shortterm recognized longterm financial fair value liability noncontrolling oncontrolling n interest subject interest subject put provision put provision recognized fair value derivative ther current non ther current non hedging purpose current financial asset current financial asset ther shortterm ther shortterm longterm financial longterm financial liability liability financial statement consolidated financial statement note 163 valuation financial instrument carrying amount financial instrument december 31 classified category follows million 2016 2015 loan receivables 5798 5342 financial liability measured amortized cost 18223 18039 asset measured fair value consolidated statement income 1 389 358 liability measured fair value consolidated statement income 1 624 411 available sale financial asset 258 257 relating category 370 65 1 financial instrument designated fair value profit loss upon initial recognition following table present carrying amount fair value well fair value hierarchy level fresenius group financial instrument december 31 classified class 2016 2015 fair value carrying fair value carrying fair value million hierarchy level amount amount cash cash equivalent 1 1579 1579 1044 1044 asset recognized carrying amount 2 5926 5926 5454 5454 asset recognized fair value 1 258 258 257 257 liability recognized carrying amount 2 18369 19421 18190 19292 liability recognized fair value 3 601 601 404 404 noncontrolling interest subject put provision recognized fair value 3 1184 1184 947 947 derivative hedging purpose 2 359 359 358 358 significant method assumption used estimate class asset recognized fair value comprised fair value financial instrument well classification share fund fair value asset calcu fair value measurement according threetier fair lated basis market information fair value value hierarchy follows available sale financial asset quoted active market cash cash equivalent stated nominal value based price quotation periodend date level 1 equal fair value therefore class classified level 1 nominal value predominant part shortterm class liability recognized carrying amount clas financial instrument trade account receivable sified hierarchy level 2 payable current financial asset shortterm finan derivative embedded convertible bond cial liability shortterm debt represents carrying included class liability recognized fair value amount reasonable estimate fair value due fair value embedded derivative calculated using relatively short period maturity instrument difference market value convertible fair value major longterm financial instrument bond market value adequate straight bond calculated basis market information financial discounted market interest rate reporting financial statement instrument market quote available mea date level 2 furthermore class comprises variable pay sured market quote reporting date fair ments outstanding acquisition recognized value longterm financial liability calculated fair value estimation individual fair value present value respective future cash flow deter based key input arrangement determine mine present value prevailing interest rate future contingent payment well fresenius group credit spread fresenius group date expectation factor level 3 fresenius group statement financial position used assesses likelihood timing achieving relevant class asset recognized carrying amount clas objective underlying assumption reviewed regu sified hierarchy level 2 larly class classified level 3 164 consolidated financial statement valuation class noncontrolling interest subject analysis credit risk derivative financial instru put provision recognized fair value determined using ments regular basis valuation derivative finan significant unobservable input therefore classified cial instrument credit risk considered fair level 3 value every individual instrument basis default derivative mainly consisting interest rate swap probability credit default swap spread counter foreign exchange forward contract valued follows party appropriate duration calculation fair value interest rate swap calculated discount credit risk considered valuation done multiplying ing future cash flow basis market interest default probability appropriate duration rate applicable remaining term contract expected discounted cash flow derivative financial date statement financial position determine instrument fair value foreign exchange forward contract con class derivative hedging purpose includes tracted forward rate compared current forward rate call option purchased hedge convert remaining term contract date ible bond fair value call option derived statement financial position result discounted market quote fair value measurement class basis market interest rate prevailing derivative hedging purpose significant observ date statement financial position respective able input used therefore class classified level 2 currency accordance defined fair value hierarchy level fresenius group credit risk incorporated currently indication decrease fair value estimation derivative liability counter value fresenius group financing receivables probable party credit risk adjustment factored valuation therefore allowance credit loss financing derivative asset fresenius group monitor receivables immaterial fair value derivative financial instrument dec 31 2016 dec 31 2015 million asset liability asset liability interest rate contract current 0 0 0 2 interest rate contract noncurrent 5 1 0 1 foreign exchange contract current 14 24 16 6 foreign exchange contract noncurrent 1 1 1 derivative designated hedging instrument 1 19 26 17 10 interest rate contract current 0 0 0 interest rate contract noncurrent 1 0 3 foreign exchange contract current 1 27 23 23 7 foreign exchange contract noncurrent 1 derivative embedded convertible bond 0 362 0 335 call option secure convertible bond 1 362 0 335 0 derivative designated hedging instrument 389 386 358 345 1 erivatives designated hedging instrument foreign exchange contract call option secure convertible bond designated hedging instrument classified derivative hedging purpose financial statement consolidated financial statement note 165 derivative financial instrument marked market derivative embedded convertible bond reporting period resulting carrying amount equal fair call option secure convertible bond recognized value reporting date noncurrent liability asset consolidated state derivative designated hedging instrument ment financial position derivative qualify hedge accounting also solely entered hedge economic business transac effect financial instrument recorded tions speculative purpose consolidated statement income derivative hedging purpose well deriva net gain loss financial instrument consisted tives embedded convertible bond recognized allowance doubtful account amount 431 gross value within asset amount 408 mil million foreign currency transaction 4 million interest lion liability amount 411 million income 96 million resulted mainly valuation current portion derivative indicated asset call option connection convertible bond preceding table recognized within current asset fresenius se co kgaa valuation derivative consolidated statement financial position embedded convertible bond fresenius medical current portion indicated liability included care ag co kgaa trade account receivable loan shortterm accrued expense shortterm liability related party interest expense 678 million resulted noncurrent portion indicated asset liability mainly financial liability recognized recognized noncurrent asset longterm fair value consolidated statement income accrued expense longterm liability respectively effect derivative designated hedging instrument consolidated statement comprehensive income 2016 gain loss recognized gain loss reclassified gain loss comprehensive accumulated recognized income loss comprehensive income consolidated statement million effective portion loss effective portion income interest rate contract 3 36 0 foreign exchange contract 19 3 0 derivative cash flow hedging relationship 1 16 39 0 1 amount gain loss recognized consolidated statement income solely relates ineffective portion 2015 gain loss recognized gain loss reclassified gain loss comprehensive accumulated recognized income loss comprehensive income consolidated statement million effective portion loss effective portion income interest rate contract 6 37 0 foreign exchange contract 27 5 0 derivative cash flow hedging relationship 1 21 42 0 1 amount gain loss recognized consolidated statement financial statement income solely relates ineffective portion 166 consolidated financial statement effect derivative designated hedging instrument consolidated statement comprehensive income gain loss recognized consolidated statement income million 2016 2015 interest rate contract foreign exchange contract 4 28 derivative embedded convertible bond 27 190 call option secure convertible bond 27 190 derivative designated hedging instrument 4 28 loss foreign exchange contract designated course normal business next 12 month hedging instrument recognized consolidated statement interest expense income faced gain underlying transac gain loss foreign exchange contract tions corresponding amount corresponding underlying transaction accounted fresenius group expects recognize net amount cost sale selling general administrative expense 4 million existing loss foreign exchange con net interest gain loss resulting interest tract deferred accumulated comprehensive income rate contract recognized net interest consoli loss consolidated statement income within dated statement income next 12 month interest rate contract fresenius 2016 gain 13 thousand 2015 loss 79 thou group expects recognize 29 million loss sand available sale financial asset recognized comprehensive income loss following table show cash flow derivative financial instrument expected occur cash flow derivative financial instrument expected period million 1 year 1 3 year 3 5 year 5 year derivative designated hedging instrument 10 2 5 0 derivative designated hedging instrument 4 1 market risk order manage risk interest rate foreign general exchange rate fluctuation fresenius group enters fresenius group exposed effect related foreign certain hedging transaction highly rated financial exchange fluctuation connection international institution authorized management board deriva business activity denominated various currency tive financial instrument entered trading order finance business operation fresenius purpose group issue senior note commercial paper enters general fresenius group conduct derivative financial statement mainly longterm credit agreement schuldschein financial instrument activity control single loan bank due financing activity centralized department fresenius group established fresenius group exposed interest risk caused change guideline derived best practice standard bank variable interest rate risk change fair ing industry risk assessment procedure supervision value statement financial position item bearing fixed concerning use financial derivative guide interest rate line require amongst thing clear segregation duty consolidated financial statement note 167 area execution administration accounting foreign exchange risk management controlling risk limit continuously monitored fresenius group determined euro financial appropriate use hedging instrument adjusted reporting currency therefore foreign exchange translation extent risk resulting fluctuation exchange rate fresenius group defines benchmark individual euro local currency financial state exposure order quantify interest foreign exchange ments foreign subsidiary prepared impact risk benchmark derived achievable sus result operation financial position reported tainable market rate depending individual bench consolidated financial statement mark hedging strategy determined generally imple besides translation risk foreign exchange transaction mented mean micro hedge risk exist mainly relate transaction denominated earnings fresenius group materially foreign currency purchase sale project affected hedge ineffectiveness reporting period since service well intragroup sale product critical term interest foreign exchange deriv fresenius group entity different currency area solely atives mainly matched critical term underlying purpose hedging existing foreseeable foreign exposure exchange transaction exposure fresenius group enters foreign exchange forward contract small scale derivative financial instrument foreign exchange option ensure foreign exchange classification risk result loan foreign currency fresenius reduce credit risk arising derivative group enters foreign exchange swap contract fresenius group concluded master netting agreement december 31 2016 notional amount bank agreement positive negative fair eign exchange contract totaled 2635 million foreign value derivative contract could offset one exchange contract entered hedge risk another partner becomes insolvent offsetting operational business connection loan valid transaction aggregate amount obliga eign currency foreign exchange forward contract hedge tions owed receivable equal insolvency risk operational business exclusively recognized occurs party owes larger amount obliged cash flow hedge fair value cash flow hedge pay party difference amount 11 million owed form one net payment hedgeeffective portion change fair value fresenius elect offset fair value derivative foreign exchange forward contract designated financial instrument subject master netting agreement qualified cash flow hedge forecasted product purchase consolidated statement financial position sale reported accumulated comprehensive december 31 2016 december 31 2015 income loss amount subsequently reclassified fresenius group 45 million 37 million deriva earnings component cost sale selling tive financial asset subject netting arrangement general administrative expense period 46 million 19 million derivative financial liability hedged transaction affect earnings subject netting arrangement offsetting derivative december 31 2016 fresenius group party financial instrument would resulted net asset 28 foreign exchange contract maximum maturity million well net liability 29 million 10 million 19 month financial statement december 31 2016 december 31 2015 respectively 168 consolidated financial statement resenius group us cashflowatrisk cfar model f rate swap notional volume 257 million fair order estimate quantify transaction risk value 2 million euro interest rate swap expire foreign currency basis analysis currency year 2017 2022 bear average interest rate risk foreign currency cash flow reasonably 041 furthermore fresenius group u dollar expected arise within following 12 month less denominated interest rate swap amount u 200 hedge cfar approach potential currency million 190 million fair value u 5 million 5 fluctuation net exposure shown probability million expire 2021 bear average interest distribution based historical volatility correlation rate 122 interest rate option outstanding preceding 250 business day calculation made december 31 2016 notional volume 200 million assuming confidence level 95 holding period fair value 4 thousand expire 2018 one year aggregation currency risk risk prehedges used hedge interest rate exposure mitigating effect due correlation transac regard interest rate relevant future tions concerned e overall portfolio risk exposure longterm debt issuance could rise respec generally less sum total underlying individual tive debt actually issued prehedges settled risk december 31 2016 fresenius group cash issuance date corresponding longterm debt flow risk amount 73 million mean proba settlement amount recorded accumulated com bility 95 potential loss relation forecasted prehensive income loss amortized interest expense eign exchange cash flow next 12 month life debt december 31 2016 december 31 higher 73 million 2015 fresenius group 45 million 68 million following table show net position foreign respectively related settlement prehedges currency december 31 2016 significant deferred accumulated comprehensive income loss influence fresenius group foreign currency risk net tax interest payable interest receivables connection nominal million 2016 swap agreement accrued recorded chinese renminbi 164 adjustment interest expense reporting date con korean 89 cerning interest rate contract unscheduled repayment south african rand 79 renegotiation hedged item may case lead russian ruble 72 brazilian real 32 dedesignation hedging instrument existed point date respective hedging transaction recognized consolidated statement interest rate risk management income fresenius group interest rate risk mainly arise money purpose analyzing impact change rel market capital market transaction group evant reference interest rate fresenius group result financing business activity operation group calculates portion financial debt fresenius group enters interest rate swap bear variable interest rate small scale interest rate option order protect hedged mean interest rate swap option ri risk rising interest rate interest rate ing interest rate particular part liability derivative mainly designated cash flow hedge fresenius group assumes increase reference rate financial statement entered order convert payment based 05 compared actual rate date variable interest rate payment fixed interest rate statement financial position corresponding additional anticipation future longterm debt issuance pre annual interest expense compared net income hedge december 31 2016 euro denominated interest attributable shareholder fresenius se co kgaa consolidated financial statement note 169 analysis show increase 05 relevant performs aging analysis trade account receivable reference rate would effect less 10 detail aging analysis allowance doubtful consolidated net income attributable shareholder account please see note 14 trade account receivable fresenius se co kgaa fresenius se co kgaa share holder equity liquidity risk liquidity risk defined risk company credit risk potentially unable meet financial obligation man fresenius group exposed potential loss regarding agement fresenius group manages liquidity financial instrument event nonperformance group mean effective working capital cash counterparties respect derivative financial instrument management well anticipatory evaluation refi expected counterparty fails meet obli nancing alternative management fresenius group gations counterparties highly rated financial insti belief existing credit facility well cash tutions maximum credit exposure derivative rep generated operating activity additional shortterm resented fair value contract positive borrowing sufficient meet company foresee fair value amounting 41 million foreign exchange able demand liquidity see note 21 debt capital lease derivative maximum credit exposure interest rate obligation derivative 5 million maximum credit risk result following table show future undiscounted con ing use nonderivative financial instrument tractual cash flow including interest resulting recog defined total amount receivables order con nized financial liability well fair value noncon trol credit risk management fresenius group trolling interest subject put provision fair value derivative financial instrument million 1 year 1 3 year 3 5 year 5 year longterm debt capital lease obligation including account receivable securitization program 1 720 3295 1768 218 shortterm debt 860 0 0 0 senior note 840 3190 2950 1922 convertible bond 4 509 402 0 trade account payable 1315 0 0 0 financial liability 2281 174 0 0 noncontrolling interest subject put provision 632 236 180 136 derivative financial instrument designated cash flow hedge 24 2 0 0 derivative financial instrument designated hedging instrument 23 268 95 total 6699 7674 5395 2276 1 uture interest payment financial liability variable interest rate calculated f using latest interest rate fixed prior december 31 2016 30 supplementary information due company diversification within health care capital management sector strong market position business seg fresenius group solid financial profile capital ments global growing noncyclical market predict financial statement management includes equity debt principal objec able sustainable cash flow generated allow tive fresenius group capital management optimize reasonable proportion debt e employment weightedaverage cost capital sought extensive mix financial instrument moreover fresenius achieve balanced mix equity debt secure growth group customer generally high credit quality longterm basis capital increase may also con sidered exceptional case instance finance major acquisition 170 consolidated financial statement shareholder equity debt developed follows fresenius group financing strategy reflected credit resenius group covered rating agen rating f shareholder equity cies moody standard poor fitch following table show company rating million dec 31 2016 dec 31 2015 fresenius se co kgaa shareholder equity 20420 18003 total asset 46447 42959 equity ratio 440 419 rating fresenius se co kgaa dec 31 2016 dec 31 2015 fresenius se co kgaa subject capital require standard poor ments provided article association fresenius se corporate credit rating bbb bbb co kgaa obligation issue share condi outlook stable stable tional capital relating exercise stock option con moody corporate credit rating baa3 baa3 vertible bond basis existing 2003 2008 outlook stable stable 2013 stock option plan see note 33 sharebased compen fitch sation plan corporate credit rating bbb bb outlook stable stable debt july 29 2016 fitch upgraded credit rating million dec 31 2016 dec 31 2015 bb bbb stable outlook debt 14780 14769 total asset 46447 42959 debt ratio 318 344 31 supplementary information consolidated statement cash flow assuring financial flexibility top priority group consolidated statement cash flow fresenius financing strategy flexibility achieved wide group fiscal year 2016 2015 shown range financing instrument high degree diver page 103 sification investor fresenius group maturity profile cash fund reported consolidated statement cash display broad spread maturity high proportion flow consolidated statement financial position medium longterm financing choice financ comprised cash hand check security cash ing instrument market capacity investor diversification bank readily convertible within three month flexibility credit condition existing maturity profile subject insignificant risk change value taken account following table provides additional information leverage ratio basis net debt ebitda key regard consolidated statement cash flow financial figure fresenius group december 31 million 2016 2015 2016 leverage ratio 24 received interest 45 65 interest paid 562 575 income tax paid 894 860 2016 fresenius helios used subsidy investment financial statement property plant equipment amount 110 mil lion 2015 104 million offset purchase property plant equipment consolidated statement cash flow consolidated financial statement note 171 cash paid acquisition without investment license resenius group follows business segment f consisted following fresenius medical care million 2016 2015 fresenius kabi asset acquired 955 428 fresenius helios liability assumed 83 45 fresenius vamed noncontrolling interest 58 84 corporate note assumed connection acquisition 251 94 cash paid 563 205 cash acquired 30 4 segment corporate mainly comprised cash paid acquisition net 533 201 holding function fresenius se co kgaa well cash paid investment fresenius netcare gmbh provides service field net cash acquired 130 166 information technology addition segment corpo cash paid intangible asset net 12 29 rate includes intersegment consolidation adjustment total cash paid acquisition investment net cash acquired well special item see note 3 special item net purchase intangible asset 675 396 detail business segment shown page 109 note proceeds sale subsidiary 1 million segment reporting region take account geographi 2016 2015 149 million cal factor similarity market term opportu nities risk allocation particular region based 32 note consolidated segment domicile customer reporting note business segment general key figure used management board assess consolidated segment reporting table shown page segment performance selected way 106 107 annual report integral part include item income expense fall note area responsibility business segment fresenius group identified business segment management board convinced suitable per fresenius medical care fresenius kabi fresenius helios formance indicator operating income ebit man fresenius vamed corresponds internal orga agement board belief addition operating nizational reporting structure management approach income figure earnings interest tax december 31 2016 depreciation amortization ebitda also help investor key data disclosed conjunction consoli assess ability fresenius group generate cash dated segment reporting correspond key data flow meet financial obligation ebitda figure internal reporting system fresenius group internal also basis assessing fresenius group compliance external reporting accounting correspond term credit agreement e g fresenius key data definition used medical care 2012 credit agreement 2013 senior credit sale proceeds segment indicative agreement actual sale proceeds agreed third party financial statement administrative service billed accordance service level agreement business segment identified accordance fasb asc topic 280 segment reporting defines segment reporting requirement annual financial statement interim report regard operating business product service business region 172 consolidated financial statement depreciation amortization presented property plant addition key indicator depreciation amorti equipment intangible asset definite useful life zation sale operating cash flow sale respective business segment also disclosed net interest comprised interest expense interest income reconciliation key figure net income attributable shareholder fresenius se consolidated earnings co kgaa defined earnings income tax non controlling interest million 2016 2015 operating cash flow cash provided used total ebit reporting segment 4358 3990 special item 0 83 operating activity general corporate expense cash flow acquisition dividend corporate ebit 31 32 operating cash flow less net capital expenditure group ebit 4327 3875 debt comprised bank loan senior note convertible interest expense 678 868 interest income 96 255 bond capital lease obligation liability relating outstand income income tax 3745 3262 ing acquisition well intercompany liability capital expenditure mainly includes addition property plant equipment reconciliation net debt consolidated acquisition refer purchase share legally statement financial position independent company acquisition business divi million dec 31 2016 dec 31 2015 sion intangible asset e g license key figure shortterm debt 847 202 shown regard acquisition present contractual pur shortterm debt related party 6 4 chase price comprising amount paid cash less cash current portion longterm debt acquired debt assumed issuance share whereas capital lease obligation 611 607 current portion senior note 473 349 purpose statement cash flow cash longterm debt capital lease purchase price component less acquired cash cash equiv obligation less current portion 5048 5502 alents reported senior note less current portion 6941 7267 ebitda margin calculated ratio ebitda convertible bond 854 838 debt 14780 14769 sale less cash cash equivalent 1579 1044 ebit margin calculated ratio ebit sale net debt 13201 13725 return operating asset rooa defined ratio ebit average operating asset operating asset defined total asset less deferred tax asset trade following table show noncurrent asset geo account payable advance payment customer graphical region well guaranteed subsidy million dec 31 2016 dec 31 2015 germany 8653 8042 europe excluding germany 3062 2968 north america 19486 18385 financial statement asiapacific 1784 1610 latin america 684 556 africa 52 43 total noncurrent asset 1 33721 31604 1 aggregate amount net noncurrent asset sum noncurrent asset less deferred tax asset less derivative financial instrument consolidated financial statement note 173 2016 fresenius group generated sale 6913 mil weightedaverage assumption calculation lion 2015 6625 million germany sale united fair value grant fresenius se co kgaa stock state 13543 million actual rate 2015 12417 option plan 2013 made 2016 2015 follows million 13511 million constant currency 2016 2016 2015 july december july december 33 sharebased compensation plan million grant grant grant grant expected dividend yield 116 122 116 109 compensation cost connection riskfree interest rate 030 009 044 034 sharebased compensation plan expected volatility 2641 2422 2652 2657 f resenius group life option 8 year 8 year 8 year 8 year 2016 fresenius group recognized compensation cost exercise price per option 6602 6715 6064 6799 amount 46 million stock option granted since 2013 stock incentive plan performancebased fresenius group recognizes compensation cost expected volatility result historical volatility cal vesting period based market value underlying culated expected life option volatility stock grant date determined fair value stock option calculated expense related cashsettled sharebased pay first time since controlled every ment transaction determined based upon fair value year upon issuance new tranche measurement date number phantom stock performance share granted recognized sharebased compensation plan resenius group recognized vesting period 2016 f fresenius se co kgaa expense 52 million connection cashsettled description fresenius se co kgaa sharebased payment transaction sharebased compensation plan place resenius se co kgaa three december 31 2016 f fair value stock option sharebased compensation plan place fresenius ag fresenius group us binomial option pricing model stock option plan 2003 2003 plan based con determining fair value stock option granted vertible bond stock option based fresenius se stock resenius stock option plan fresenius se co kgaa f option plan 2008 2008 plan f resenius se co kgaa medical care ag co kgaa option valuation model require long term incentive program 2013 2013 ltip input highly subjective assumption including expec based stock option phantom stock 2016 stock ted stock price volatility fresenius group assumption option phantom stock solely granted based upon past experience market trend expe 2013 ltip riences entity size similar indus try incorporate effect expected early exercise model early exercise vested option assumed soon share price exceeds 150 exercise price fresenius group stock option characteristic vary significantly traded option change financial statement subjective assumption materially affect fair value option 174 consolidated financial statement 2013 ltip fresenius management se determines participant 2013 ltip comprised fresenius se co kgaa 2013 sop stock option granted stock option plan 2013 2013 sop fresenius se exercise price option shall equal volume co kgaa phantom stock plan 2013 2013 psp combine weighted average stock market price closing price granting stock option granting phantom nonpar value ordinary bearer share fresenius se stock award entitle holder receive cash payment co kgaa electronic xetra trading deutsche börse upon exercising phantom stock 2013 sop ag frankfurt main comparable successor system 2013 psp making 2013 ltip established last 30 calendar day prior respective grant date standalone legal documentation option granted eightyear term exer cised fouryear vesting period exercise 2013 sop option subject condition precedent case 2013 sop approved annual gen annual success target within fouryear waiting eral meeting fresenius se co kgaa may 17 2013 period achieved success target achieved fresenius management se originally authorized issue case granting option respective 84 million subscription right amount 84 entitled person either consolidated net income attrib million nonpar value ordinary bearer share fresenius se utable shareholder fresenius se co kgaa according co kgaa may 16 2018 u gaap adjusted extraordinary effect con 84 million option 16 million option stant currency basis increased least 8 per designated member management board annum comparison previous year case within fresenius management se 44 million option waiting period ii case com designated member management directly indi pounded annual growth rate consolidated net income rectly affiliated company except fresenius medical attributable shareholder fresenius se co kgaa care 24 million option designated exec according u gaap adjusted extraordinary effect utive employee fresenius se co kgaa affiliated constant currency basis four year company except fresenius medical care waiting period amount least 8 event connection stock split 2014 total volume success target within fouryear waiting period yet granted subscription right increased achieved individual year compounded proportion subscribed capital factor 3 far option annual growth rate option issued case yet granted 2013 sop feited proportion nonachievement success applies subset subscription right attrib target within waiting period e one quarter two utable individual group participant stock option quarter three quarter completely performance tar granted stock split 2014 came effect get 2013 2014 2015 2016 met entitlement participant receive new share adjusted net income attributable shareholder exercise stock option increased fresenius se co kgaa according u gaap currency proportion subscribed capital factor 3 partici adjusted change thereto compared adjusted pant entitled receive three bearer ordinary share net income according u gaap without currency adjust fresenius se co kgaa exercise price reduced ment relevant comparison year shall verified proportionally binding effect case auditor fresenius se financial statement granting option shall occur five annual co kgaa basis audited consolidated financial tranche last monday july first monday statement upon exercise vested option fresenius se december respect new option supervisory co kgaa right grant treasury share lieu board fresenius management se determines stock increasing capital issuance new share option granted member fresenius management s expiration waiting period option management board whereas management board respect success target achieved may exercised time outside designated black period consolidated financial statement note 175 2013 psp success target within fouryear waiting period fresenius se co kgaas 2013 psp established may achieved individual year compounded 2013 together 2013 sop line 2013 ltip annual growth rate phantom stock award issued award phantom stock granted stock case forfeited proportion nonachievement option grant date phantom stock awarded 2013 success target within waitingperiod e one quarter psp may granted member fresenius manage two quarter three quarter completely performance ment s management board member manage target 2013 2014 2015 2016 met ment directly indirectly affiliated company except adjusted net income attributable shareholder fresenius medical care executive employee fresenius se co kgaa according u gaap currency fresenius se co kgaa affiliated company except adjusted change thereto compared adjusted net fresenius medical care income according u gaap without currency adjust holder phantom stock issued ment relevant comparison year shall verified stock split 2014 came effect granted eco binding effect case auditor fresenius se nomic compensation retroactively tripling num co kgaa basis audited consolidated financial ber phantom stock granted stock split 2014 statement came effect expiration waiting period exercisable 2013 sop supervisory board fresenius phantom stock deemed exercised cashed management se determines phantom stock granted march 1 following end waiting period resenius management s management board member f following banking day whereas management board fresenius management se determines participant 2013 psp stock option plan 2008 phantom stock granted 2008 fresenius se adopted 2008 plan grant phantom stock award 2013 psp entitle subscription right member management board holder receive cash payment phantom stock award executive employee company affiliated com shall entitle holder receive volumeweighted aver panies 2008 plan originally 62 million age stock market price closing price nonpar value option could issued carried entitlement ordinary bearer share fresenius se co kgaa elec exclusively obtain 62 million ordinary share tronic xetra trading deutsche börse ag frankfurt stock option granted stock split main comparable successor system last three 2014 came effect entitlement participant month prior date phantom stock exercised receive new share exercise stock option exercise phantom stock subject condition increased proportion subscribed capital precedent case annual success target within factor 3 participant entitled receive three fouryear waiting period achieved success target bearer ordinary share fresenius se co kgaa achieved case granting subscription maximum number ordinary share issued increased right respective entitled person either consoli accordingly exercise price reduced proportionally dated net income attributable shareholder fresenius se option granted sevenyear term co kgaa according u gaap adjusted extraordinary exercised threeyear vesting period vesting effect constant currency basis increased option granted mandatorily subject condition financial statement least 8 per annum comparison previous year case annual success target within three case within waiting period ii year vesting period achieved year case compounded annual growth rate consolidated success target achieved consolidated net income net income attributable shareholder fresenius se attributable shareholder fresenius se co kgaa co kgaa according u gaap adjusted extraordinary adjusted extraordinary effect increased least effect constant currency basis four 8 compared respective adjusted net income attrib year waiting period amount least 8 event utable shareholder fresenius se co kgaa pre vious fiscal year year success target 176 consolidated financial statement met onethird option granted shall 234987 phantom stock 2013 ltip including feit adjusted net income attributable shareholder 34574 phantom stock granted member manage fresenius se co kgaa shall calculated basis ment board fresenius management se measure calculation method accounting principle ment date december 31 2016 fair value 7134 according u gaap purpose 2008 plan total fair value 17 million revalued adjusted net income attributable shareholder fair value change amortized fouryear vesting fresenius se co kgaa determined verified period resenius se co kgaas auditor binding effect f resenius se co kgaa received fiscal year 2016 f audit consolidated financial statement cash 31 million exercise 1480421 stock performance target met year condition option average stock price ordinary share fulfilled stock option may exercised throughout exercise date 6730 intrinsic value convertible year exception certain predetermined black bond stock option exercised 2016 65 million period 284062 convertible bond outstanding exercisable stock incentive plan replaced 2013 sop 2003 plan december 31 2016 member last option granted 2012 fresenius management se management board held convertible bond december 31 2016 2560201 stock option plan 2003 outstanding exercisable stock option issued 2003 fresenius ag adopted 2003 plan mem 2008 plan 248280 held member fresenius bers management board executive employee management se management board 8056013 stock option incentive plan based convertible bond issued 2013 ltip outstanding december 31 replaced 2008 plan last convertible bond 2016 member fresenius management se man granted 2007 2003 plan eligible employee agement board held 1046250 stock option 1056188 right acquire ordinary share fresenius se phantom stock issued 2013 ltip outstanding co kgaa bond expire 10 year one third december 31 2016 member fresenius exercised beginning two three four year management se management board held 202055 phantom grant date respectively stock stock option transaction summarized follows transaction 2016 weighted resenius se co kgaa awarded 2254663 stock 2016 f average number ordinary share number exercise price option option 2013 ltip including 348750 option dec 31 option exercisable member management board fresenius manage balance 2014 12903766 2627 5325004 ment se weightedaverage exercise price 6603 granted 2260465 6076 exercised 4195350 2108 weightedaverage fair value 1531 total fair forfeited 319572 3300 value 35 million amortized four balance 2015 10649309 3544 4335892 year vesting period fresenius se co kgaa also awarded granted 2254663 6603 exercised 1480421 2110 forfeited 523275 4154 balance 2016 10900276 4342 2844263 financial statement consolidated financial statement note 177 following table provides summary fully vested option outstanding exercisable ordinary share december 31 2016 option ordinary share option outstanding option exercisable range weightedaverage weightedaverage remaining weightedaverage remaining weightedaverage exercise price contractual life exercise price contractual life exercise price number option year number option year 1501 2000 560164 050 1846 560164 050 1846 2001 2500 730602 149 2376 730602 149 2376 2501 3000 1553497 251 2624 1553497 251 2624 3001 3500 1761462 462 3225 0 3501 4000 1942548 558 3692 0 6001 6500 2062465 658 6064 0 6501 7000 2289538 757 6606 0 10900276 506 4342 2844263 185 2407 december 31 2016 aggregate intrinsic value exer ltip 2016 variable compensation program long cisable option ordinary share 143 million term incentive effect pursuant ltip 2016 plan december 31 2016 total unrecognized compensation participant may granted socalled performance share cost related nonvested option granted 2008 annually semiannually 2016 2018 performance plan 2013 ltip 57 million cost expected share nonequity cashsettled virtual compensation recognized weightedaverage period 29 year instrument may entitle plan participant receive cash payment depending achievement predefined fresenius medical care ag co kgaa performance target defined well fmc sharebased compensation plan ag co kgaas share price development december 31 2016 fresenius medical care ag co kgaa member management board supervisory fmcag co kgaa various sharebased compensation board due exercise discretion taking plan may either equity cashsettled account individual responsibility performance management board member determine initial value fresenius medical care ag co kgaa longterm grant award management board member incentive program 2016 plan participant member man may 11 2016 issuance stock option phan agement board determination made man tom stock fmcag co kgaa longterm incen agement board initial grant value determined tive program 2011 ltip 2011 longer possible order currency respective participant receives continue enable member management base salary time grant order determine board member management board affiliated number performance share plan participant receives company managerial staff member adequately par respective grant value divided value per ticipate longterm sustained success fresenius performance share time grant mainly financial statement medical care management board supervisory determined based average price fmcag co kgaas board fresenius medical care management ag share period 30 calendar day prior respec approved adopted fmcag co kgaa longterm tive grant date incentive plan 2016 ltip 2016 successor program number granted performance share may change effective january 1 2016 performance period three year depending level achievement following revenue growth 178 consolidated financial statement ii growth net income attributable shareholder fmc achievement level three performance target ag co kgaa net income growth iii return invested weighted annually onethird determine yearly capital roic improvement target achievement year threeyear performance revenue net income roic determined according period level overall target achievement ifrs euro based full year result revenue growth threeyear performance period determined net income growth purpose plan deter basis mean three average yearly target mined constant currency achievement overall target achievement annual target achievement level 100 reached range 0 200 revenue growth performance target revenue growth number performance share granted plan 7 individual year threeyear performance participant beginning performance period period revenue growth 0 lead target achieve multiplied level overall target achieve ment level 0 maximum target achievement level ment order determine final number performance 200 reached case revenue growth share least 16 revenue growth range value final number performance share generally deemed degree target achievement linearly interpo earned four year day respective grant vest lated value ing period number vested performance share annual target achievement level 100 net multiplied average fmcag co kgaa share income growth performance target reached net price period 30 day prior lapse four income growth 7 individual year three year vesting period respective resulting amount year performance period case net income growth paid plan participant cash compensation 0 target achievement level also 0 maxi mum target achievement 200 reached fresenius medical care ag co kgaa long term case net income growth least 14 incentive program 2011 value degree target achievement determined resenius medical care ag co kgaa may 12 2011 f mean linear interpolation stock option plan 2011 2011 sop established reso regard roic improvement annual target lution fresenius medical care ag co kgaas fmcag achievement level 100 reached target roic co kgaa annual general meeting agm 2011 sop defined respective year reached target together phantom stock plan 2011 estab roic 73 2016 increase 02 percentage lished resolution fresenius medical care management point per year 75 2017 77 2018 79 2019 ag fmc management ag management supervisory 81 2020 target achievement level 0 board form fmcag co kgaas long term incentive reached roic fall target roic program 2011 2011 incentive program 2011 respective year 02 percentage point whereas incentive program participant granted award maximum target achievement level 200 consisted combination stock option phantom reached target roic respective year exceeded stock final grant 2011 incentive program 02 percentage point degree target made december 2015 award 2011 incen achievement determined mean linear interpola tive program subject fouryear vesting period tion roic range value case vesting award granted subject achievement financial statement annual roic target achievement level third year predefined performance target 2011 sop estab performance period equal higher roic target lished conditional capital increase 12 million achievement level two previous year subject issue 12 million nonpar value bearer performance period roic target achievement level ordinary share nominal value 100 third year deemed achieved year exercised obtain one ordinary share respective performance period consolidated financial statement note 179 stock option granted 2011 incentive program option granted amended 2006 plan u eightyear term exercised first time participant nonqualified stock option united fouryear vesting period exercise price stock state internal revenue code 1986 amended option option granted 2011 incentive program shall amended 2006 plan transferable par average stock exchange price frankfurt stock exchange ticipant participant heir may pledged fmcag co kgaas share 30 calendar day assigned otherwise disposed immediately prior grant date stock option granted 2011 incentive program u participant transaction 2016 nonqualified stock option united state internal first award ltip 2016 granted july 25 revenue code 1986 amended stock option 2016 2016 ltip 2016 fmcag co kgaa 2011 incentive program transferable participant awarded 642349 performance share including 79888 per participant heir may pledged assigned formance share awarded member manage disposed otherwise ment board fmc management ag measurement date phantom stock award 2011 incentive program weightedaverage fair value 7619 total fair entitle holder receive payment euro fmc value 49 million revalued fair value ag co kgaa upon exercise phantom stock payment change total fair value amortized four per phantom share lieu issuance stock shall year vesting period based upon share price frankfurt stock exchange 2016 fmcag co kgaa received cash 39 one fmcag co kgaas share exercise date million exercise stock option intrinsic value phantom stock award fiveyear term exer stock option exercised 2016 31 million fmc cised first time fouryear vesting period ag co kgaa recorded related tax benefit 8 million participant u tax payer phantom stock 2016 connection cashsettled sharebased payment deemed exercised event month march transaction ltip 2011 ltip 2016 fmc following end vesting period ag co kgaa recognized expense 35 million 11 million year ending december 31 2016 2015 stock option plan 2006 respectively resenius medical care ag co kgaa stock option plan f december 31 2016 management board member 2006 amended 2006 plan established condi fmc management ag held 1010784 stock option tional capital increase 128 million subject issue employee fmcag co kgaa held 5056383 stock option 5 million nonpar value bearer ordinary share various stockbased compensation plan nominal value 100 exercised fresenius medical care obtain one ordinary share connection share split december 31 2016 management board member effected 2007 principal amount adjusted fmc management ag held 81019 phantom stock proportion share capital capital increase employee fmcag co kgaa held 812970 phantom 15 million issue 15 million new non stock 2011 incentive program par value bearer ordinary share december 31 2016 management board member december 2010 grant issued fmc management ag held 79888 performance share amended 2006 plan option granted employee fmcag co kgaa held 555148 perfor financial statement plan exercisable december 2017 mance share ltip 2016 180 consolidated financial statement table provides reconciliation option outstanding december 31 2016 compared december 31 2015 weightedaverage number option exercise price thousand balance december 31 2015 option ordinary share 8737 5875 granted 0 exercised 908 4345 forfeited 1762 5208 balance december 31 2016 option ordinary share 6067 6298 following table provides summary fully vested option ordinary share outstanding exercisable december 31 2016 weightedaverage number remaining weightedaverage aggregate option contractual life exercise price intrinsic value thousand year million option ordinary share 1162 202 4968 36 december 31 2016 total unrecognized compensation cost related nonvested option granted plan 21 million cost expected recognized weightedaverage period 2 year financial statement consolidated financial statement note 181 34 related party transaction 2016 14 million 2015 18 million paid fresenius prof dr h c roland berger partner roland berger management se compensation management board strategy consultant holding gmbh member supervisory board general partner fee supervisory board fresenius management se reimbursement outof pocket expense december 31 fresenius se co kgaa may 13 2016 2016 2016 outstanding liability payable fresenius roland berger group provide consulting service management se amount 38 million december 31 fresenius group 2015 discussion 2015 34 million consisting mainly pension obligation approval supervisory board fresenius management management board compensation se fresenius se co kgaa fresenius group paid aforementioned payment net amount addi 005 million affiliated company roland berger tion vat insurance tax paid group consulting service rendered 2015 fresenius medical care provided unsecured loan dr dieter schenk deputy chairman supervisory amount 60 million associated company board fresenius management se partner customary condition fully repaid international law firm noerr llp provides legal ser june 30 2016 vice fresenius group 2016 discussion approval mandate supervisory board 35 subsequent event fresenius management se fresenius group paid january 31 2017 fresenius helios closed acquisition 09 million law firm legal service rendered 100 share capital idc salud holding slu 2015 14 million amount paid includes also pay quirónsalud spain largest private hospital operator ments service already provided 2015 purchase price 576 billion detail paid 2016 acquisition financing see note 2 acquisition divestiture investment 21 debt capital lease obli gations 22 senior note 23 convertible bond 26 fresenius se co kgaa shareholder equity significant change fresenius group operating environment following end fiscal year 2016 february 21 2017 event material importance asset liability financial position result operation group occurred following end fiscal year financial statement 182 consolidated financial statement note accordance cash compensation paid management board german commercial code hgb performance responsibility 14573 thousand 2015 13998 thousand thereof 5319 thousand 2015 36 compensation management 6055 thousand performancebased 9254 thou board supervisory board sand 2015 7943 thousand performancebased individualized information regarding compensation amount performancebased compensation depends member management board supervisory achievement target relating net income board disclosed audited compensation report see fresenius group business segment longterm incen page 87 ff part management report tive component member management board compensation management board whole received 348750 stock option fresenius se performancebased composed three element co kgaa stock option plan 2013 sharebased compen fiscal year 2016 sation cash settlement amount 5140 thousand total compensation management board nonperformancebased compensation 25051 thousand 2015 27065 thousand fixed compensation fringe benefit total compensation paid supervisory board shortterm performancebased compensation fresenius se co kgaa fresenius management se oneyear variable compensation committee 4388 thousand 2016 2015 component longterm incentive effect 3648 thousand amount 220 thousand fixed severalyear variable compensation comprising stock compensation 2015 206 thousand 100 thousand option sharebased compensation cash compensation committee service 2015 100 thousand settlement phantom stock postponed payment 4068 thousand variable compensation 2015 oneyear variable compensation 3342 thousand 2016 based pension commitment former mem bers management board 1094 thousand 2015 1081 thousand paid pension obligation person amounted 23183 thousand 2016 2015 17835 thousand fiscal year 2016 2015 loan advance payment future compensation component made member management board fresenius manage ment se financial statement consolidated financial statement note accordance german commercial code hgb 183 37 auditor fee 2016 2015 fee auditor kpmg ag wirtschaftsprüfungsgesellschaft berlin affiliate expensed follows 2016 2015 million total germany total germany audit fee 17 6 17 6 auditrelated fee 2 2 1 1 tax consulting fee 1 0 1 0 fee 5 5 7 7 total auditor fee 25 13 26 14 leading auditor responsible audit 39 proposal distribution consolidated financial statement since 2012 earnings general partner supervisory board 38 corporate governance fresenius se co kgaa propose annual general consolidated stock exchange listed entity decla meeting earnings 2016 fresenius se ration pursuant section 161 german stock corpo co kgaa distributed follows ration act aktiengesetz issued made available shareholder website fresenius se co kgaa wwwfreseniuscomcorporategovernance fresenius payment dividend 062 per bearer ordinary share 553316547 ordinary medical care ag co kgaa wwwfreseniusmedicalcarecom share entitled dividend 34305625914 balance carried forward 59317056 retained earnings 34364942970 financial statement 184 consolidated financial statement 40 responsibility statement group management report includes fair review devel best knowledge accordance opment performance business position applicable reporting principle consolidated financial group together description principal oppor statement give true fair view asset liability tunities risk associated expected development financial position profit loss group group bad homburg v h february 21 2017 fresenius se co kgaa represented fresenius management se general partner management board sturm dr f de meo dr j götz henriksson r powell dr e wastler financial statement auditor report 185 auditor report management report detected reasonable assurance knowledge business activity economic fresenius se co kgaa legal environment group expectation possi ble misstatement taken account determination audited consolidated financial statement prepared audit procedure effectiveness accounting fresenius se co kgaa bad homburg v höhe com related internal control system evidence supporting prising consolidated statement income consolidated disclosure consolidated financial statement statement comprehensive income consolidated state group management report examined primarily ment financial position consolidated statement cash test basis within framework audit audit flow consolidated statement change equity includes assessing annual financial statement note consolidated financial statement busi entity included consolidation determination ness year january 1 december 31 2016 prepa entity included consolidation accounting ration consolidated financial statement accordance consolidation principle used significant estimate accounting principle generally accepted made legal representative well evaluating united state america u gaap responsibility overall presentation consolidated financial statement legal representative company responsibility believe audit provides reasonable basis express opinion consolidated financial statement opinion based audit addition engaged audit led reservation express opinion whether voluntarily prepared opinion based finding audit group management report agreement group consolidated financial statement comply u gaap management report fresenius se co kgaa bad homburg give true fair view net asset financial position v höhe prepared accordance 290 315 result operation group accordance hgb handelsgesetzbuch german commercial code apart requirement voluntarily prepared group management appropriate incorporation u gaap financial data report consistent consolidated financial statement conducted audit consolidated financial prepared accordance u gaap apart statement accordance 317 hgb german generally appropriate incorporation u gaap financial data agree accepted standard audit financial statement ment group management report fresenius se promulgated institut der wirtschaftsprüfer idw co kgaa prepared accordance 290 315 hgb standard require plan perform audit issued unqualified statutory audit opinion misstatement materially affecting presentation based group management report complies net asset financial position result operation german statutory requirement whole provides consolidated financial statement accordance suitable view group position suitably present applicable financial reporting framework group opportunity risk future development frankfurt main february 21 2017 kpmg ag wirtschaftsprüfungsgesellschaft auditor report rohrbach walter german public auditor german public auditor 186 report supervisory board report supervisory board 2016 supervisory board fresenius se co kgaa fulfilled obligation respective term accordance provision law article association rule procedure regularly advised management board general partner fresenius management se regarding manage ment company supervised management accordance supervisory board responsibility cooperation management supervisory board carrying monitoring advisory activity management board regularly kept supervisory board informed timely comprehensive oral written manner among thing supervisory board informed important matter relating business policy course business profitability position company group strategy planning risk situation risk management compliance well important business event report supervisory board report supervisory board 187 based report submitted management board general partner supervisory board discussed business transaction important company committee meet ings management board general partner also discussed company strategic direction supervisory board supervisory board passed resolution within framework legal statutory authority supervisory board fresenius se co kgaa held four regular meeting 2016 march may october december addition extraordinary meeting september mem bers supervisory board informed acquisition spanish hospital group idc salud holding slu quirónsalud fresenius helios financing transaction meeting management board general partner sent detailed report comprehensive approval submission member supervisory board meeting supervisory board discussed general business development detail based report general partner management board addition dealt important business decision company matter requiring supervisory board approval submitted sufficient time proper scrutiny reviewing related approval document detailed consultation management board general partner supervisory board approved matter submitted supervisory board also kept informed meeting important business event addition chairman general partner management board regularly informed chairman supervisory board separate conversation current development business forthcoming decision discussed member supervisory board attended meeting march 2016 may following election employee representative european work council election shareholder representative annual general meeting supervisory board reconstituted member participated meeting supervisory board 2016 attendance supervisory board audit committee meeting shown member individually company website information found section supervisory board main focus supervisory board activity 2016 supervisory board mostly focused monitoring advisory activity business operation investment business segment furthermore supervisory board discussed detail significant business activity management board concerned acquisition especially report supervisory board 188 report supervisory board acquisition quirónsalud fresenius helios investment planned expansion group headquarters supervisory board also dealt following topic 2017 budget midterm strategy fresenius group corporate strategy especially business outlook fresenius kabi fresenius helios digitalization initiative business sector also regularly informed risk analysis risk management compliance within group audit committee plenary session another focus discussion proposal election shareholder representative annual general meeting fresenius se co kgaa may 2016 meeting march 11 2016 supervisory board intensively dealt review approval financial statement consolidated financial statement ifrs u gaap well man agement report group management report fresenius se co kgaa based detailed report chairman audit committee presentation auditor result fiscal year 2015 discussed meeting vote taken proposal general partner fresenius management se distribution earnings addition business segment reported detail business performance first two month fiscal year included discussion competi tive situation fresenius kabi north america well innovation pharmaceutical division furthermore supervisory board informed plan extend group headquarters based document prepared nomination committee supervisory board also discussed length proposal election shareholder representative annual general meeting company may 2016 supervisory board considered international activity group potential conflict interest question independence candidate well diversity term qualification light requirement appoint woman member supervisory board finally supervisory board carried annual efficiency review meeting meeting may 13 2016 immediately following election shareholder representative annual general meeting supervisory board reconstituted supervisory board elected chairman two deputy chairman supervisory board well member chairman audit committee nomination committee furthermore rule procedure approved report supervisory board report supervisory board 189 management board reported eu market abuse regulation consequence company director especially regarding reportable security transaction management board also reported business performance january april 2016 september 5 2016 extraordinary meeting held form conference call meet ing acquisition spanish hospital group quirónsalud fresenius helios intensively dealt member supervisory board provided comprehensive information spanish health care market well range medical service provided economic environment quirónsalud operates supervisory board meeting october 14 2016 took decision utilizing authorized capital finance acquisition quirónsalud well setting committee deal aspect equity financing transaction business performance january september 2016 pre sented member supervisory board detail particular focus business segment fresenius helios addition four business segment presented digitalization initiative inter company project focus supervisory board meeting december 9 2016 one hand business per formance 2016 hand budget planning year 2017 2019 presented respect group well individually business segment chairman audit committee reported detail status preparation financial statement topic declaration conformity accordance german corporate governance code well informa tion supervisory board compliance regulatory issue legal risk addition supervisory board meeting october 13 2016 comprehensive onboarding event held meeting group four business segment presented newly constituted supervisory board also covering topic relating governance finance well else krönerfresenius foundation corporate governance supervisory board management board general partner jointly issued declaration conformity accordance german corporate governance code pursuant section 161 german stock corporation act aktg december 20 2016 management board general partner supervisory board fresenius se co kgaa duty act best interest company performing activity pursue report supervisory board 190 report supervisory board personal interest bestow unjustified benefit others sideline activity transaction company member corporate body must reported approved supervisory board prof dr med michael albrecht member supervisory board company medical director spokesman management board university hospital carl gustav carus dresden well member supervisory board university hospital aachen fresenius group maintains regular business relationship hospital ordinary course business market condition klauspeter müller member supervisory board chairman audit committee company member supervisory board fresenius management se also chairman supervisory board commerzbank ag fresenius group maintains business relationship market condition michael diekmann deputy chairman supervisory board well member supervisory board fresenius management se also nonexecutive director board director allianz australia ltd 2016 fresenius group paid insurance premium allianz market condition direct consultant service agreement company member supervisory board 2016 various company fresenius group advised company internation ally active law firm noerr dr dieter schenk deputy chairman supervisory board fresenius management se also partner law firm noerr llp reporting period fresenius group paid total 09 million law firm noerr 2015 14 million corresponds less 05 total amount paid fresenius group service legal advice 2016 2015 1 payment also includes payment service provided 2015 actually paid 2016 total amount year 2016 less 01 million attributable service group company related usiness business segment fresenius medical care service rendered group company b segment fresenius medical care require separate approval supervisory board fresenius medical care management ag fresenius medical care ag co kgaa supervisory board fresenius management se closely examined mandating approved dr schenk abstained voting supervisory board fresenius se co kgaa dr schenk member dealt volume legal fee paid law firm noerr relation fee volume paid law firm payment mentioned section net amount euro addition vat paid information corporate governance fresenius please refer corporate governance declaration report page 72 84 annual report fresenius disclosed information related party quarterly report page 181 annual report report supervisory board report supervisory board 191 work committee reporting year audit committee held three meeting four conference call main focus monitoring activity preliminary audit annual financial statement fresenius se co kgaa group 2015 discussion auditor report term reference audit another matter dealt audit committee recommendation super visory board regarding auditing firm propose annual general meeting election auditor annual financial statement fresenius se co kgaa group 2016 supervisory board proposal annual general meeting 2016 elect kpmg ag wirtschaftsprüfungsgesellschaft berlin auditor based recommendation audit committee finally audit committee also reviewed detail 2016 quarterly report controlling report development acquisition compliance risk management system internal control system internal auditing system approval nonaudit service kpmg ag wirtschaftsprüfungsgesellschaft berlin chairman audit committee reported regularly supervisory board work audit committee respective subsequent meeting company nomination committee met march 2016 preparation supervisory board election may 2016 joint committee whose approval necessary certain important transaction fresenius se co kgaa certain legal activity company else krönerfresenius foundation meet 2016 transaction effected required joint committee approval mediation committee supervisory board fresenius se co kgaa appoint management board member fresenius management se information committee composition work method please refer corporate governance declaration report page 76 77 195 annual report personnel term office member supervisory board company ended annual general meeting fresenius se co kgaa may 13 2016 would like thank retiring member supervisory board valuable cooperation contribution successful development company report supervisory board 192 report supervisory board regular election six shareholder representative carried annual general meeting may 13 2016 prof dr iris löwfriedrich m hauke star elected first time twelveperson panel prof dr michael albrecht mr michael diekmann dr gerd krick mr klauspeter müller reelected european work council elected mr konrad kölbl mr rainer stein mr niko stumpfögger employee representative already member supervisory board also elected m stefanie lang m frauke lehmann mr oscar romero de paco first meeting may 13 2016 supervisory board elected dr gerd krick chairman supervisory board fresenius se co kgaa upon proposal shareholder representative mr michael diekmann upon proposal employee representative mr niko stumpfögger elected deputy meeting m hauke star mr konrad kölbl dr gerd krick mr klauspeter müller mr rainer stein elected member audit committee mr klaus peter müller elected chairman audit committee furthermore may 13 2016 meeting mr michael diekmann dr gerd krick mr klauspeter müller elected member nomina tion committee dr gerd krick elected chairman composition management board supervisory board general partner fresenius management se also changed annual general meeting fresenius management se may 13 2016 supervisory board member elected regularly dr kurt bock newly joined board mr michael diekmann dr gerd krick mr klauspeter müller dr dieter schenk dr karl schneider reelected effective july 1 2016 mr stephan sturm appointed chairman management board previ ously served 11 year chief financial officer company time mr stephan sturm proved outstanding finance expert entrepreneur contributing significantly design execution business strategy delivered continued growth appointment chair man management board demonstrates continuity company leadership mr stephan sturm succeeded dr ulf schneider left company request june 30 2016 take new professional challenge supervisory board would like thank dr ulf schneider tremendously successful effort behalf fresenius previous 13 year played central role company rapid sustained growth time chairman management board fresenius quadrupled sale increased earnings 12fold dr ulf schneiders distinguished achievement helped make fresenius today report supervisory board report supervisory board 193 financial statement consolidated financial statement accounting record financial statement prepared according german commercial code hgb 2016 management report company audited kpmg ag wirtschaftsprüfungsgesell schaft berlin done accordance resolution passed annual general meeting fresenius se co kgaa may 13 2016 subsequent appointment supervisory board auditor kpmg issued unqualified audit opinion company financial statement manage ment report applies company consolidated financial statement prepared accordance ifrs accounting principle regulation govern statement pursuant section 315a german commercial code hgb also applies company consolidated financial statement prepared voluntarily according u gaap financial statement consolidated financial statement management report auditor report submitted member company supervisory board timely manner meeting march 9 10 2017 first audit committee supervisory board discussed document detail auditor delivered detailed report result audit meeting found weakness risk management system internal control system regard accounting process auditor attended meeting supervisory board meeting conference call audit committee audit committee supervisory board approved auditor result also audit committee supervisory board review found objection company financial statement management report consolidated financial statement group management report meeting march 10 2017 supervisory board approved financial statement manage ment report presented general partner statement contained therein respect future development company supervisory board concurs general partner proposal allocation 2016 distrib utable profit supervisory board would like thank member management board general partner employee outstanding achievement bad homburg v h march 10 2017 supervisory board report supervisory board dr gerd krick chairman 194 board board supervisory board fresenius se co kgaa dr gerd krick dario anselmo ilossi prof dr med iris löwfriedrich former chairman fresenius ag may 13 2016 since may 13 2016 chairman trade union collaborator femca cisl chief medical officer und executive office energy fashion chemical vice president head development supervisory board fresenius management se chairman medical patient value practice fresenius medical care ag co kgaa chairman fresenius medical care management ag konrad kölbl ucb sa vamed ag austria chairman fulltime work council member office supersivory board evotec ag prof dr med michael albrecht member manual worker work medical director spokesman council vamedkmb krankenhaus klauspeter müller management board universitäts management und betriebsführungs chairman supervisory board klinikum carl gustav carus dresden ge mbh commerzbank ag office supervisory board chairman group work council office gök consulting ag supervisory board universitätsklinikum aachen vamed ag commerzbank ag chairman fresenius management se deputy chairman european work board director prof dr h c roland berger parker hannifin corporation usa council fresenius se co kgaa may 13 2016 corporate office supervisory board dieter reuß management consultant vamedkmb krankenhausmanagement und betriebsführungsges mbh austria may 13 2016 office supervisory board fresenius management se may 13 2016 fulltime work council member rocket internet se stefanie lang schuler ag wmp eurocom ag july 27 2016 deputy chairman since may 13 2016 chairman joint work council board director fresenius se co kgaa banzai spa italy since april 14 2016 fulltime work council member geox spa italy may 19 2016 bad homburg site chairman work council deputy chairman general work michael diekmann fresenius medical care deutschland council fresenius se co kgaa former chairman management gmbh board allianz se gerhard roggemann frauke lehmann deputy chairman may 13 2016 since may 13 2016 office supervisory board management consultant basf se deputy chairman fulltime work council member fresenius management se office linde ag deputy chairman supervisory board siemens ag chairman work council bremer ag since august 16 2016 deutsche beteiligungs ag deputy chairman board director helios kliniken schwerin gmbh deutsche börse ag may 11 2016 allianz australia ltd australia december 31 2016 gp günter papenburg ag chairman nonexecutive director wave management ag deputy chairman member european work council board fresenius se co kgaa corporate office supervisory board helios kliniken schwerin gmbh deputy chairman board 195 supervisory board fresenius se co kgaa oscar romero de paco hauke star niko stumpfögger since may 13 2016 since may 13 2016 secretary trade union verdi head company industry politics staff member production member executive board health care social affair deutsche börse ag member european work council office deputy chairman fresenius se co kgaa supervisory board eurex frankfurt ag deutsche börse ag group mandate gfk se may 20 2016 klöckner co se may 13 2016 stefan schubert administrative board may 13 2016 eurex zürich ag deutsche börse ag group mandate kühne nagel international ag since may 3 2016 hospital nurse fulltime work council member rainer stein fulltime work council member chairman work council helios klinik bad schwalbach chairman group work council helios klinik idstein helios kliniken gmbh chairman group work council chairman european work wittgensteiner kliniken gmbh council fresenius se co kgaa september 9 2016 member european work council fresenius se co kgaa committee supervisory board audit committee nomination committee joint committee 1 prof dr h c roland berger dr gerd krick chairman dr dieter schenk chairman may 13 2016 chairman prof dr h c roland berger michael diekmann klauspeter müller may 13 2016 dr gerd krick since may 13 2016 chairman michael diekmann dr karl schneider konrad kölbl klauspeter müller since may 13 2016 dr gerd krick gerhard roggemann may 13 2016 board hauke star since may 13 2016 rainer stein 1 committee consists equally two member supervisory board fresenius se co kgaa fresenius management se 196 board management board fresenius management se general partner fresenius se co kgaa dr ulf schneider dr francesco de meo rice powell june 30 2016 business segment fresenius helios business segment corporate office fresenius medical care chairman supervisory board helios beteiligungs ag chairman corporate office corporate office helios kliniken schwerin gmbh chairman administrative board supervisory board vifor fresenius medical care renal pharma ltd fresenius kabi ag june 30 2016 chairman switzerland vice chairman medical care management ag june 30 2016 chairman dr jürgen götz board director fresenius medical care holding inc usa board director chief legal compliance officer chairman fresenius kabi usa inc usa june 30 2016 labor relation director office board director dr ernst wastler e du pont de nemours company usa mat henriksson business segment fresenius vamed business segment fresenius kabi corporate office stephan sturm supervisory board corporate office charité cfm facility management gmbh chairman since july 1 2016 supervisory board deputy chairman fresenius kabi austria gmbh austria vamedkmb krankenhausmanagement und chief financial officer chairman betriebsführungsges mbh austria chairman fresenius kabi españa sau spain corporate office labesfal laboratórios almiro sa portugal supervisory board fresenius kabi ag deputy chairman august 29 administrative board 2016 chairman since august 29 2016 fresenius kabi italia spa italy chairman fresenius medical care management ag since may 11 2016 chairman since june 30 2016 board director vamed ag austria deputy chairman fenwal inc usa fhc holding ltd great britain office fresenius kabi pharmaceutical holding inc usa supervisory board fresenius kabi singapore pte ltd singapore deutsche lufthansa ag fresenius kabi usa inc usa sinoswed pharmaceutical corp ltd china board board 197 supervisory board fresenius management se general partner fresenius se co kgaa dr gerd krick michael diekmann dr karl schneider chairman former spokesman südzucker ag klauspeter müller office foundation board prof dr h c roland berger else krönerfreseniusstiftung deputy chairman may 13 2016 dr dieter schenk lawyer tax consultant dr kurt bock deputy chairman since may 13 2016 office supervisory board chief executive officer basf se bank schilling co ag chairman fresenius medical care ag co kgaa deputy chairman fresenius medical care management ag deputy chairman gabor shoe ag chairman greiffenberger ag deputy chairman toptica photonics ag chairman foundation board else krönerfreseniusstiftung chairman board 198 glossary glossary health care term product service administrative data dialysis machine epo erythropoietin data transmitted sickness fund part hemodialysis process controlled dial hormone stimulates red blood cell produc billing process federal agency like ysis machine pump blood add anti tion recombinant ie artificially produced german federal statistical office due coagulant regulates cleansing process human epo commonly prescribed patient legal requirement germany includes control mixture dialysate flow dialysis suffer anemia information coded diagnosis pro rate system cedures fda u food drug administration dialysis solution dialysate official authority food observation drug albumin fluid used process dialysis order registration united state protein indicative patient general remove filtered substance excess nutritional status water blood hd hemodialysis treatment method dialysis patient blood volume substitute dialyzer blood patient cleansed dia used temporary stabilization special filter used hemodialysis removing lyzer solute exchange blood maintenance blood volume exam toxic substance waste product metabolic dialysate dominated diffusive process ple event major blood loss process excess water blood dialyzer sometimes referred artifi hemoglobin dialysis cial kidney component red blood cell transport form renal replacement therapy oxygen around body insufficient level semipermeable membrane peritoneal dial enteral nutrition hemoglobin indicative anemia ysis peritoneum patient hemo application liquid nutrition tube sip typically occurs patient chronic kidney dialysis membrane dialyzer used feed via gastrointestinal tract failure besides dialysis anemia treated clean patient blood iron supplement hormone compound erythropoietin epo glossary glossary 199 health care term product service kt v value parenteral nutrition prevalence provides information urea content application nutrient directly blood number patient suffer specific blood urea mostly excreted healthy kid stream patient intravenously disease within defined period prevalence ney dialysis patient must filtered necessary condition patient rate indicates number people blood renal replacement ther allow absorb metabolize essential nutri specific disease eg terminal kidney failure apy kt v value show whether patient ents orally sip tube feed suffi treated per million population detoxified effectively dialysis cient quantity ppp publicprivate partnership model medicare medicaid pd peritoneal dialysis publicprivate partnership describes govern program developed federal u social dialysis treatment method using patient ment service private business venture security administration reimburses health peritoneum filter cleanse blood funded operated partnership insurance company provider medi government one privatesector cal service medical care individual phosphate company case ppp accompanies 65 people chronic kidney failure phosphate concentration show whether treat partprivatization governmental service disabled ing patient dialysis medication sufficient body absorb phosphate threechamber bag outpatient clinic ingested food healthy people excrete threechamber bag contains macro interdisciplinary facility outpatient care excess phosphate via kidney diseased nutrient like amino acid glucose lipid managed physician responsible body kidney unable phosphate well electrolyte three separate cham medical care center includes service concentration blood high bers immediately infusion nutrient provider physician pharmacist lead severe condition mixed thoroughly within bag simply health care facility authorized opening individual chamber reduces treat patient statutory health insurance risk contamination save time preparing infusion glossary 200 glossary financial term 1 special item cash flow acquisition dividend ebitda earnings interest tax order measure operating performance fresenius us cash flow acquisi depreciation amortization extending several period key perfor tions dividend financial measure ebitda calculated ebit adding mance measure adjusted special item free cash flow cash flow acquisition depreciation recognized income applicable adjusted measure dividend calculated operating cash deducting writeups recognized income labelled special item reconcil flow less investment net net investment intangible asset well property iation table available within respective calculated payment purchase plant equipment quarterly annual report present property plant equipment less proceeds composition special item sale property plant equipment ebitda margin ebitda margin calculated ratio cash flow constant currency ebitda sale financial key figure show net balance constant currency income expense incoming outgoing payment calculated using prior year average rate net debt ebitda reporting period constant currency asset liability net debt ebitda financial measure reflect calculated using midclosing rate ing ability fresenius fulfill pay operating cash flow date respective statement financial ment obligation net debt ebitda cal operating cash flow financial measure position culated ltm last twelve month average showing cash inflow operating activity exchange rate respectively period operating cash flow calcu day sale outstanding dso lated subtracting noncash income add indicates average number day take calculation net debt ing noncash expense net income receivable paid shortterm debt shortterm debt related party cash flow investing activity ebit earnings interest tax current portion longterm debt capital cash flow investing activity financial ebit include depreciation writeups lease obligation measure opposing payment acquisition property plant equipment current portion senior note purchase property plant equipment longterm debt capital lease obligation investment versus proceeds sale ebit calculated subtracting cost sale less current portion property plant equipment invest selling general administrative expense senior note less current portion ments research development expense convertible bond sale debt cash flow financing activity less cash cash equivalent cash flow financing activity financial ebit margin net debt measure showing investment ebit margin calculated ratio ebit reporting period financed sale nopat net operating profit tax nopat cash flow financing activity calculated calculated operating income ebit addition equity plus proceeds stated profit loss statement less exercise stock option less dividend paid income tax plus proceeds debt increase loan bond senior note etc less repayment debt plus organic growth change noncontrolling interest plus pro growth generated company ceeds hedge exchange rate effect existing business acquisition due corporate financing divestiture foreign exchange impact glossary 1 integral part management report glossary 201 financial term 1 reconciliation average invested capital roic december 31 december 31 december 31 million except roic 2016 2015 2014 total asset 46447 42959 39788 plus cumulative goodwill amortization 551 537 495 minus cash cash equivalent 1579 1044 1175 minus loan related party 51 109 65 minus deferred tax asset 560 540 727 minus account payable 1315 1291 1052 minus account payable related party 57 9 5 minus provision current liability 1 5470 4963 4384 minus income tax payable 478 416 377 invested capital 37488 35124 32498 average invested capital december 31 2016 2015 2 36495 33811 operating income 3 4 4316 3958 income tax expense 1213 1164 nopat 3 4 3103 2794 roic 85 83 1 includes noncurrent provision payment outstanding acquisition include pension liability noncontrolling interest subject put provision 2 includes adjustment acquisition respective reporting period purchase price certain level 2016 378 million 2015 3 includes adjustment acquisition respective reporting period purchase price certain level 2016 11 million 2015 4 2015 special item reconciliation average operating asset rooa december 31 december 31 december 31 million except rooa 2016 2015 2014 total asset 46447 42959 39788 minus payment received account 87 75 68 minus cash held trust 61 57 52 minus loan related party 51 109 65 minus deferred tax asset 560 540 727 minus account payable 1315 1291 1052 minus account payable related party 57 9 5 minus approved subsidy due hospital funding act krankenhausfinanzierungsgesetz khg 180 191 177 operating asset 44136 40687 37642 average operating asset december 31 2016 2015 1 42622 39165 operating income 2 3 4316 3958 rooa 101 101 1 includes adjustment acquisition respective reporting period purchase price certain level 2016 421 million 2015 glossary 2 includes adjustment acquisition respective reporting period purchase price certain level2016 11 million 2015 3 2015 special item 1 integral part management report 202 glossary financial term 1 roe return equity rooa return operating asset soi scope inventory measure corporation profitability reveal calculated ratio ebit operating indicates average number day ing much profit company generates asset average receiving good inventory sale money shareholder invested finished product roe calculated fiscal year net income operating asset total asset deferred tax total equity x 100 asset trade account payable cash held calculated inventory cost good trust payment received account approved sold x 365 day roic return invested capital subsidy calculated ebit tax invested capital working capital current asset including deferred asset invested capital total asset accumulated accrual trade account payable liabili amortization goodwill deferred tax asset tie deferred charge cash cash equivalent trade account pay able accrual without pension accrual liability bearing interest glossary 1 integral part management report 204 imprint imprint commercial register bad homburg v h hrb 11852 chairman supervisory board dr gerd krick general partner fresenius management se registered office commercial register bad homburg v h hrb 11673 management board stephan sturm president ceo dr francesco de meo dr jürgen götz mat henriksson rice powell dr ernst wastler chairman supervisory board dr gerd krick german version annual report legally binding editorial closing date annual report march 15 2017 published march 16 2017 annual report financial statement fresenius se co kgaa consolidated statement accordance ifrs accounting principle available website may obtained upon request investor relation find information current news company website wwwfreseniuscom forwardlooking statement annual report contains forwardlooking statement statement represent assessment made basis information available u time assumption statement based occur risk arise mentioned risk report sec filing fresenius medical care ag co kgaa actual result could differ materially result currently expected design concept realization hilger boie design wiesbaden print ziegler gmbh co kg neckarbischofsheim germany imprint financial calendar report 1st quarter 2017 conference call live webcast may 3 2017 annual general meeting frankfurt main germany may 12 2017 payment dividend 1 may 17 2017 report 2nd quarter 2017 conference call live webcast august 1 2017 report 3rd quarter 2017 conference call live webcast november 2 2017 1 subject prior approval annual general meeting schedule update information live webcasts event wwwfreseniuscomeventsandpresentations fresenius share adr ordinary share adr security identification 578 560 cusip 35804m105 ticker symbol fre ticker symbol fsnuy isin de0005785604 isin us35804m1053 bloomberg symbol fre gr structure sponsored level 1 adr reuters symbol fregde ratio 4 adr 1 share main trading location frankfurt xetra trading platform otcqx contact corporate headquarters postal address contact shareholder contact journalist elsekrönerstraße 1 fresenius se co kgaa investor relation corporate communication bad homburg v h 61346 bad homburg v h telephone 49 61 72 6 0824 87 telephone 49 61 72 6 0823 02 germany germany telefax 49 61 72 6 0824 88 telefax 49 61 72 6 0822 94 email irfrefreseniuscom email prfrefreseniuscom